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RESUME 
 
Les fumonisines (FBs) sont les principales mycotoxines produites par Fusarium 
verticillioides et Fusarium proliferatum, qui se retrouvent partout dans le monde dans le 
maïs et ses produits dérivés. Les doses toxiques et les signes cliniques de toxicité 
provoqués par les FBs varient d’une espèce à l’autre. La toxicité des FBs est 
généralement liée à leur capacité à bloquer le métabolisme des sphingolipides chez 
les espèces animales, y compris chez les espèces aviaires. De précédentes études ont 
démontré que les canards présentent une plus grande sensibilité à la toxicité des FBs 
que les dindes, alors que l’accumulation de sphinganine (Sa) dans les tissues est plus 
importante chez les dindes que chez les canards. 
L’objectif de nos travaux était de comprendre les différences de toxicité entre 
les dindes et les canards los d’une exposition aux FBs. Les trois hypothèses suivantes 
ont été explorées : i) La toxicocinétique de la fumonisine B2 chez les dindes et les 
canards. ii) La capacité des cellules aviaires à se protéger de l’importante 
accumulation de sphingolipides libres en augmentant leur catabolisme 
(phosphorylation). iii) Des mécanismes de toxicité des FBs autre que leur altération 
via le métabolisme des sphingolipides (stress oxydatif et les réponses 
inflammatoires).  
L’analyse des paramètres de toxicocinétique de la fumonisine B2 n’a pas mis 
en évidence de différence significative entre les dindes et les canards. Les mesures de 
la toxicité simultanée de plusieurs FBs chez les dindes et les canards ont confirmé la 
forte sensibilité des canards. L’accumulation de shingasine-1-phosphate (Sa1P) dans 
le foie a également été corrélée avec la quantité de Sa mais pas avec les paramètres 
hépatiques de toxicité.  De plus cette étude a mis en évidence que la quantité de Sa 
dans le foie était fortement dépendante de la teneur en FBs. Cependant les FBs n’ont 
eu aucun effet sur les paramètres de stress oxydatif pour les deux espèces. De 
manière intéressante, les FBs ont eu une légère réponse inflammatoire chez les 
canards mais pas chez les dindes. Des investigations plus poussées sur les effets des 
FBs sur le métabolisme des céramides et sur les processus inflammatoires seraient 
nécessaires pour comprendre les différences de toxicité entre les dindes et les canards 
exposés aux FBs. 
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SUMMARY 
 
Fumonisins (FBs) are the major mycotoxins produced by Fusarium 
verticillioides and Fusarium proliferatum, which are found worldwide in maize and 
maize products. FBs toxic dose and clinical signs of toxicity vary from one species to 
another. FBs toxicity is commonly linked to their ability on blocking sphingolipids 
metabolism in all animal species, including avian species. Previous studies have 
demonstrated that ducks exhibit higher sensitivity to FBs toxicity than turkeys, 
whereas, the accumulation of sphinganine (Sa) in tissues is more pronounced in 
turkeys than in ducks.  
The objectives of our works were to investigate the causes which lead to 
different toxicity between ducks and turkeys to FBs exposure. The following three 
hypotheses were investigated:  i) Toxicokinetics of fumonisin B2 in ducks and 
turkeys. ii) Ability of bird cells to protect themselves against high accumulation of 
free sphingolipids by increasing their catabolism (phosphorylation). iii) Other 
toxicity mechanisms of FBs rather than their alteration of sphingolipids metabolism 
(oxidative stress damage and inflammatory responses).  
The analysis of toxicokinetic parameters of fumonisin B2 did not provide a 
significant difference between ducks and turkeys. The measurement of simultaneous 
toxicity of FBs in ducks and turkeys confirmed higher sensibility of ducks. Also the 
accumulation of Sphingasine-1-Phosphate (Sa1P) in the liver correlated with the 
amount of Sa but not parameters of hepatic toxicity. Moreover, this study revealed 
that the amount of Sa in the liver was strongly dependent on the amount of FBs. On 
the other hand, FBs had no effect on oxidative damages parameters in both species. 
Interestingly, FBs had mild inflammatory response effect in ducks but not in turkeys. 
Further investigation on the effects of FBs on ceramide metabolism and inflammatory 
processes would be necessary to understand the different toxicity between ducks and 
turkeys to FBs exposure.  
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INTRODUCTION 
Fumonisins (FBs) are the most important mycotoxins produced by Fusarium 
verticillioides and Fusarium proliferatum fungi, which are widely found as 
contaminants in corn and corn screenings [48]. Although a number of different FBs 
have been isolated from culture, the most common is fumonisin B1 (FB1), with lesser 
amounts of fumonisins B2 (FB2) and B3 (FB3) being known to naturally occur [1-18-
21-150]. Many researchers considered that FBs have a strong relation to certain 
diseases in different animal species such as encephalomalacia in horses [9], 
pulmonary edema pigs [11-12], and hepatic and renal toxicities in equines, pigs, 
sheep, rodents and poultry [15-16-17]. Additionally, FB1 is considered as a cancer 
initiator and a strong cancer promoter for hepatocarcinoma in rats [10-94]. The 
carcinogenic properties of FB1 have been confirmed by the National Toxicology 
Program (NTP) study, which demonstrated FB1 to be nephrocarcinogenic in male 
rats and hepatocarcinogenic in female mice [207]. Furthermore, FB1 had implicated 
in the high incidence of human esophageal cancer in South Africa and China [4-21-
77], and it was considered a primary risk factor for human liver cancer in China [77-
273]. Currently, all animal species appear to be sensitive to FB1 exposure, but its 
toxicity differs from one species to another. In short term, carcinogenesis studies on 
rats have indicated that fumonisin B2 (FB2) and FB3 have similar effects to FB1 in 
terms of toxicity and hepatocarcinogenicity [48]. IARC (International Agency for 
Research on Cancer) classified FB1 and FB2 as class 2B derived carcinogenic [267]. In 
order to solve these problems, several recommendations and regulations have been 
made by the FDA, JECFA and EU to limit FB1, FB2 and FB3 in food consumed by 
humans and animals [25-157-160-267-289]. For example, in France mycotoxin 
inspections showed that 67% of corn samples were contaminated by Fusarium 
verticillioides and that more than 80% of these strains were able to produce very high 
levels of FB1 in laboratory conditions [276]. Moreover, around 10% of corn samples 
analyzed by the Toxicological group (department) at the Veterinary school of 
Toulouse were contaminated at levels between 10 and 20 mg of FB1/kg [158]. Very 
high levels of FB1 (100 to 200 mg/kg) were recorded in the feed of horses suffering 
from ELEM in Toulouse [105].   
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Actually, there is little data available concerning fumonisins in poultry which 
consume high quantities of corn during their lives particularly in France where ducks 
consume about 1Kg of corn per day during the force-feeding program to produce 
fatty liver [158]. All those facts pushed the Toxicological group (Department) at the 
Veterinary school of Toulouse to induce several researches to investigate the effects 
of fumonisins and their consequences on poultry. The results obtained from those 
researches demonstrated that ducks were more sensitive to FB1 toxicity than turkeys 
[156-158-165].  By contrast, absorption and persistence of FB1 were higher in turkeys 
than in ducks, and excretion of FB1 is lower in turkeys than in ducks [23-24].  
The objective of the PhD is to investigate the causes which lead to different 
toxicity between ducks and turkeys to FBs exposure. Two experiments (FB2-
Toxicokinetics and FBs-Toxicity) on ducks and turkeys at same time were conducted 
in order to explain the aim of the PhD.  
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CHAPTER 1: LITERATURE REVIEW 
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I. Fumonisin general introduction  
1. Historical background of fumonisins 
In 1900, fumonisin toxic effects were observed for the first time after sporadic 
fatal conditions in horses in countries such as the United States, China, Japan, 
Europe, South Africa and Egypt [18-1]. In 1902, Mr.Butler named the disease equine 
leukoencephalomalacia (ELEM) after inducing its symptoms in tested horses fed with 
moldy feed. Other names used to describe it were blind staggers, foraging disease, 
moldy corn poisoning, leucoencephalitis, and cerebritis [2-3].   
 In 1970, an outbreak of ELEM in horses in South Africa was associated with 
the contamination of corn by the fungus Fusarium verticillioides in certain areas [19].  
In 1971, Wilson confirmed that causative agents of ELEM are maize and 
cereals infected with genus Fusarium mold. In particular, Fusarium moniliforme was 
implicated [4]. Nevertheless, this explanation was not very precise, because Fusarium 
moniliforme could produce a range of mycotoxins, including trichothecenes, 
zearalenone, fusaric acid, moniliformin, fusarin C, and the fumonisins [5].  
In 1988, the real causative agent of ELEM in South Africa was discovered by 
Marasas’s group (Program on Mycotoxins and Experimental Carcinogenesis-
PROMEC), when the two toxic metabolites (FB1 and FB2) were isolated from 
contaminated maize with Fusarium verticillioides (synonym Fusarium moniliforme) [1-
18-21]. 
In 1990, Kellerman observed typical symptoms of ELEM after horses were 
exposed to purified FB1 by oral route [9].Since then numerous studies have been 
performed to better understand the adverse effects of FB1 on different animal 
species. The results obtained from those studies confirmed that FB1 was implicated 
in hepatic and renal toxicities in equines, pigs, sheep, rodents and poultry [15-16-17], 
pulmonary oedema in pigs [11-12], and liver cancer in rats [10]. FB1 had not shown to 
cause esophageal cancer in all tested animal species [13-14]. However, high 
incidences of esophageal cancer were observed in 1970, in Transkei - South Africa 
among people who ate homegrown corn [4-21]. In addition, in 1988, Marasas and his 
group-conducted a fungus isolated comparative study between esophageal cancer 
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areas and non-esophageal cancer areas. The main type of fungus isolated from 
infected areas was Fusarium verticillioides [7-20-21].  
2. Chemical and physical characteristics of fumonisins  
Fumonisin B1 is the most widespread type of FBs [1-18-21-150]. Chemical 
formula of FB1 is C34H59NO15, and it is the diester of propane-1.2.3-tricarboxylic 
acid and 2-amin 12.16 dimethy-3.5.10.14.15-pentahydroxyeicosane (molecular weight: 
721), (figure 1, and table 1) [18]. The pure substance of FB1 is a white hygroscopic 
powder which is soluble in water, acetonitrile-water or methanol-water. It is stable in 
acetonitrile-water (1:1), food-processing temperature and light. FB1 is unstable in 
methanol [18].   
In nature, there are about 15 different structures of fumonisin which are 
classified to four groups (A, B, C and P). Each group is divided in subclasses as FA1, 
FA2, FA3, FAK1, FB1, FB2, FB3, FB4, FC1, FC2, FC3, FC4, FP1, FP2 and FP3 [18-21-
167].  
The B class fumonisins are esters of 2-amino-12, 16-dimethyl- 14, 15-
dihydroxyecosane, and propan-1, 2, 3-tricarboxylic acid. FA1, FA2 and FA3 are N-
acetyl derivates of FB1, FB2 and FB3. FAK1 is like FA1. FCs differs from other 
fumonisins by lack of a methyl group. FPs have 3-hydroxypyridium group instead of 
the amine group in the FBs (figure 1, table 1) [18].  
 
Figure 1:  Chemical Structure of FBs [21-167] 
  
7 
Table 1: Classification of fumonisins [167] 
Fumonisins R1 R2 R3 R4 R5 
FA1 OH OH CH2CO CH3 H 
FA2 H OH CH2CO CH3 H 
FB1 OH OH H CH3 H 
FB2 H OH H CH3 H 
FB3 OH H H CH3 H 
FC1 OH OH H H H 
3. Occurrence of fumonisins 
 Incidence of cereals contamination by Fusarium moniliforme increased in hot-
humid regions, and it is related to insect invasions [81]. Maize, compared to other 
cereals, is most frequently contaminated by fumonisins. In addition, fumonisins have 
been found at high level in wheat, asparagus, tea, and cowpea [150]. In fact, it is very 
difficult to obtain uncontaminated maize, even if the contamination level is not 
significant. Fumonisins have been detected in cereals at very low concentration as 
0.02 mg/kg (it is the limit of detection in many investigations), but sometimes they 
reach up to tens of mg/kg [150]. In most samples of investigation, FB1 is the most 
prevalent toxin, with co-occurrence of FB2 and FB3 [18-150]. Several countries in 
Africa, North- and South America, Asia, and Europe have reported FB1 in cereals at 
levels from 0.02 to 25.9 mg/kg, and FB2 at levels from 0.05 to 11.3 mg/kg [224]. 
However, quantity of fumonisins in animal feed is reported in South Africa at level 
from 4.0 to 11.0 mg FB1/kg [225], in Uruguay from 0.2 to 6.3 mg FB1/kg [226], and in 
France up to 2.1 mg FB1/kg and 0.9 mg FB2/kg [227]. The studies conducted on dry 
milling maize reported that the highest level of FB1 occurred in germ, bran and 
animal feed flour, respectively. Also FB1 is present at higher levels in small corn grits 
compared to large corn grits and human food flour [228-229-230]. Therefore, 
preparation of human and animal food from cereal fractions (germ alone or bran 
alone) could contain higher levels of FB1 than the feed made by raw materials. In 
addition, there is some evidence that maize silage contains low levels of FB1 (around 
0.6 mg FB1/kg) [231].  
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II. Fumonisin toxicokinetic 
 Toxicokinetic is the study of the rate of a chemical in the body and what 
happens to it after it reached the plasma. These studies are divided in four steps 
called absorption, distribution, metabolism and elimination (ADME) [70]: 
 Absorption, measured by the bioavailability, represents the amount of the 
administered compound that reaches the plasma and the kinetic of it 
appearance in this fluid. The absorption reveals the relation between dose of 
exposure and systemic exposure of the body. It permits to extrapolate 
parenteral and oral exposure, to reveal differences between species, and, in a 
lesser extent, to predict risk of persistence in the body (risk of residues). 
 Distribution, measured by the volume of distribution, represents the 
compartments of the body where the toxin reaches. It could explain toxicity 
(accumulation in a tissue), and is linked with the ability of a toxic to be 
metabolized (see below). A large distribution often goes with high systemic 
exposure to a toxic whereas a low one is generally observed for compound 
that known a rapid excretion (see below).  
 Metabolism represents the biochemical transformation of a toxic by systems 
known as”drug metabolizing enzyme”. These transformations can increase or 
decrease toxicity. Strong variations have been observed between species 
concerning their ability to metabolize a compound. These differences are often 
involved to explain interspecies differences of toxicity.   
  Elimination, measured by the clearance, represents the output of a compound 
from the body. Different mechanisms are involved: metabolisation into a new 
compound, excretion in body fluid (urine, bile, milk…). High clearance of a 
compound represents a rapid disappearance of this compound from the body. 
It generally goes with a low ability to accumulate. By contrast, a low clearance 
means that the compound accumulates within the body, which has 
consequences in terms of toxicity (chronic exposure) and persistence of 
residual. 
 The ADME parameters are obtained after administration of the compound by 
oral and parenteral route and monitoring of the plasma concentrations. Sometimes, 
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direct measurements of the toxic within the tissues are available. Metabolizing 
studies can also be performed in vivo or vitro (cell cultures) by using purified drug 
metabolizing enzymes. Usually, the kinetic of the toxic in the plasma is modelized by 
using one, two or three exponential. The calculation of the toxicokinetic parameters 
and their unit are described in the materials and methods section of this document 
for the toxicokinetic of FB2 (page 89). In this chapter, the toxicokinetic parameters of 
FBs are presented to reveal differences between species that could explain differences 
of toxicity and, when available, differences between fumonisins (FB1, FB2 and FB3). 
A specific focus will be done on the avian species. 
Fumonisins toxicokinetic and metabolism data for humans are not available. 
Many efforts have been made to understand the kinetics and metabolism of FB1 in 
different animal species like cows, pigs, rats and poultry. In the past, global research 
was conducted by radiolabelled [14C] FB1 [18]. Whereas recently, a new method was 
developed to determine non-radio-labelled FB1 (unlabelled) in serum by using strong 
anion exchange (SAX) cartridges to extract fumonisin, OPA (ortho-phtalaldehyde)  to 
give fluorescent properties to FB1, and HPLC to quantify FB1 [22-23-24-32]. By 
contrast, the kinetics and metabolism of FB2 have been very poorly documented. The 
first study describing toxicokinetics of FB2 in rats was done in 1995. And a second 
one was conducted on non-human primates in 1999. These studies were carried out 
by Shephard [28-51]. In addition, data related to pharmacokinetics of fumonisin 
hydrolyzed forms in all animals species, and FB2 in avian are not available.  
1. Absorption 
 Until recent times, there has been no evidence of absorption of fumonisins 
by inhalation or skin contact. However, natural presence of fumonisins in F. 
verticillioides cells (mycelia, spores and conidiophores) increase the possibility of 
absorption by inhalation or buccal exposure. FBs are water soluble and polar 
compounds. Thus their ability to penetrate an intact skin is not strong. Although it 
may be stronger if the skin is damaged [18].  
 In general, all tested animal species confirmed that FB1 has poor absorption 
ability (less %5 of dose), with approximately Tmax from 3 to 5 hr, as synthetized in 
table 2.  
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Table 2: Absorption of fumonisins in different animal species 
Animals 
Dose 1 FB1 
(mg/kg b.w) 
Tmax  
(hr) 
Cmax  
(µg/ml) 
Bioavailability 
(%  of dose) 
Ref 
Rats 10  1  0,18  3,5 [32] 
Monkeys 6,42* 1-2  < 0.21  2 [35] 
Pigs 
0,5* 1,10 0.033  4 [31] 
5  2  282  NC [63] 
Cattle 1 or 5  ND ND 0 [34] 
Layer hens 2*  1,5-2,5  0.028-0.103   0.7 [30] 
Turkeys 100  3  0.991   3.2  [24] 
Ducks 100  1  0.559  2.1 [23] 
Animals 
Dose 1  FB2 
(mg/kg b.w), 
Tmax  
 (hr) 
Cmax  
 (µg/ml) 
Bioavailability 
(%  of dose) 
Ref 
Rats 7,5   ND ND ND [28] 
Monkeys 7,5  3-5  0.025-0.04  NC [51] 
1 single oral dose of FB1 or *[14C] FB1 or FB2 
Cmax: maximum serum concentration; Tmax: time of the Cmax; NC: not conducted; ND: 
non detected. 
 
The absorption of radiolabelled [14C] FB1 is fairly close in avian and 
mammalian species, 0.71% and 2-4% of dose, respectively [30-31-35]. Quite similar 
results were announced by administering different dosage of unlabelled FB1 via oral 
route to rats, ducks and turkeys. The results concluded that avian and mammalian 
species have similar bioavailability. It is 2.1-3.2 and 3.5 % of administered dose, 
respectively, (table 2). Overall, the rates of bioavailability between avian species and 
mammals are close to each other [23-24-32-51].   
Analogous bioavailability can be found in avian species by using little single 
dose 2 mg/kg b.w. of radiolabelled FB1 for laying hens, or by using high single dose 
100 mg/kg b.w. of unlabelled FB1 for ducks and turkeys. Those experiments 
demonstrated that maximum absorption time was between 60 to 180 min. And the 
bioavailability was 0.71%, 2.3% and 3.2% respectively (table 2) [23-24].  
In literature, there is data clarifying that bioavailability of FB1 is poor in 
ruminants compared to that obtained in monogastric animals. FB1 is unable to being 
recovered in serum after single oral dose of 1 or 5 mg FB1/kg b.w. [34]. Rice and Ross 
(1994) demonstrated that lower FB1 absorption in cattle and sheep is related to 
rumen micro-flora metabolic activity, which converts FB1 to hydrolyzed forms 
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(HFB1). This explanation is given after exposing cattle to 50-400 mg FB1/kg of feed, 
for one month. The results obtained in this experiment showed that 60-90% of total 
FB1 recovered in feces was in hydrolyzed form HFB1. It is believed that rumen 
metabolism could interfere with FBs absorption, which reaches less than 1% of the 
dose [18-36]. By contrast, Smith and Thakur (1996) mentioned that more than 80% of 
fumonisins (FB1 and FB2) in ruminant feces is unmetabolized or unhydrolyzed. This 
result was obtained by feeding steers with 400 mg FB1/kg and 130 mg FB2/kg of 
feed for one month [52]. 
It has been demonstrated that absorption of HFB1 in rats is higher than FB1 by 
two folds, but it was not significant. This experiment does not depend on a 
toxicokinetic study, but rather on excretion percentage of molecules from the urine 
after gavage of single dose 0.69 µmol of 14C- FB1 and 14C- HFB1/kg b.w. [71]. 
Lack of detection of FB2 in the plasma at any time after oral administration of 
7.5 mg FB2/kg b.w. in rats and monkeys, shows that bioavailability of FB2 is as 
limited as the one of FB1. Even if trace levels of FB2 was detected in plasma after an 
oral exposure dose in monkeys. That means bioavailability of FB2 is still less 
important than bioavailability of FB1 in mammals [28-51]. 
 
2. Distribution 
Fumonisin B1 has a rapid distribution, with a distribution half-life (T1/2α) less 
than 3 min in all tested animals [23-24-30-32-34-53].  
In avian species, the same time of distribution half life of FB1 (T1/2α) is 
recorded in laying hens and ducks (2.5 and 2.6 min, respectively), by using different 
types of FB1 (radiolabel and unlabelled) [23-30]. On the other hand, equal 
distribution half life of FB1 (T1/2α) is obtained (1.7 min) in different species of 
turkeys and cattle by using the same type of FB1 (unlabelled FB1) [24-34]. All those 
results indicate that the distribution half-life of FB1 is equal in the same species by 
using different types of FB1 (radiolabel and unlabelled). Also, the same type of FB1 
(unlabelled FB1) has same distribution half life (T1/2α) in different species (table 3).  
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Table 3: Distribution of FB1 in different animal species after IV dosing  
Animals Dose1 Exponential Parameters  Ref 
Rats 2  Two Vd area: 0.11 L/kg [32] 
Pigs 0.4* Three 
T1/2α: 2.2 min 
Vd area: 2.41 L/kg 
[31] 
Cow 0.05 – 0.2  Two 
T1/2α: 1.7 min.  
Vd area : 0.26 L/kg 
Vc 0.05 L/kg  
[34] 
Laying Hens 2*  Two 
T1/2α: 2.5 min 
Vd area: 0.08 L/kg 
Vc : 0.005 L/kg 
[30] 
Turkeys 10  Three 
T1/2α: 1.7 min 
Vd area: 1 L/kg 
Vc: 0.1 L/kg 
[24] 
Ducks 10  Two 
T1/2α: 2.6 min 
Vd area: 0.8 L/kg 
Vc: 0.2 L/kg 
[23] 
1 single IV dose (mg/kg b.w.) of FB1 or *[14C] FB1;  
T1/2α: distribution half-life; Vd area: volume of distribution; Vc: volume of central 
compartment.  
The distribution of radiolabelled FB1 in laying hens is less important than the 
distribution of unlabelled FB1 in ducks and turkeys. This description depends on the 
volume of distribution (Vd-area) in laying hens, ducks and turkeys (Vd area: 0.08, 0.8 
and 1 L/kg, respectively). That means ducks and turkeys are more susceptible to 
residual FB1 in their tissues than laying hens [23-24-30]. The difference in the volume 
of distribution (Vd-area) in avian species is not related to the difference in the 
administrated types of FB1 (radiolabel or unlabelled), but it is rather related to avian 
classification. That point was proven by the volume of distribution of FB1 obtained in 
rodents which was quite similar to that of laying hens (Vd (area) 0.11 and 0.08 L/kg, 
respectively), even though they were different species exposed to different types of 
FB1 (table 3) [30-32].  
In rodents, Vd-area was 0.11 L/kg in a rat injected with a single dose of 2 mg 
FB1/kg b.w., by IV route [32]. In pregnant rats, one hour after administration of 101 
mg [14C- FB1]/kg b.w. by intravenous, around 14.5% and 4% of radiolabelled FB1 is 
distributed to the liver and kidneys, respectively (table 3). Moreover, only a trace 
element is recovered in the uterus 0.24% to 0.44%, placenta 0 to 0.04% and total fetus 
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recovery < 0.015% of dose. These results signified that FB1 is incapable of crossing rat 
placenta, (table 3) [53].  
In pigs, FB1 shows higher distributing ability through their bodies when 
compared to avian or mammalian species. Those results were obtained after pigs 
were intravenously exposed to a single dose of 0.4 mg [14C-FB1]/kg b.w. The data 
obtained established that distribution half life (T1/2 α) was 2.2 min. In addition, the 
volume of distribution (Vd area) is 2.41 L/kg [31]. 
The data collected from lactating dairy cows confirmed that the distribution of 
FB1 does not depend on the quantity of the dose exposure or the animal species. That 
information was collected after exposing cows to low and high intravenous doses of 
0.05 or 0.2 mg of FB1/kg b.w. Their results demonstrated that T1/2 α in both 
concentrations was 1.7 min. Volume of distribution (Vdarea) in low and high 
concentration doses were 0.251 and 0.278 L/kg, respectively. During that time, the 
volume of central compartment (Vc) was 0.054 and 0.046 L/kg, respectively [34]. 
Same number of distribution half life (T1/2 α) was obtained in cattle and turkeys [24-
34].  
Unfortunately, data concerning distribution of FB2 are not available. All those 
researches are simplified in table 3, to give idea about FB1 distribution in different 
animal species in comparison with avian species. 
3. Metabolism  
The liver is generally the principal site to xenobiotic metabolism, but 
occasionally it can take place in the gastrointestinal tract, lungs, kidneys, or serum. 
Moreover, xenobiotic can be degraded by intestinal microflora to less or higher active 
molecules [67-70].  
Fumonisin B1 molecule consists of long chain aminopentol backbone (AP1), 
with two ester-linked to tricarballylic acids (TCA). FB1 that lack TCA at one side of 
the chain replaced by hydroxyl group (OH) are called partially hydrolyzed (HFB1/2) 
or aminopolyols (AP1/2). Concurrently, they are called fully hydrolyzed (AP1) when 
the lack of TCA occurs at both sides of the chain [18-57-68-74]. 
Vervet monkeys were exposed to a single dose of 1.72 mg (intravenous) and 
42 mg (gavage) [14C- FB1] / kg b.w. The results obtained from gut contents and feces 
  
14 
after IV exposure demonstrated that 7.5%, 33% and 1.5% of the dose was recovered 
as unhydrolyzed, partially hydrolyzed and full hydrolysis form (aminopentol-AP1), 
respectively. Concurrently, the results obtained by oral route demonstrated that 48%, 
13.5% and <0.1% of the dose were recovered as unhydrolyzed, partially hydrolyzed 
and full hydrolyzed, respectively. Overall, in both ways of toxin administrations no 
hydrolyzed forms in bile and urine secretions were detected. Thus, it was 
demonstrated that the principal site of fumonisin metabolism is in the gut (and not in 
the liver) [35].  
In the case of pigs, they were fed 45 mg FB1/kg b.w., for 10 days. It was 
established that from 1 to 3.9 % of the administered dose was converted into 
aminopentol and partially hydrolysed FB1 in chymus (intestine contents). 41%, 47% 
and 12 % of total FB1 in feces were recovered as unhydrolyzed, partially hydrolysed 
and totally hydrolysed (AP1) forms, respectively. While, 65%, 24% and 16% of total 
FB1 in urine was detected as intact, partially hydrolysis and full hydrolysis forms, 
respectively [74].  
In the case of ruminants, Rice and Ross (1994) estimated that rumen microflora 
could metabolize 60-90% of FB1 oral dose to hydrolyzed forms (aminopolyols and 
aminopentol) in cattle and sheep feces [36]. In contrast, Smith and Thakur (1996) 
mentioned that more than 80% of FB1 oral dose were excreted in feces as 
unmetabolized form, and that there was no detection of hydrolyzed form in feces or 
urine [52]. These results were confirmed by F. Caloni (2000-2002), which proved that 
FB1 is poorly metabolized in the rumen, after incubating 1 mg/ml of FB1 in ruminal 
fluid for up to 72 hours. HFB1 is not detected at the end of experiment [69-136].  
There is no evidence concerning FB1 metabolized by liver microsomal 
enzymes, such as cytochromes P450. Spotti-m (2001) published the results that 
bovine liver microsomal enzymes are unable to metabolize FB1 to any hydrolyzed 
forms such as aminopolyol 1, aminopolyol 2 or aminopentol after incubating FB1 
with bovine microsomes for 1 hr [61]. This result conforms to previous data obtained 
in rats, which had established that FB1 was not metabolized by microsomal enzyme 
[62]. Therefore, the tolerance of ruminants to FB1 is apparently not related to their 
detoxification activity by rumen or hepatic microsomes activity. However, it is 
dependent on their lower bioavailability.  
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Second metabolism of HFB1 to N-acyl-derivatives (Cn-HFB1 = C16, C18, C20, 
C22, C24 and C24:1) by the ceramide synthase were documented for the first time in 
rats, after intraperitoneal injection of 1120 µg/kg b.w. for four days. Those acylation 
metabolites products have fluctuated cytotoxic effects comparing to HFB1. C16 and 
C24:1 has potential reducing effect on the number of viable HT29 cells, and inhibits 
ceramide synthase in cell culture [72-192].  
There is no data regarding avian ability to hydrolyze FB1.  
Concerning FB2, in feces of monkey after oral exposure to single oral dose 7.5 
mg FB2/kg b.w., 6% of the dose was recovered as not metabolized, 47% was detected 
as partially hydrolyzed and 1.1% as fully hydrolyzed (aminopolyols) [51]. By 
contrast, pig gut microflora was unable to metabolize FB2. This description was 
carried out after feeding pigs with 8.6 mg FB2/kg b.w. for 10 days. 23% and 6% of 
total FB2 in feces and urine respectively were detected as intact molecules 
(unhydrolyzed form) [74].  
Consequences of fumonisin metabolism in terms of toxicity are not fully 
documented. A study was conducted in piglets exposed by gavage to purified 2.8 
µmol FB1 or HFB1/kg b.w. /day, for 2 weeks. Histopathology results recorded mild 
to moderate hepatic damage, which indicated by presence of nuclear vacuolization of 
hepatocytes, megalocytosis and signs of hepatic necrosis in animal group exposure to 
FB1. By contrast, animals exposed to HFB1 have similar results as control animals. 
That means that HFB1 does not induce liver damages. Biochemical analyses also 
introduced evidence of liver damage by increased concentrations of serum albumin, 
total protein, cholesterol, triglycerides, fibrinogen and gamma-glutamyl transferase 
(GGT) in groups treated with FB1 at the 7 th and 14 th days after exposure. Conversely, 
no change in the serum biochemical analysis was detected at the 7 th and 14 th days in 
animals which had ingested HFB1. Mild to moderate small intestinal lesions 
indicated by lymphatic vessel dilation and interstitial edema in the proximal small 
intestine, a decrease in villi height and atrophy were obtained in FB1 treated animals. 
No significant intestinal lesions were obtained in HFB1 and control groups. Sa:So 
ratio increased by 8–10 times in the serum and 28 times in the liver of treated animals 
with FB1 compared to control animals. By contrast, only slight augmentations in 
Sa:So ratio was recorded in liver treated animals with HFB1. FB1 had significant 
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alterations in cytokines production in liver and small intestine lymph nodes, which 
led to increase IL-1β and IL-8, and decrease IL-2, IL-6, INFα and INFγ in them. 
Conversely, HFB1 had only slightly decreasing effect on IL-6 of liver and small 
intestine lymph nodes [166].Thus, it is suggested that the less toxic effect of HFB1 is 
related to its slight disrupts of sphingolipids metabolism and slight 
immunosuppression. Therefore, conversion of FB1 to hydrolyzed forms could be a 
good strategy to reduce FB1 toxicity. Nevertheless, the secondary metabolism of 
HFB1 does have cytotoxic effects in vitro and small immunosuppression in vivo [166]. 
4. Excretion 
Data obtained in different animal species by using FB1 are synthetized in table 
4, and compared to results obtained with FB2 in table 5. Studies conducted with 
radiolabelled or unlabelled FB1 demonstrate a rapid elimination half- life (10 to 180 
min) and a rapid clearance (below 30 ml/min/kg). Because FB1 is poorly absorbed, 
the elimination kinetics of FB1 is not easy to describe after oral administration. In 
addition, bile secretion plays an important role in elemination of FB1. 
 In rats, 67% and 25% of administered single dosage of 7.5 mg FB1/kg b.w, by 
ip injection and gavage were recovered in bile secretion and urine, respectively, after 
24hr post toxicant [33-64].  
In pigs, a single dose of 0.4 mg [14C] FB1 /kg b.w. was applied intravenously 
to normal pigs and bile duct cannulated pigs. The results obtained proved that, 70.8% 
of the applied dose was recovered in the biliary within 72 hours. Furthermore, the 
elimination half life in cannulated pigs was ten times faster than in non-cannulated 
pigs (T1/2β was 17.1 and 182 min, respectively). That means FB1 is accumulated in 
the bile gland then re-absorbed from the intestines [31]. 
Excretion of FB1 seems more important in ducks than in turkeys and laying 
hens. Clearance in ducks, turkeys and laying hens were 19.6, 7.6 and 1.18 
ml/min/kg, respectively. Elimination half-life was 26, 85 and 48 min, respectively, 
(table 4) [23-24-30].  
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Table 4: Excretion of FB1  
Animals Route Dose1 Parameters  Ref 
Rats 
Oral 0.69*  
0.5% of dose recovered in urine, 1.4% excreted in bile at 
4 hr after dosing 
[71] 
IV 2 
T1/2β: 62 min  
CL: 1.2  
[32] 
IP 7,5 
16-25% recovered in urine 48 hr after dosing 
67% recovered in bile 24 hr after dosing 
[33-
64] 
Oral 7,5 2% recovered in bile 24 hr after dosing [64] 
Oral 10 T1/2β: 205 min [32] 
Monkeys 
Oral 6,4* 62% of dose recovered in feces 24 hr after dosing [35] 
IV 1,6 T1/2β: 40 min [55] 
Pigs 
IV 0.4* 
Pig: T1/2β :182 min 
Cannulated pig : T1/2β :17.1 min 
70.8% of dose recovered in bile 72 hr after dosing  [31] 
Oral 0.5* 
90% of dose recovered in feces , less than 1% excreted in 
urine and bile 72 hr after dosing 
Cow IV 0,05-0,2 T1/2β: 17 min [34] 
Laying 
Hens 
IV 2* 
T1/2β: 48.8 ± 11.2  
CL: 1.18 ± 0.15 
98.6 % of dose recovered in excreta 24 hr after dosing [30] 
Oral 2* 
T1/2β: 116. 
6.6 % of dose recovered in excreta 24 hr after dosing 
Turkeys 
IV 10 
T1/2β: 85  min                    
CL: 7.6 
[24] 
Oral 100 
T1/2β: 214 min                   
CL: 7.5 
Ducks 
 
IV 10 
T1/2β: 26 min                    
  CL: 19 
[23] 
Oral 100 
T1/2β: 70 min                      
CL: 17 
1 single dose (mg/kg b.w.) of FB1 or *[14C] FB1;  
T1/2β (min): Elimination half life; Cl ( ml/min/kg): Clearance 
Concerning FB2, in rats, eliminated quantity via renal route is lower (1.2% of 
dose) than FB1 (16-25% of dose) by using same dose of toxin and protocol of 
experimental (table 4 and 5) [28-64]. Also in pigs, the eliminated quantity of FB2 was 
lower than FB1 by 9 and 14 times through urine and feces, respectively, after oral 
adminstration of 50, 20, and 5 mg of FB1, FB2, and FB3 respectivily, per animal, per 
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day, for 22 days [206]. In contrast, in monkeys the elimination half-life of FB1 (40 
min) was longer than the one of FB2 (18 min) (table 4 and 5) [51-55].  
Table 5: Excretion of FB2 
Animals Route Dose1 Parameters Ref 
Rat 
IP 7.5  
T1/2β: 26 min.  
84.1% recovered in feces 72 hr after dosing 
1.2 % recovered in urine 72 hr after dosing [28] 
Oral 7.5  
82% recovered in feces 72 hr after dosing 
0.2 %recovered in urine 72 hr after dosing 
Monkeys 
IV 2  
T1/2β: 18 min 
Less than 50% recovered in feces 168 hr after dosing 
4.1 % recovered in urine 168 hr after dosing [51] 
Oral 7.5  
Less than 50% recovered in feces 168 hr after dosing 
0.2 % recovered in urine 168 hr after dosing 
1 single dose (mg/kg b.w.) of FB2;  
T1/2β (min): Elimination half life; CL ( ml/min/kg): Clearance 
5. Residual  
Residual of FB1 labelled and unlabelled in tissues are presented in tables 6 and 
7. The accumulation of FB1 was more significant in the kidneys than in the liver in 
rats treated with single oral dose of 10 mg FB1/kg b.w. [32]. These results are 
supported by other data obtained with rats, which demonstrates that FB1 residual in 
kidneys was 10 times higher than in the liver [26]. By contrast, residual of FB1 was 
more pronounced in liver than in kidney in pigs feed 45 mg/kg b.w., for 10 days [26], 
in monkey exposure to single oral dose of 6.42 mg14C-FB1/kg b.w. [55], in turkeys 
feed 20 mg FB1+FB2/kg b.w., for 9 week [24], and in ducks feed 20 mg FB1+FB2/kg 
b.w., for 12 days [23], (table 6 and 7).  
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Table 6: Residual of [14C-FB1]  
Animals Route Dose1       Organs residual Ref 
Monkeys 
IV 1.72 
Dose recovered 24 hr after dosing:   
Liver: 1.92%.  
Kidney: 0.37%.  
Muscles: 0.62%.   
Brain, Lung, heart and spleen: traces 
[35] 
oral 6.42  
Dose recovered 24 hr after dosing:  
Liver: 0.64%.  
Kidney: 0.03%.  
Muscles: 0.14%.  
Brain, Lung, heart and spleen: traces  
oral 8  
24 hr post dosing. Muscle: 1%. Liver: 0, 4%. 
brain : 0,2% 
[55] 
Pigs 
IV 0.4 
1076 ng/g recovered in liver 72 hr after dosing. 
486 ng/g recovered in kidneys 72 hr after dosing. 
[31] 
Oral 0.5 
107 ng/g recovered in liver 72 hr after dosing. 
48 ng/g recovered in kidneys 72 hr after dosing  
Laying 
hens 
IV 2 
Traces recovered in liver, kidney and crop, but 
not in eggs 24 hr after dosing 
[30] 
Oral 2 
Traces recovered in liver, kidney and crop, but 
not in eggs 24 hr after dosing 
1 single dose (mg/kg b.w.)  
 
In another experiment, pigs were exposed to contaminated feed with mixture 
of FB1, FB2 and FB3 (45, 8.6 and 4.6 mg/kg b.w., respectively) for 10 days. One 
should ignore the numbers obtained in this study, because the sampling time was not 
recorded precisely. Nevertheless, the results showed that, accumulation of FB1, 
HFB1, AP1 and FB2 could be detected in many parts of the carcass such as liver, 
kidneys, lung, spleen, brain, muscle and fats at different percentages. Liver has the 
highest residual quantity of FB1 compared to other organs, and equal residual 
quantity was obtained in kidneys and muscles. HFB1 residue is more concentrated in 
muscles compared to other tissues. HFB1 is not recovered in the brain. AP1 residual 
is more pronounced in muscles and fats compared to other tissues. The percentage 
shares of FB1 and its metabolic forms residue in the overall body tissues are: 50% in 
the form of intact FB1, 20% in the form of partially hydrolyzed and 30% in the form 
of aminopentol. Ten days after the last toxin exposure dosages, FB1 residual could be 
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detected in all organs and tissues tested. The highest one was observed in the liver, 
and smallest one detected in the brain. Only small quantity of HFB1 remained in the 
spleen and fat, while AP1 still presents overall small quantities in all animal tissues. 
Concurrently, ten days after the last administration dose of FB2, small quantities 
were recovered in muscles and kidneys, (table 7) [74].   
Table 7: Residual of fumonisins after oral exposure 
Animals Dose  Organs residual (µg/kg or µg/L) Ref 
Rats 
One dose 10 mg 
FB1/kg b.w. 
FB1: 2% in liver, and 30% in kidneys [32] 
Pig 
10 days feeding  
FB1, FB2 and FB3  
45, 8.6 and 4.6 mg/kg 
feed, respectively 
FB1: 17 liver, 10 kidney, 8 muscles and < 5 in other tissues. 
HFB1: 5 muscles, < 2.5 in other tissues  
AP1: 7.5 kidneys, 5.6 abdominal fat, < 1 in other tissues. 
FB2: 6 muscles, < 1 in other tissues  
[74] 
3 week  0.91 mg 
FB1+FB2/kg feed 
then 4 weeks: 2.34 
FB1+FB2/kg feed 
FB1: 28 liver 
FB2: < 10 in all tissues 
 [73] 
Cattle 
One dose 
1-5 mg FB1/kg b.w. 
FB1 and AP1: < 0.00 7 and 0.025 in milk, respectively  
[34-
38] 
3 mg FB1/kg b.w. / 
day, 14 days 
FB1 and AP1: < 0.005 in milk  [137] 
Turkey 
20mg FB1+FB2/kg 
feed,  9 week 
8 hours after the last meal: 
Liver: 117; Kidney: 22  
Muscles: < 13 
[24] 
Duck 
20 mg FB1+FB2/kg 
feed, for 12 days  
8 hours after the last meal: 
Liver: 20; Kidney and  muscles: < LD 13 
[23] 
 
At present, there is no information regarding ability of FB1 to persist in cattle 
tissues or bovine products. For example, cows were inculcated directly into the 
rumen with 1.0 mg or 5.0 mg FB1/kg of b.w. The results showed that there was no 
FB1 detected in the serum or milk. This phenomenon was expected due to lower 
bioavailability of FB1 in ruminants, (table 7) [34].  
In avian species, such as laying hens, it has been demonstrated that less than 1% 
of oral dose [14C] FB1 is residual in the tissue, but none in the eggs, (table 6) [30]. 
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Similar results have been obtained with unlabelled FB1 in ducks and turkeys after 
feeding them for several days with contaminated maize with 20 mg FB1 + FB2/kg of 
feed. The findings show that less than 1% of the oral dose is residual in the livers of 
ducks and turkeys. In addition, FB1 residual in liver is more distinct than the one in 
kidneys and muscles in both species. Also, the FB1 residual is more pronounced in 
turkey livers than duck livers (117- 20µg/kg of tissue, respectively) (table 7) [23-24]. 
Residual of FB1 in kidneys and liver are less pronounced in ducks and turkeys than 
in rats even if the animals have similar bioavailability. This result is probably due to 
the high clearance in ducks and turkeys, compared to rats (19.6, 7.5 and 1.2 min, 
respectively) (table 4) [23-24-32]. 
Data concerning the residual of FB2 has been poorly documented. However, 
residual of FB1 and FB2 was found in the lungs, heart, liver, kidneys, spleen, brain, 
serum, bile, muscle and fat by varying percentages in pigs fed on a mixture of FB1, 
FB2 and FB3 (50, 20 and 5 mg /head/day, respectively), during a 22 day period. The 
highest FB1 concentrations were found in the liver and kidneys (99.4 and 30.6 ng/g 
of tissue, respectively), While the highest concentrations of FB2 were detected in the 
fat and liver (2.6 and 1.4 ng /g of tissue, respectively). The ratio of FB1/FB2 residuals 
in different pig organs is 19/1%, whereas in fat samples it is 4/1%. That means 
residual of FB1 is more important than FB2 in all body tissues [206]. That revealed to 
residual of FB1 was more pronounced than FB2 in all body tissues.  
Other study has recovered the FB2 residual in all body tissues of pigs, with high 
concentration in fat, muscles tissues, and liver after ten days of last administered 
dose, (table 7) [73-74]. These data allude to the risk of FBs residual being present if 
introduced to a consumer (animals or human) with other mycotoxins.  
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6. Conclusion  
The literature reviews reveal that fumonisins generally have low 
bioavailability (less than 5% of an administration dose). However, differences 
between species can be observed. For example, absorption is four times higher in 
pigs than in cattle, and residual of fumonisin is detected in all parts of a pig carcass, 
while it is not recovered in cow’s milk or tissues. Concerning the avian species, 
bioavailability of FB1 it is around three times lower in layer hens than in turkeys. In 
ducks and turkeys, it appears that the bioavailability of FB1 in turkeys represents 
160% of the value in ducks (table 8). 
Table 8: Toxicokinetic and residual of FB1 in ducks and turkeys 
Parameter Duck Turkey 
FB1 single dose  
(100 mg/kg b.w.) 
  
T max (min) 120 180 
C max (µg/ml) 0.628 ± 253 0.991 ± 0.061 
T1/2α (min) 74 ± 4 29.4 ± 3.3 
T1/2β (min) 71 ± 3 214 ± 36 
T1/2 Ka (min) 66 ± 4 44 ± 4 
AUC (µg/ml/min) 121 ± 9 443 ± 32 
F (%) 2 ± 0.1 3.2 ± 0.2 
MRT (min) 200 ± 12 408 ± 43 
MAT (min) 176 356 
Cl (ml/min/kg) 16.7 7.5 
Vdarea (L/kg) 1715 ± 82 2313 ± 388 
Vc (ml/kg) 179 ± 14 111 ± 21 
FB1+ FB2  
(20 mg /kg feed) 
2 weeks  9 weeks 
FB1 liver (µg/kg) 20± 6 117 ± 50 
FB1 kidneys (µg/kg) <LD 22 ± 8 
Values are expressed as mean ± SE  
Tmax: time of occurrence of maxima concentration of FB1 in serum; Cmax: maxima concentration 
of FB1 in serum; T 1/2 α: half-life at α; T 1/2 β: terminal elimination half-life; T1/2Ka: absorption 
half-life; AUC: area under plasma concentration-time curve from t = 0 to infinity; F: extent of 
systemic absorption based on the determination of the ratio between AUC obtained after oral 
administration and the AUC obtained following the oral administration corrected by the dose 
used; MRT: mean residence time; MAT: mean absorption time; Cl: total plasma clearance; Vdarea: 
volume of distribution; Vc: volume of the central compartment; LD: limit of detection = 13µg/kg  
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Interspecies variations are also observed concerning the elimination half-life 
and clearance. Although elimination half-life is short in all tested animals species 
(T1/2β: 10 to 180 min), the toxicity of FBs appeared cumulative (see below) and 
residual appeared to cumulate in pigs. Concerning the avian species, clearance of FB1 
it is around six times lower in layer hens than in turkeys. In ducks and turkeys, it 
appears that the clearance of FB1 in ducks represents 220% of the value in turkeys 
(table 8). Finally, together absorption and clearance could explain that the residual of 
fumonisins in turkey livers are 585% of those in ducks liver (table 8). 
Only few data are available concerning the metabolism of fumonisins and the 
toxicokinetics of FB2 other than FB1. There is a disagreement about the possibility of 
metabolism FB1 to HFB1 in ruminants whereas HFB1 and AP1 were detected in pig 
carcass. No data is available in the avian species. Concerning FB2, absorption and 
elimination seem lower than FB1 in rats and monkeys whereas, residual of FB2 is 
recovered in all body tissues of pigs, suggesting that the toxicokinetic of FBs is quite 
different from FB1. No data is available in the avian species. 
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III. Fumonisin toxicity  
This chapter will present the most important toxicological studies in 
laboratory and farm animals which are at the origin of the recommendations of 
maximum levels for fumonisins in animals and human foods.  
Toxicity in laboratory animals was presented according to the duration of the 
study (acute, short term, long term exposure) to present organ toxicity and risk of 
cumulative effect. Genotoxicity and reproductive toxicity were also presented as 
target for fumonisins toxicity. When data are available, specific analysis of the effect 
of sex and strain were reported. A table was done to present the NOEL (no observed 
effect level) in this species. 
Toxicity in farm animal was presented depending on the species naturally 
exposed to fumonisins to show species difference in toxicity (dose) and target organs. 
Data concerning the avian species were specially analyzed and synthetized to 
understand interspecies variation in this group of animal species, that is often 
considered as a homogeneous group. High, low and intermediate sensitivity species 
were separated depending on the dose necessary to produce an effect. A species was 
considered as "resistant" when no adverse effect is observed in farming condition (no 
report of toxicity) whereas it was called “sensitive” when toxicity (clinical signs or 
mortality) could occur. At the end of this chapter, two tables report the European and 
FDA (food drug administration) guidance levels for fumonisins in animal feed. A 
specific table was done for the FDA-recommended maximum levels for fumonisins 
in human food. 
Specific effects of fumonisins on sphingolipids metabolism and biochemistry 
are shortly presented in this chapter. A specific analysis of the consequences of FBs 
exposure on theses parameters is done in paragraph VI, after presentation of 
mechanism of action of the toxins. 
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1. Laboratory animals 
1.1. Acute toxicity (single dose exposure) 
No studies have been published on the lethality of single doses of pure FB1 on 
laboratory animals. In previous data, it was demonstrated that FB1 had no fatal effect 
after mice had been given a single dose of 25 mg/kg b.w. by gavage or subcutaneous 
injection. Results showed reversible alterations in cytokine expression, serum 
enzymes activity, and blood cell counts [81].  
Renal tubules proliferation, death of cells (apoptosis) and severe nephrosis 
were observed in male Sprague-Dawley rat after intravenous single dose of 1.25 mg 
FB1/kg b.w. Cell proliferation was also detected in the liver [75]. 
Male Wistar rats were treated with single FB1 doses 5, 50, and 500µg/kg b.w. 
by gavage route. The animals were sacrificed at the 4th, 24th   and 48 th hours after 
treatment. No difference between control and treated animals was found in relation 
to oxidative stress. Histopathological changes in liver were spelled out by a 
significant increase in apoptotic cells and cell necrosis. Cell necrosis was observed at 
the end of study with all dose levels. Increase in apoptotic cells was observed 24 
hours after applying a dose of 5µg/kg b.w. meanwhile, at doses of 50, and 500µg/kg 
b.w. it took between 4 and 48 hours [86]. This study proved that fumonisin toxicity is 
time and dose-dependent 
1.2. Short-term studies of toxicity 
1.2.1. Animal Species   
Previous studies had reported that rabbits were more sensitive to FB1 
nephrotoxicity effects than rats and mice. These findings were recorded after 
exposing animals to different doses of toxins, via different administration routes as 
follows:  
Rabbits were treated intravenously with 0.15, 0.3, 0.5, and 1.0 mg FB1/kg b.w., 
for 4 or 5 days. After multiple doses, signs of animal toxicity appeared in lethargy, 
and decreased urine production. At the end of the experiment, signs of 
nephrotoxicity, such as elevation of serum creatinine and urea nitrogen, and urine 
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protein, and signs of hepatotoxicity like elevation in liver biochemical parameters 
(enzymes and total bilirubin), ballooning degeneration, hepatocellular swelling, and 
bile stasis were observed with all doses. Disturbance of sphingolipids metabolism 
appeared in the liver, kidneys, muscles, serum, and urine, but not in the brain. This 
disturbance of sphingolipids metabolism was more pronounced in the kidneys than 
in other tissues [78].  
Males and females of B6C3F1 mice and Fischer 344 rats were fed diets 
containing 0, 1, 3, 9, 27, or 81mg FB1/kg/day for 13 weeks. In both species, no 
differences were recorded between control and treated groups concerning animal 
behaviour, appearance, body weight, or food consumption. Male and female F344 
rats show nephrotoxicity by consuming 27 mg FB1/kg/day. No effect on 
nephrotoxicity was obtained in both sexes of mice for all doses. These results 
demonstrated that Fischer 344 rats were more sensitive to renal toxicity than B6C3F1 
mice [79]. 
Male and female B6C3F1 mice were fed diets containing 100-500 mg FB1/kg 
for 28 days, whereas, Fischer 344 rats were fed diets containing 99, 163, 234 or 484mg 
FB1/kg for 28 days. No signs of nephrotoxicity were obtained in mice, whereas, 
hepatotoxicity was obtained in males and females mice fed with diets containing 250-
500 mgFB1/kg. In both sexes of rats, nephrotoxicity was achieved with the lower 
contaminated diet; hepatotoxicity signs such as biliary hyperplasia and 
hepatocellular degeneration were observed at the 163 mgFB1/kg level in diet. These 
results matched with previous studies which had reported that rats were more 
sensitive to nephrotoxicity than mice [80].  
1.2.2. Animal Strains 
In the case of male BD IX rats which consumed a diet containing 1 g FB1/kg of 
feed for 28 days the mean body weight reduction was 50% lower than the control 
group [8]. Concurrently, in male Fischer 344 rats fed 1g FB1/kg of feed for 26 days 
the mean body weight reduction was 80% lower than the control group [89]. 
In male Sprague-Dawley rats and male F-344 rats, nephrotoxicity symptoms 
such as nephrosis, necrosis epithelial cells, and apoptosis were observed at all 
exposure doses of FB1. By contrast, no signs of nephrotoxicity were observed in 
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BDIX- male rats after consuming high doses of FB1. These results came to light after 
feeding male Sprague-Dawley rats with contaminated diets at concentration of 0, 1.4, 
4.4, and 13.5 mg FB1/kg b.w. per day for 4 weeks, male F-344 rats were fed on diets 
containing 0.7, 3.5, 6.8, 15 and 25 mg FB1/kg b.w. per day for 21 days, and BDIX- 
male rats fed diet contain 70mg FB1/kg b.w. per day for 90 days [76-79-81-84]. 
Male transgenic p53+/− and corresponding wild-type mice were fed diets 
containing FB1 (97%) at levels of 0, 5, 50 or 150 mg/kg diet, for 26 weeks. In both 
strains liver weight was not affected. In mice transgenic p53, hepatic necrosis and 
apoptosis were observed at medium and high dose treated groups, whereas in wild-
type mice, hepatic necrosis and hepatic apoptosis was only recorded in the high dose 
treated group [88]. 
It can be summarized that Sprague-Dawley and Fischer rats are more sensitive 
to body weight reduction and nephrotoxicity caused by FB1 toxicity than male BDIX-
rats. Also, wild-type mice are more resistant than p53 mice to the FB1 effects of 
decreased body weight and hepatic apoptosis. Based on the above mentioned 
information, it can summarize that fumonisin toxicity is different between same 
animal species, and animal strains play important role in the progression of FB1 
toxicity 
1.2.3. Animal Sex 
Male and female Sprague-Dawley rats were fed diets containing 0, 15, 50 and 
150 mg FB1/kg, for 4 weeks. Daily intake was estimated to be 1.4, 4.4, and 13.5 
mg/kg b.w. In both sexes, hepatotoxicity signs such as modification of biochemistry 
and hepatocellular necrosis were observed only with dietary level 150 mg FB1/kg. 
The NOEL of liver was 4.1–13 mg/kg b.w. per day. On the other side, nephrosis was 
obtained in males fed contaminated diet of more than 15 mgFB1/kg, and in females 
fed contaminated diet of more than 50 mg/kg. The NOEL of kidneys is less than 1.4 
mg/kg b.w. per day in males, and about 1.4 mg/kg b.w. per day in females. These 
results demonstrated that male Sprague-Dawley rats are more sensitive to FB1 
nephrotoxicity than female [76-79]. 
Male and female F344 rats consumed diets contaminated by 99, 163, 234 and 
484 mg FB1/kg of feed, for 28 days. Hepatic toxicity signs (biliary hyperplasia, 
  
28 
hepatocellular degeneration, and hepatocellular apoptosis) were more pronounced in 
female rats which had received contaminated diet of more than 163 mg FB1 /kg, and 
in male rats which had received contaminated diet of more than 234 mg FB1 /kg. By 
contrast, renal toxicity signs more was pronounced in males fed with dose of 99 mg 
FB1/kg, and in females fed with dose of 163 mg FB1/kg. These results proved that 
female rats are more sensitive than males regarding hepatotoxicity. By contrast, renal 
toxicity is more pronounced in male than in female [77-80]. 
B6C3F1 mice and Fischer 344 rats were fed diets containing 0, 1, 3, 9, 27, or 81 
mg FB1/kg/day for 13 weeks. No difference in behavior, appearance, and body 
weight or food consumption between control and treated groups was detected.  
Male rats were more sensitive than female rats F344 to nephrotoxicity (3 < 
male NOEL ≤ 9 mg FB1/kg/day, and 27 < female NOEL ≤ 80 mg FB1/kg/day). 
Hepatotoxicity was observed in female rats fed contaminated diet of more than 27mg 
of FB1 (27 < female NOEL ≤ 80 mg FB1/kg/day), whereas, male rats were not 
affected even with contaminated diets of 81 mg FB1/kg for 90 days (81mg < male 
NOEL).  
Concerning B6C3F1 mice, nephrotoxicity was not recorded in male and 
female, whereas, hepatotoxicity was only observed in female. Those results 
illustrated that male Fischer 344 rats were considerably more sensitive to renal 
toxicity than female rats. By contrast, female Fischer 344 rats were more susceptible 
than male rats to liver toxicity. Also female B6C3F1 mice were more sensitive to 
hepatotoxicity than male mice [79].  
1.2.4. Animal Organs 
Male and female Sprague-Dawley rats were fed diets containing 0, 15, 50 and 
150 mg FB1/kg, for 4 weeks. Estimated daily intake was about 1.4, 4.4, and 13.5 mg 
FB1/kg b.w. per day. Data compiled for both sexes demonstrated that liver was less 
sensitive to fumonisin toxicity than kidneys. The average of liver NOEL was about 
4.1–13 mg/kg b.w. per day, while kidney NOEL was equal or less than 1.4 mg/kg 
b.w. per day, (table 9). [76-79].  
The results obtained with Sprague-Dawley rats were supported by a study 
conducted on rats F-344 fed with contaminated diets 10, 50,100,250 and 500 mg 
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FB1/kg for 21 days. Intake was estimated at 0.7, 3.5, 6.8, 15 and 25 mg FB1/kg b.w. 
per day. Nephrosis, cells necrosis and apoptosis were obtained with a lower 
contamination diet 10 mg FB1/kg, or 0.7 mg FB1/kg b.w. per day. Meanwhile, 
hepatic cell necrosis, apoptosis, and endothelial cell proliferation were observed on 
animals fed a diet of 50 mg/kg or 3.5mg/kg b.w. per day. These results proved that 
kidneys were more sensitive to fumonisin toxicity than liver [84]. 
Male BALB/c mice received a subcutaneous dose of FB1 at 0.3, 0.8, 2.3, or 6.8 
mg/kg b.w. per day for 5 days. Decreased kidney weight was observed one day after 
the last injection at all doses. While liver weight did not show any effects by all 
dosages. Dose-dependent increase apoptosis and accumulation of free sphingolipids 
were obtained in liver and kidneys. Apoptosis was detected in the livers of mice at 
doses > 0.8 mg/kg b.w. per day and in the kidneys at all doses. If it is assumed that 
10% of an oral dose would be absorbed in mice, the estimate of NOEL for oral 
administration would be less than 0.3 and 0.8 mg FB1/kg b.w. per day in kidney and 
liver, respectively, (table 9) [82-83]. 
1.3.  Long-term studies of toxicity and carcinogenicity 
F344 rats and B6C3F1 mice were fed for two years a diet containing the 
following concentrations of FB1: female rats, 0, 5, 15, 50, and 100 mg FB1/kg of feed; 
male rats, 0, 5, 15, 50, and 150 mg FB1/kg of feed; female mice 0, 5, 15, 50, and 80 mg 
FB/kg of feed; male mice, 0, 5, 15, 80, and 150 mg/kg of feed. Decrease in body 
weight was observed only in female F344 rats which had consumed contaminated 
diet of 100 mg/kg. Whereas, no difference in body weight between control and 
treated groups was observed in Male F344 rat, female and male mice fed highest level 
of contaminated diets. Tubule adenomas and carcinomas were demonstrated in male 
F344 rats with mild and high dose 50-150 mg FB1/kg. No tumorigenic signs were 
mentioned in females with a high dose of 100 mg FB1/kg. Hepatocellular adenoma 
and carcinoma were demonstrated in female mice with all concentrated diets. 
Whereas, those signs were not observed in male mice fed 150 mg FB1/kg. This study 
proved that FB1 is a rodent carcinogen that induces renal tubule tumours in male 
F344 rats and hepatic tumours in female B6C3F1 mice [90]. 
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Male BDIX rats received diet containing 50 mg FB1/kg of diet, equivalent to 
1.6 mg FB1/kg b.w. per day, for 26 month. Signs of hepatic preneoplastic changes 
such as hepatic nodules and cirrhosis were observed at 18 months after exposure. 
Development of primary hepatocellular carcinoma was reported 18-26 months after 
exposure. At the end of the study, no lesions were demonstrated in the esophagus, 
and heart [10]. 
The dose–response relationship between FB1 and hepatocarcinogenesis was 
investigated in BD IX rats fed a diet containing FB1 at a concentration of 1, 10, or 25 
mg/kg of feed, for 2 years. The carcinogenicity markers such as apoptosis, 
proliferation of duct epithelial cells, and mild fibrosis led to a slight distortion of the 
liver architecture in some rats. Necrosis, apoptosis and calcification were observed in 
the tubular epithelium cells of the kidneys. All these lesions were mainly present 
with 25 mg/kg of diet and to a lesser extent with 10 mg/kg of diet, or mean daily 
intakes of 0.8 and 0.3 mg/kg b.w, respectively [45]. 
Male BDIX rats were fed maize contaminated with F. verticillioides MRC 826 
culture material for 849 days. This strain was isolated from an esophageal cancer 
outbreak area in South Africa. Rats were fed a diet containing 6.9 mg FB1/kg b.w. 
per day, for 288 days. Then, they were administered a diet containing 3.2 mg FB1/kg 
b.w. per day, for 606 days. 80% and 63% of the cases developed hepatocellular 
carcinoma and ductular carcinoma in the liver, respectively. Indeed, in several cases 
there were occurrences of cirrhosis and nodular hyperplasia in the liver, pulmonary 
metastases, adenofibrosis, neoplastic lesion and endothelial hyperplasia of the 
endocardium membrane. Esophageal hyperplasia was obtained in 50% of the treated 
rats. No lesions were found in the kidneys [19]. 
Male and female vervet monkeys were fed contaminated diets with F. 
verticillioides MRC 826 for 13.5 years. The equivalent to average doses was 
approximately 8.2-13 mg FB1/kg diet. Toxicity monitors such as clinical chemical 
analysis, serum biomarkers and blood accounts were conducted bimonthly. Liver 
biopsy samples were taken at regular intervals for the first 4.5 years. Typical liver 
lesions were obtained at high doses including: portal fibrosis, hepatocytes nodules, 
bile duct proliferation and apoptosis. Kidney histopathological changes examinations 
were not conducted. Lower observed effected level (LOEL) for sphingolipids changes 
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in serum was 22 to 48 mg/kg diet, equivalent to 0.29-0.64 mg/kg b.w. per day. Other 
parameters that were also affected throughout the study included lipid parameters 
associated with hypercholesterolemia. Blood account refered to significant decreased 
in white and red blood cell and platelet counts [81]. 
1.4. Genotoxicity 
Genotoxicity of FB1 has been measured in vivo and in vitro. The results of 
several independent studies showed evidence indicating that FB1 can damage DNA 
indirectly by increasing oxidative stress. Oxidative damage was closely associated 
with FB1-induced hepatotoxicity and induction of preneoplastic lesions in vivo. 
Serum microsomal membranes, mitochondria and nuclei appeared to be significantly 
affected by lipid peroxidation [81]. Kidneys DNA damage due to increased ROS 
production was observed in male Wistar rats exposed to intraperitoneal injections of 
500 µg FB1/kg b.w. per day for 7 days [93]. Also, liver DNA damage was obtained in 
Wistar rats after single oral doses of 5, 50 and 500 µg FB1 /kg b.w. [86]. Male F344 
rats consumed initiated phase diets consisting of a control diet or a diet containing 
FB1 at 250 mg/kg for 3 weeks. Those were followed by promotion phase diets 
consisting of control diets or diets containing phenobarbital at 500 mg/kg for up to 
30 weeks. The results obtained showed that liver foci associated with hepatotoxicity 
were observed only in rats treated with FB1 and followed by Phenobarbital.  
Consequently, those results suggested that FB1 may have cancer-promoting 
potential via oxidative damage and genotoxicity properties [94]. 
1.5. Reproductive toxicity 
The neural tube is responsible for forming the brain and spinal cord.  Failure 
of the neural tube to close in the first few weeks of embryonic development leads to 
congenital malformations called neural tube defects (NTDs). The real etiology of 
NTDs is unknown, but there are many implicated factors such as: FB1 contaminated 
diet, B12 deficiency or over activation of S1P receptor-mediated signaling pathways 
[81-89-208]. 
In 1990-1991, NTDs were highly occurring in the state of Texas, United States 
of America, affecting approximately 29 of every 10,000 babies born. Concurrently, the 
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Health department of Texas suggested that Texan population was consuming large 
quantities of corn. Therefore pregnant women may have been exposed to high levels 
of FB1, which increased the risk of NTDs [209-210]. The statistical data of the Health 
department of Texas from the period 1999 - 2004 recorded significant decline in 
NTDs down to approximately 5 to 6 of every 10,000 babies in pregnant women who 
took supplements with folic acid (B12) [211]. 
In vitro the inhibitor effect of FB1 on biosynthesis of the folate receptor (GPI-
anchored protein) is proved. This inhibition leads to deficiency in folate (B12), which 
is associated with an increased risk of neural tube defects (NTDs). However, the 
inhibition of the folate transporters by FB1 in vivo has not been confirmed by feeding 
studies [81-89].  
Neural tube defects (NTDs) were induced in pregnant LM/BC mice at 
embryonic days 7.5 and 8.5, via intraperitoneal injection with pure FB1 0, 5, 10, 15, 20 
mg/kg b.w. per day, and the fetuses were collected at embryonic day 17.5.  The 
results proved that embryonic malformations were dose-dependent. 79% of the mice 
fetuses exposed to the highest dose of 20 mg/kg b.w. per day had exencephaly 
(when brain is located outside of the skull), whereas NTDs was observed at all 
dosage levels. Also, FB1 induced a significant alteration of sphingolipids metabolism 
in the liver, kidneys, and placenta of pregnant dams mice, as well as in the embryonic 
tissue. Therefore, suggesting that FB1 is capable of crossing dam placenta and 
inhibiting de novo sphingolipids biosynthesis within the embryo [95].   
Over activation of S1P receptor by excessive production of sphingoid bases 1-
phosphate (S1P) is increase the risk of NTD as mentioned in LM/Bc and SWV mice, 
after they were injected by IP with 20 mg/kg b.w. at embryonic days 7.5 and 8.5 
[208]. 
Pregnant New Zealand White rabbits were exposed to purified FB1 at 0.10, 
0.50, or 1.00 mg/kg b.w. /day, via gavages, on gestations days 3 to 19. Maternal body 
weight was not affected. Male and female pups which were exposed to 0.50 and 1.00 
mg/kg/day had a reduction in their body weight when compared to a control group, 
by 13 and 16%, respectively. Fetal liver and kidney weights also decreased at these 
doses. At day 20 of gestation, modification of the sphingolipids metabolism appeared 
in maternal urine, serum, and kidneys when compared to controls, whereas the 
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embryo was not affected. Therefore, that suggested that FB1 was unable to cross 
rabbit placenta. Furthermore, a decrease in pups body and organ weight was a 
consequence of maternal toxicity, rather than any developmental of fetal toxicity 
produced by FB1 [212]. 
1.6. Conclusion  
The lethal single dose of FB1 in laboratory animals has not been recorded, nor 
lethal effect of FB1 administered at a single dose of 25 mg/kg b.w. by gavage or 
subcutaneous injection in rodents. Possibility of FB1 to crossing dams placenta and 
inducing embryonic disorders are proven in rats, but not in rabbits.  
Liver and kidneys are the major target organs to fumonisin toxicity, which is 
characterized by apoptotic necrosis and regeneration. Fumonisin B1 toxicity varies 
depending on:  
 Species: rabbits are more sensitive to FB1 nephrotoxicity effects than rats and 
mice. 
 Organs: in rodents, liver and kidneys are target organs, although differences 
depending on the species, strain and sex are observed.  
 Strains: Sprague-Dawley and Fischer rats are more sensitive than BDIX-rats to 
fumonisin toxicity. Also, wild-type mice are more resistant than p53 mice to 
hepatic apoptosis.  
 Sex: males Sprague-Dawley and F344 rats are more sensitive to FB1 
nephrotoxicity than females. Whereas, female rats F344 are more sensitive 
than males to hepatotoxicity. Also, Female B6C3F1 mice are more sensitive to 
FB1 hepatotoxicity than male ones.  
Carcinogenic effects of FB1 such as renal tubule tumours, hepatocellular 
carcinoma, liver cirrhosis and hyperplasia are reported in rodents consumed FB1 for 
long time. In addition, genotoxicity effect, by oxidative damage, is observed in 
rodents. Thus, FB1 is considered as a cancer initiator and a strong cancer promoter 
for rodents. It is classed as “possibly carcinogenic to humans (Group 2B)”. 
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NOEL of FB1 in rodents based on hepatic and kidney toxicity are presented in 
table 9. 
Table 9: No observed effect level (NOEL) of FB1 in rodents 
Species Duration Target Organ 
NOEL  
(mg FB1/kg b.w.) 
Ref 
Rats and 
Mice 
Short-term Liver          < 0.75 [50-79-82-
83] Sub-chronic Kidney 0.2 
Mice 
Sub-chronic Liver 1.8 
[79-207] 
Chronic Liver 0.6 
Rats 
Chronic Liver 1.25 
[150-207] 
Chronic Kidney 0.25 
 
It appered from this table that kidney is more sensitive than liver, mice are 
more sensitive than rat for chronic toxicity, whereas short-term and sub-chronic 
toxicity for the liver seems more important than chronic toxicity in rats. The NOEL of 
0.2 mg/kg b.w. on kidney toxicity in rat being the lowest observed in all the studies 
conducted in rodents. Thence, by using a factor of security of 100, the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) has recommended 
provisional maximum tolerable daily intake (PMTDI) of 2 μg/kg b.w., for fumonisins 
B1, B2 and B3, alone or in combination,  (JECFA, 2001)[25-267-289]. 
2. Farm animals: mammals  
2.1. High sensitivity species 
2.1.1. Equines  
Equine species (horses, mules, donkeys, ponies) are apparently the most 
sensitive to FB1 toxicity. Animal disorders can appear after ingestion of 
contaminated feed at concentrations >10 mg FB1/kg (equivalent to 0.2 mgFB1/kg 
b.w. per day), for few weeks [106-107-110]. The target organs in horses are the central 
nervous system, the liver and the heart [168]. Leukoencephalomalacia, 
hepatotoxicosis, and cardiotoxicity are dose-dependent. 
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2.1.1.1. Equine leukoencephalomalacia (ELEM) 
ELEM was described for the first time in the United States in 1850, and later on 
in South Africa [103-104]. Since then, cases have been observed everywhere in the 
world including the South-west of France [105]. In August 2007 an outbreak of ELEM 
occurred in Argentina in Arabian horses fed native grasses supplemented with corn 
kernels and wheat bran. The morbidity and mortality rates were 11.6% and 10%, 
respectively [143]. It has been hypothesized that equine leukoencephalomalacia is a 
result of cerebral oedema due to an inability to shut down blood flow to the brain 
when the horse lowers its head to eat or drink [81]. Equine leukoencephalomalacia 
syndrome is a sporadic disease characterized by the presence of liquefaction necrotic 
and yellow discoloration in the cerebral hemispheres, brainstem and cerebellum 
[144]. The disease appears to be exclusive to equines, but the brain lesions have also 
been reported in rabbits [101] and pigs [102].  
The routes of administration and dose concentration are significant factors in 
the appearance of the ELEM. One study carried out in 1990 by Kellerman, showed 
that oral administration of between 1 and 4 mg FB1/kg b.w., over 29 days was able to 
produce the ELEM in horses [9]. In the same manner, the administration of 0.125 mg 
FB1/kg b.w., over 7 days by intravenous route is sufficient to cause an onset of ELEM 
[106]. ELEM has been mentioned in experiments carried out by Wilson and Collar on 
ponies, which received naturally contaminated corn with 22 mg FB1/Kg b.w., for 55 
days [109]. By contrast, another study conducted on horses fed 15 mg FB1/kg feed, 
for 150 days (equivalent to 0.3 mg of FB1/kg b.w. /day) did not obtain any clinical 
signs or any alteration in serum biochemical parameters (including disruption of 
sphingolipids metabolism) [81].  
All these results have been supported by analyzing feed coming from 
confirmed cases infected with ELEM in the USA. The above indicated that 
consumption of contaminated feed with FB1 at concentration > 10 mg/kg of diet 
(equivalent to 0.2 mg/kg b.w. per day) was associated with an increased risk for 
development of ELEM, whereas a concentration < 6 mg/kg of diet (equivalent to 0.12 
mg/kg b.w. per day) did not induce ELEM [110]. Therefore, Shephard and Collar 
recommend the tolerable maximum content of FB1 in feed to avoid risks of ELEM to 
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be 5 mg FB1/kg of diet [108]. Those results were supported by other investigations in 
equines, which showed that the minimum oral dose sufficient to induce ELEM 
appeared to be ≥15 mg/kg of diet, and the minimum oral dose of pure FB1 that 
induces equine leukoencephalomalacia is unknown [81]. On the other hand, cerebral 
lesions were obtained by intravenous injection of pure FB1 at concentration from 0.01 
to 0.05 mg FB1/kg b.w. /day. If considered that an oral dose represents 5% of an 
intravenous dose, the equivalent of oral dose inducing a brain lesion will be 0.2–1.0 
mgFB1/kg b.w. per day.  
More recent data obtained in 2007 in Argentina supported all previous 
studies.  It reported that horses which consumed native grasses supplemented with 
contaminated corn kernels and wheat bran at a concentration of 12.5 mg FB1/kg and 
5.3 mg FB2/kg had very clear signs of ELEM [143].  
Ross and Collar demonstrated that FB2 at a concentration of 75 mg/kg diet 
was able to induce hepatitis and ELEM lesions in ponies after 150 days of exposure. 
By contrast, FB3 at concentration 75 mg/kg of diet was unable to induce any effect on 
serum enzymes, clinical signs and histopathology changes in ponies after 57 to 65 
days of exposure [111]. Few years later, Riley and Showker conducted the same 
experiment on ponies with the same dose of 75 mg FB2/kg diet for 136 - 223 days, or 
75 mg FB3/kg diet for 57 - 65 days. After 48 days, ponies fed with FB2 had an 
increase in serum enzymes of liver toxicity and clinical signs (head shaking, gait 
problems, and muscle tremors), whereas ponies fed with the FB3 diets did not show 
any increase in serum enzymes or clinical signs for as long as 65 days . Disruption of 
sphingolipids metabolism was obtained 4 and 11 days after FB2 and FB3 exposure, 
respectively [112]. Thus, it was suggested that FB3 was less toxic than FB2 or FB1 in 
equine.  
The nature and intensity of the symptoms observed were very variable, and 
they do not show a specific direct relationship between the importance of the clinical 
signs and the degree of the cerebral lesion. The clinical signs which have been 
observed due to nervous disorders are: hyperesthesia, hyper-excitability, ataxia, 
euthanasia, trembling, reluctance to move, walk in a circle, push the wall, and fall on 
one side, paresis of the lower lip and tongue, and inability to eat or drink [113-144-
145]. Depression, paralyses and jaundice symptoms are also linked to the disease [4 -
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111]. Death can be sudden or proceeded by convulsions and a state of coma. In all 
cases, death is expected and occurs within a few hours or a few days after the onset 
of the disorders [105-109-114]. Among autopsy findings, the main one observed was 
necrosis in brain white matter, brain stem, cerebellum, and spinal cord. Hemorrhages 
in CNS and abdominal cavities, edematous brain and perivascular hemorrhage were 
occasionally present [9-115]. 
2.1.1.2. Hepatotoxicosis  
Hepatotoxicosis is a fatal disease produced by consumption of high quantity 
of FB1, while exposures to lower quantity of toxin probably produce ELEM. The dose 
limit between the hepatotoxicosis and ELEM is not clear.  Hepatotoxicosis and ELEM 
are accompanied by lesions on the nervous system and hepatic modifications [115]. 
Cases of hepatotoxic syndrome are less frequent than those of the neurotoxic form, 
and death often occurs within 5–10 days of clinical signs onset. Global clinical 
symptoms of hepatotoxicosis are loss of appetite and depression followed by oedema 
of the head and a clear icterus. More specific markers are an increase in serum 
bilirubin and liver enzyme activities. At a necropsy investigation, liver becomes 
solid, yellow and small in size [168]. 
Hepatosis was observed in an experiment conducted on two horses after 
feeding them cultivated corn with Fusarium moniliforme MRC 826 through a stomach 
tube. One horse developed severe hepatosis and mild edema of the brain after 6 
doses of 2.5 g of culture material/kg b.w. /day in 7 days. The second horse, which 
received a half dosage of 1.25 g/kg b.w. /day, developed mild hepatosis and 
moderate oedema of the brain [253]. 
In another study, hepatic necrosis and mild encephalopathy were observed in 
ponies receiving 44 mg FB1/kg feed, for 9 - 45 days. While hepatic necrosis 
accompanied by ELEM was found in the animals treated with a high dose of 88 mg 
FB1/kg feed for 75 - 78 days by oral route [116-252]. 
2.1.1.3. Cardiotoxicity 
Evidence of cardiovascular dysfunction was detected after neurologic 
symptoms appeared in horses receiving daily IV injections of 0.01, or 0.20 mg FB1/kg 
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b.w. for 7 to 28 days. That evidence was represented by a decrease in heart rate, 
cardiac output, right ventricular contractility and coccygeal artery pulse pressure. 
Alteration of sphingolipids metabolism in serum and myocardial were observed in 
all animals treated. The NOEL for cardiovascular abnormalities was 0.2 mg/kg b.w. 
per day, but the NOEL for serum biochemical abnormalities was less than 0.2 mg/kg 
b.w. per day, [81-150-168-169]. 
2.1.2. Swine 
Fumonisin toxicosis in swine is characterized by injury to pulmonary, hepatic, 
cardiovascular, and immune systems as well as alteration of sphingolipids 
metabolism and effects on growth rate [119]. 
2.1.2.1. Porcine pulmonary edema (PPE) 
In 1981, it was the first time that pulmonary edema was induced in 
experimental swine fed with corn contaminated with F. verticillioides [118]. In 1989, 
thousands of pigs died from pulmonary edema after ingesting corn contaminated by 
fumonisins in the mid-western and south-eastern parts of the United States. 
Following autopsy it was established that the cause of death was related to 
pulmonary oedema and hydrothorax with the thorax cavity filled by a yellow liquid. 
Feed samples were taken from the outbreak areas, and the presence of detected FB1 
was in the range of 20-330 mg/kg of feed. It was then that the disease was named 
Porcine Pulmonary Edema Syndrome (PPE) [21-120]. This disease was linked to 
ELEM by means of having the same causative agent [129]. Many studies were 
conducted by using contaminated feed and purified toxin to confirm the disease. The 
results obtained from those studies demonstrated that pulmonary edema in pigs was 
recorded only with high levels of FB1, while animals fed with low levels of FB1 
suffered from hepatotoxicosis as will be explained later the section of swine [21]. 
Lethal pulmonary oedema was observed within 4–7 days after consumption of 
feed contaminated with FB1 at concentrations of higher than 16 mg/kg b.w. /day 
[21-121-122-123-124].  Similarly, lethal pulmonary edema was obtained after 5 days in 
pigs which received daily high dose of 0.4 mg FB1/kg b.w. by intravenous route. 
Meanwhile, pigs which received daily low dose at concentration 0.174 mg FB1/kg 
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b.w. for 7 days by intravenous route did not develop pulmonary edema [121]. 
Concurrently, weaning pigs fed lower doses of FB1 in a culture material (10–40 
mg/kg of diets) for 4 weeks did not show any clinical signs of toxicity [125].  
Weaned piglets had a chronic oral exposure to contaminated diets at levels 0, 
10, 30 mg of FB1/kg of feed for 28 days. All signs of toxicity were only localized in 
the highest dose group, which was characterized by a decrease in feed consumption 
and body weight gain, an increase in organ weight (lung, liver and heart), an increase 
in hematological and biochemical parameters.  After 20 days of feeding animals with 
high dose (30 mg of FB1/kg diet) the typical clinical signs of pulmonary edema were 
appeared, such as, cyanosis of ears, tail, eyes sclera and mucosal membranes, 
increased heart and respiratory rate with shallow breathing [159].  
Pulmonary edema was also observed in piglets at one week of age after 
feeding pregnant sows with high dose 300 mg FB1/kg of diets during the last week 
of gestation and the first week after parturition. That means, possibility of FB1 to 
cross sow placenta and excreted in its milk is possible [126].   
Clinical signs in the twelve hours preceding development of pulmonary 
edema and death are: inactivity, increased respiratory rate, and decreased heart rate 
[127]. During the dying hours animals show more exhausted respiratory distress, 
increased respiratory rate and effort with abdominal and open mouth breathing 
[122,128]. Autopsy finding are mainly localized in severe pulmonary oedema, 
hydrothorax and perivascular oedema [21-25]. 
FB1 decreases cardiac contraction, mean systemic arterial pressure, heart rate 
and cardiac output. At the same time, FB1 increases mean pulmonary artery pressure 
and pulmonary artery wedge pressure [130-131]. On the other hand, FB1 inhibits L-
type calcium channels by modification of sphingolipids metabolism in the heart. All 
of those events lead to acute left-sided heart failure, which is considered the first 
cause of pulmonary edema [127]. More recent studies have implied that other causes 
of pulmonary oedema are a consequence of vascular alterations due modification of 
sphingolipids metabolism after exposure to FB1 in vitro [132].  
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2.1.2.2. Hepatic injury (hepatotoxicosis) 
Hepatic injury is dependent on the dose and exposure time to a toxin. That 
means the toxic dose necessary to induce hepatic injury is lower than the toxic dose 
necessary to induce pulmonary oedema. This hypothesis was defended by a study 
conducted on pigs fed with different concentrations of FB1. The results demonstrated 
that only hepatic lesions without clinical of pulmonary oedema were obtained in 
group fed on a diet containing less than 4 mg of FB1/kg b.w. /day by oral route for 2 
weeks. Whereas, pulmonary oedema and hepatotoxicosis were observed in pigs 
which had consumed diets containing 4.5 and 6.3 mg of FB1/kg b.w. /day for 2 
weeks [122, 125,130]. 
2.1.2.3. Immunosuppression effect of fumonisin in pigs  
In vitro, incubation of alveolar macrophages with 2, 5 ,10 and 25g FB1/ml, for 
72 hours decreased production of interleukin-1β (IL-1β) and tumor necrosis factor-α 
(TNF-α) at all dose levels after 24 hours of incubation. Whereas, FB1 at 
concentrations of 5 and 25 g/ml, for 72 hours of incubation was able to reduce the 
number of alveolar macrophages viability down to 65 and 45%, respectively, 
comparing to control levels [232]. 
In vivo, weaning piglets were fed contaminated diet of 8 mg FB1/kg of feed, 
for 28 days. The animals were vaccinated with inactivated mycoplasma agalactiae at 
the 8th and 22nd days of the experiment. Results obtained demonstrated that FB1 
induced a significant decrease in IL-4 expression in the blood. On the other hand, FB1 
had no effect on serum concentration of the immunoglobulin subset (IgG, IgA, and 
IgM) [233]. 
A new study was conducted in 2012 on piglets treated with purified 2.8 µmol 
FB1 or HFB1/kg b.w. /day, by gavage, for 2 weeks. The FB1 treated group had a 
significant increase in liver IL-1β and IL-8, and a significant decrease in IL-2, IL-6, 
INFα and INFγ of liver and small intestine lymph nodes. Conversely, the HFB1 
treated group showed only a slight decrease in IL-6 in liver and small intestine 
lymph nodes. Hence, it was deduced that FB1 has a stronger immunosuppressive 
ability when compared to HFB1 [166].  
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2.2. Low sensitivity species 
Ruminants   
Cattle are less sensitive to FB1 toxicity when compared to horses and pigs. 
Ruminant resistance to FB1 toxicity is an outcome of their lower bioavailability (F = 
0.5 – 1 % of oral dose), and ability of their micro-flora to degradation FB1 to 
hydrolyzed forms (HFB1/2 or AP1), as it was explained earlier in fumonisin 
pharmacokinetics chapter (absorption and metabolism sections) 
Two Jersey cows ingested contaminated feed at a concentration of 75 mg 
FB1/kg (equivalent to 3 mg FB1/kg b.w. /day) for 14 days. The results did not 
demonstrate any important sign of toxicity. Transient diarrhea was obtained at the 
start of the feeding program, as well as an increase in serum cholesterol 
concentration and decreased feed intake and milk production [137]. 
An experiment carried out on eighteen feeder calves which were fed 
contaminated diets with mixture fumonisins (FB1, FB2, and FB3) at total ranges:  5, 31 
and 148 mg/kg for 31 days. No effect was observed at all concentrations relative to 
average feed intake and body weight gains. Slight loss of appetite was recorded in 
calves fed with the high dose of the contaminated diet. Only some biochemical 
parameters were modified in two of the calves which had consumed 148 mg/kg of 
feed after 10 days of exposure [133]. Autopsy revealed that gastrohepatic lymph 
nodes of animals that had received high FB1 doses were mildly enlarged, 
oedematous and contained petechial hemorrhages. These lesions were not specific, 
and there are no other reports available on cattle for comparison. By contrast, 
gastrohepatic lymph nodes of control animals were not affected. Moreover, under 
microscopic lesion examination, mild hydropic degeneration and cloudy swelling 
were observed in the livers of animals fed highly contaminated diet, but not in 
control animals [133]. 
Long term experiments conducted on five Holstein steers which consumed 
mildly contaminated diet with an average of 94 mg FB1/kg of feed daily for 253 
days. No clinical signs or either gross lesions were obtained at the end of study. Only 
some biochemical parameters were significantly increased in serum of the treated 
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group. There was presence of mild histological evidence to hepatocellular injury and 
biliary epithelial hyperplasia [138]. 
Milk-fed calves were treated with 1 mg FB1/kg b.w. daily for 7 days by 
intravenous route. On the fourth day of treatment, loss of appetite and anorexia were 
observed. Evidence of sever hepatic and bile duct injury were detected by an increase 
of serum activity of some enzymes after 4 days of treatment [139]. Renal functions 
injury was diagnosed by an increase of some biochemical biomarkers in the serum, 
and by urine specific gravity at the end of the experiment [139]. 
Lambs were injected intra-ruminally with culture material in different doses of 
11.1, 22.2 or 45.5 mg (FB1, FB2 and FB3)/kg b.w., for 4 days. Severe nephrosis and 
hepatosis were the main consequences of a fumonisins exposure at high dose in 
sheep. Theses damages were indicated by changes of biochemistry in the dosed 
lambs serum. Liver and kidney damages were confirmed at the end of study by 
histological examinations which detected renal tubular necrosis and mild 
hepatopathy [140]. These results harmonized with previous data obtained in 1981 by 
Kriek NP [141]. 
Similar effects of FB1 in sheep were obtained in weaning Angora goats after 
consumption of feed containing 95 mg FB1/kg of feed, for 112 days. Liver damage 
and kidney dysfunction enzymes were elevated in the blood.  [142]. 
3. Farm animals: poultry 
In general, poultry is less sensitive to FB1 toxicity when compared to pigs and horses. 
Poultry are classified according to their sensitivity to FB1 exposure as follows: 
3.1. Low sensitivity species (layer hens and broiler) 
A long term experiment was conducted on laying hens at 24 weeks of age, fed 
on 100 or 200 mg FB1/kg of feed for 420 days. No effects on body weight with 
significant decrease in egg production were observed at both concentrations during 
the study. Increased egg weight was observed in hens fed the 100 mg FB1/kg diet at 
the end of the egg production cycle (252 days of egg production). In general no 
significant mortality was detected during the 420 days of the experiment. One death 
case was recorded each in the control group and the treatment group with 200 mg 
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FB1/kg. Furthermore, there were four death cases due to uterine prolapses, which 
may be attributed to the increased egg weights in the treatment group with 100 mg 
FB1/kg. After 112 days, the group fed the highest contaminated level 200 mg FB1/kg 
feed had some modification of seum biochemistry (table 10) [155]. 
Table 10: Adverse effects of FB1 on chickens 
Dose and duration Descriptions Ref 
Laying hens 
100, 200 mg FB1/kg 
feed/ 420 days 
No mortality, no BW decrease  
Weak effect on biochemistry 
Decrease egg production.  
Weak egg weight increase.  
[155] 
Broiler 
20- 80 mg FB1/kg 
feed/ 21 days 
No signs of toxicity  
No effect on biochemistry 
Alteration of sphingolipids  
[146] 
Broiler 
125, 274 mg FB1/kg 
feed/ 14 days 
Increased mortality (20 - 50%) 
Young more sensitive  
[147] 
Broiler 
100-400 mg FB1/kg 
feed/ 21 days 
400 mg/kg decrease BW and increased body organ 
weights Necrotic hepatic foci  
Altered biochemistry 
[148] 
Broiler 
33 - 627 mg FBs/kg 
feed/ 21 days 
Reduction in weight gain and feed conversion 
Hepatocellular hyperplasia 
[150] 
Broiler 
75- 525 mg FB1/kg 
feed/ 21 days 
> 450 mg/kg : decrease feed intake, BW gains, increase 
liver and kidney weights. 
> 150 mg/kg Hepatocellular hyperplasia  
All doses: alteration of sphingolipids 
[151] 
Broiler 
50-200 mg FB1/kg 
feed/ 21 days  
with infectious 
challenge  
200 mg /kg: 
decrease lymphocyte proliferation 
enhance bacterial colonies in blood, spleen, and liver. 
decrease secondary antibody response. 
[152] 
Broiler 
25,  50 mg FB1/kg  
feed/ 42 days 
No mortality, no BW decrease  
Unexpected effects on biochemistry 
All doses: alteration of sphingolipids in liver  
[153] 
Broiler chickens of one day age were fed purified FB1 at concentrations 0, 20, 
40, and 80 mg/kg feed for 21 days. No signs of toxicity such as decrease of body 
weight and growth rate were observed. In liver, a significant disruption of 
sphingolipids metabolism was detected in all treated groups, whereas, it appeared in 
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serum only in the group fed with 80 mg FB1 /kg. Biochemistry was not affected in 
chickens fed the highest FB1 level 80 mg/kg, (table 10) [146].  
Reduced weight gain was observed in one-day old male broiler chickens 
exposed to high doses of purified FB1, either 125 or 274 mg FB1/kg of feed for 14 
days. The mortality percentages with the low and high contaminated diets were 20% 
and 50%, respectively. The spontaneous death is only observed during the first three 
days of life, which illustrated that younger chickens were more sensitive to FB1 
toxicity than older chickens, (table 10)  [147]. 
One day-old chicks were fed diets containing 0, 100, 200, 300, or 400 
mg FB1/kg of feed, for 21 days. After 4 days of treatment bird excreta became dark, 
sticky and adhered around the vent area of the birds. These symptoms declined after 
13 days and excreta become normal after 21 days.  Body weight gain was not affected 
in the first week, but a 20% decline was recorded with the highest level of FB1 in the 
second week of the experiment. Also, at the end of the experiment, the weight of the 
liver, proventriculus and gizzards increased. Whereas no significant effects were 
obtained concerning the weight of the kidneys, heart, spleen, pancreas, and the bursa 
of fabricius. In histological examinations, only in chicks receiving ≥100 mg FB1 /kg 
hepatocellular hyperplasia and small multiple foci of hepatic necrosis appeared. 
Necrotic foci were consistent in size at all dosages, but were present in greater 
numbers in chicks fed 300 or 400 mg FB1/kg. Biliary epithelial hyperplasia was 
observed in the livers of chicks fed 300 or 400 mg FB1/kg. Some serum biochemical 
parameters increased at higher FB1 levels (table 10) [148].  
One-day old chickens consumed F. moniliforme culture material containing 
total amounts of fumonisins (FB1, FB2 and FB3) at concentrations of 33, 99, 132, 330, 
429 and 627 mg/kg of feed, for 21 days. Weight gain and feed conversion were 
reduced depending on the dose of toxin exposure. Slight hepatocellular hyperplasia 
was obtained at concentrations 99 to 132 mg/kg, while moderate hepatocellular 
hyperplasia was detected at concentration 330 mg/kg, and with severe hyperplasia at 
the highest contaminated diets 429 and 627 mg/kg, (table 10) [150].  
One-day old chicks were fed a diet treated with FB1 at levels 0, 75, 150, 225, 
300, 375, 450, and 525 mg/kg of feed, for 21 days. Birds which consumed the highest 
toxin level at concentrations of 450 and 525 mg FB1/kg of diet had a decrease in feed 
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intake and body weight gain, increased liver and kidney weight, increased mean cell 
haemoglobin concentrations compared to the control group. Hepatocellular 
hyperplasia was observed in chicks fed diets equal to or more than 225 mg FB1/kg of 
diet. Disruption of sphingolipids metabolism was observed at all concentrations of 
contaminated diets. Thus, it was suggested that diets containing 75 mg FB1/kg of 
feed may be toxic to young broiler chicks, (table 10) [151]. 
Three experiments with one-day old broilers were conducted to measure 
immunosuppression in chicks. Experiment (1) – Chickens were give free feed access 
at concentrations of 50, 100 or 200 mg FB1/kg of feed for 3 weeks and were injected 
intravenously with 4.6 × (10x6) Escherichia coli for 21 days. Experiment (2) - 
Chickens were fed 50, 100 or 200 mg FB1/kg of feed for 4 weeks, and then were 
injected with 0.5 ml inactivated Newcastle Disease vaccine on weeks 2 and 3 of the 
experiment. Primary and secondary antibody titrations were measured at 7 days 
after each injection. Experiments (3) – Chickens were fed 200 mg FB1/kg of feed for 3 
weeks, without any supplements. The results obtained in the first experiment 
showed that chicks with the highest concentrated feed 200 mg FB1/kg diet have 
higher significant numbers of bacterial colonies in blood, spleen and liver when 
compared to the control group. The second experiment results recorded significant 
decrease in titration of secondary antibody response with high contaminated feed 200 
mg FB1/kg. The results obtained in the third experiment showed a significant 
decrease of lymphocyte proliferation in chicken fed with 200 mg FB1/kg when 
compared to the control group, (table 10)  [152]. 
In 1-week old broilers were fed culture contaminated diets 0, 25, or 50 mg 
FB1/kg of diet, for 42 days. Feed intake, body weight gain, and feed conversion of 
chicks were not affected. No significant differences between control and treated 
groups were observed in the weight of the liver, heart, kidneys, pancreas, bursa of 
fabricius, gizzards or spleen. Except, chicks fed 25 mg FB1/kg which showed a 
significant decrease in proventriculus weight compared to control groups or the 
highest dosage 50 mg FB1/kg group. The results from the serum biochemistry 
analysis showed that chicks fed 50 mg FB1/kg had decreased serum calcium and 
increased serum chloride levels. No hematological effects were obtained relative to 
hemoglobin, RBC counts, hematocrit, MCV, MCH, or MCHC. Liver disruption of 
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sphingolipids metabolism was observed at all concentrations of contaminated diets, 
(table 10) [153]. 
3.2. Mild sensitivity (turkeys) 
One day- turkey poults were fed contaminated diets at levels of 75, 150, 225, or 
300 mg FB1/kg of feed for 21 days from culture material (FCM). The lowest 
concentration corresponded to a daily dose of approximately 9 mg FB1/kg b.w. on 
average. Decrease in feed intake and body-weight gain and increase in liver weight 
were dependent on the exposure dosage. Poults fed low contaminated diet 75 mg 
FB1/kg consumed more feed than other groups. Therefore, they had pronounced 
lower body-weight gains than controls or poults fed high contaminated diet. 
Alteration of sphingolipids in serum and hepatocellular hyperplasia lesions were 
detected in all FB1 treatment groups, whereas biliary hyperplasia was established in 
poults fed 150 to 300 mg FB1/kg, (table 11) [154]. 
Table 11: Adverse effects of FB1 on turkeys 
Dose and duration Descriptions Ref 
75-300 mg FB1/kg 
feed/ 21 days 
Decrease feed intake , BW gain 
Increase in liver weight, hepatocellular, biliary hyperplasia 
>75 mg/kg: alteration sphingolipids serum 
[154] 
75 mg FB1/kg 
feed/126 days 
Decrease BW gain  
Increase liver weight  
[161] 
25-475 mg FB1/kg 
feed/ 21 days 
Dose depending hepatocellular hyperplasia 
>250 mg /kg:  decrease feed intakes and B.W. gains 
≥ 175 mg /kg increase liver, pancreas weight 
>325 mg/kg ateration of biochemistry 
>25 mg/kg: alteration sphingolipids liver  
[149] 
25, 50 mg FB1/kg 
feed/91 days 
50 mg /kg: decrease feed intake 
 
[
[153] 
5-20 mg FB1+FB2/kg 
feed/63 days 
>5 mg/kg: alteration sphingolipids liver and kidney  [156] 
A chronic toxicity study was conducted on one-day old turkeys fed balanced 
rations containing 75 mg FB1/kg of feed, for 18 weeks. Nil mortality was noted. 
Decrease in body weight gain was demonstrated on weeks 4, 10, and 12 of 
experimental. At the end of the treatment the liver had become significantly heavier, 
(table 11) [161].  
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One-day old turkey poults were selected randomly for dietary treatments 
containing 0, 25, 50, 75, 100, 175, 250, 325, 400, and 475 mg FB1/kg of feed, for 21 
days. Poults fed 325 to 475 mg FB1/kg diet had a significant decline in feed intake 
and body weight gain. Increased liver and pancreas weights were observed in poults 
fed ≥ 175 mg FB1/kg. Increase in red blood cell counts and serum biochemical 
parameters appeared in birds fed 400 and 475 mg FB1/kg of diet. Hepatocellular 
hyperplasia was mild at 75 and 100 mg FB1/kg diet, moderate to severe at 250 mg 
FB1/kg, and severe at 325 to 475 mg FB1/kg. Liver alteration of sphingolipids 
increased at all diet doses. These results indicated that diets containing ≥ 75mg FB1 
/kg are toxic to young turkeys, (table 11) [149]. 
In 2002, Broomhead conducted a study to evaluate the chronic effects of FB1 
by applying doses lower than the ones recommended by US-FDA (2001). one week 
old broiler chicks and turkey poults, were fed culture contaminated diets 0, 25, or 50 
mg FB1/kg of diet, for 42 days in chicks, and a 90 days in turkeys. Feed intake, body 
weight gain, and feed conversion of chicks were not affected by consumption of FB1. 
Whereas, Turkeys fed 50 mg FB1/kg had significantly lower feed intake than the 
controls. No significant differences were observed in the weight of internal organs in 
both species. Except, chicks fed 25 mg FB1/kg had a significant decrease in 
proventriculus weight compared to control groups. No haematological effects were 
obtained in both species relative to haemoglobin, RBC counts, hematocrit, MCV, 
MCH, or MCHC. Liver alteration of sphingolipids was significantly increased in both 
species at all doses. Results indicate that 50 mg FB1/kg diet is harmful to turkeys but 
it is not toxic to broilers fed to market age, (table 10 and 11) [153]. 
The first study which investigated the maximum level of fumonisins in avian 
feed recommended by the European Union (2006) was conducted on turkeys after 
exposing them to contaminated diets with 0, 5, 10, and 20 mg of FB1+FB2/kg of feed, 
over a period of 9 weeks. The results obtained indicate that no sign of toxicity and no 
effects were observed concerning turkey general performance, feed consumption, 
growth and weight of tissues at all level of fumonisins in the feed. Fumonisins did 
not induce a disturbance on biochemical parameters with any level of fumonisins. 
Marked modifications of sphingolipids metabolism in liver and kidney were 
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recorded for all doses. For the first time it was demonstrated in turkeys, that 
alteration of sphingolipids occurred a few days after exposure to fumonisins at a 
level of 20 mg of FB1 + FB2/ kg of feed. Finally, this study confirmed that the level of 
fumonisins in avian feed of 20 mg of FB1 + FB2/kg recommended by the European 
Commission could be considered as safe for these animals. However, the lack of 
effect of fumonisins on performance and on biochemistry does not mean that these 
mycotoxins have no effect on turkeys (table 11) [156]. 
3.3. High sensitivity (ducks) 
Pekin ducklings were fed rations containing 100, 200 or 400 mg FB1/kg feed, 
for 21 days. Mortality was observed only in ducks fed high dose 400 mg FB1/kg feed, 
two out of eight treated cases died. Additionally, the results exposed that a decrease 
in feed intake and weight gain and an increase in the weight of the liver, heart, 
kidneys, and proventriculus were dose-dependent. An alteration of sphingolipids in 
liver was observed at all contaminated diets levels. Histopathology investigation 
revealed hepatocellular hyperplasia in all ducklings fed FB1, and mild to moderate 
biliary hyperplasia was obtained only at the highest toxic dose, (table 12) [162]. 
Table 12: Adverse effects of FB1 on ducks   
Dose and duration Descriptions Ref 
100- 400 mg FB1/kg 
feed/21 days 
400 mg/kg:  increase mortality 
>100 mg/kg: decrease feed intake, B.W. gain 
>100 mg/kg: increase organ weights, hepatocellular 
hyperplasia  
>100 mg/kg: alteration sphingolipids.  
[162] 
5- 45 mg FB1/kg 
b.w. /12 days.  
>5 mg/kg: Increase  liver weight 
All doses: alteration of biochemistry and sphingolipids serum. 
[163-
164] 
2- 128 mg FB1/kg 
feed/ 77 days. 
>8 mg/kg: decrease BW, increase organs weight.  
>8 mg/kg: alteration of biochemistry 
All doses: alteration of sphingolipids (liver, kidney, serum) 
[165-
170-
171] 
10, 20 mg FB1/kg 
feed/ 12 days. 
20 mg/kg: increase mortality 
All doses: alteration of sphingolipids liver, serum 
[158] 
Mallard ducks received 0, 5, 15 or 45 mg FB1/kg b.w., daily by force-feeding, 
over 12 days. No signs of toxicity were observed relative to mortality or decreased 
body weight. Increased weight of liver was dose-dependent. Hepatic biochemistry 
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was modified at all doses. By contrast, kidneys biochemistry was not affected. The 
above results concluded that liver was more affected to FB1 toxicity than kidneys. 
Sphingolipids were modified in serum at all doses after six days of treatment. Only 
two days with ≥ 5 mg FB1/kg of diets were necessary to induce sphingolipids 
modifications in serum, (table 12) [163-164].  
Seven-day old male Mallard ducks were exposed by oral route to purified FB1 
at different levels of 0, 2, 8, 32, and 128 mg of FB1/kg of feed, for 77 days. No 
mortality was observed in any of the treated groups. Feed consumption and body 
weight gain were not affected at the end of experimental. Decreased body weight 
was observed in groups which ingested feed at levels of 32 and 128 mg/kg, from day 
28 to 63 and from day 7 to 63, respectively. Ducks which had received 32 and 128 mg 
FB1/kg had increases in the weights of their gizzards, spleens, and livers. Some 
serum biochemical parameters were elevated after one week of exposure to mild and 
high contaminated diets. Other ones were not affected at any dosage. Alterations of 
sphingolipids metabolism in serum, liver, and kidney were established at all diet 
levels from 2 to 128 mg of FB1/kg of feed, and the highest disruption value was 
recorded in the kidneys. Thus, it was suggested that the kidney is the most sensitive 
organ to FB1 exposure. The lowest investigated dose which could increase Sa and 
Sa:So ratio in liver and kidneys after 7 days of exposure was 2 mg/kg of feed, (table 
12) [165-170-171].  
Mallard ducks at 12 weeks of age received by force-feeding for 12 days, 
contaminated maize at the maximum level permitted by the European Union - 0, 10 
and 20 mg FB1/kg of feed. That corresponded to a final average feed intake of 
approximately 10 kg of maize per duck. 8% mortality was observed only in ducks fed 
20 mg of FB1/kg of feed. It was difficult to identify FB1 effects on the liver weight 
and serum biochemical parameters, because they normally increase with force-
feeding. All FB1 treated groups had disruption of sphingolipids metabolism in the 
liver and serum. Force-feeding did not create any alteration in sphingolipids, (table 
12). Thus, sphingolipids alteration could be used as the best parameter to FB1 
exposure [158]. 
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3.4. Conclusion  
Fumonisin B1 induces a spontaneous disease in horses and pigs while cattle 
and poultry are much more resistant. Horses show more susceptibility to FB1 toxicity 
than other animal species. FB1 attacks specific species and specific target organs. For 
example, the target organ in horses is the brain where equine leukoencephalomalacia 
(ELEM) is induced, while the target organs in pigs are the lungs and porcine 
pulmonary oedema (PPE) is induced. These differences impose specific 
recommendations concerning the tolerable levels of fumonisins in feed. 
Concerning the avian species, strong differences seems observed depending 
on the age and species. FB1 induces mortality in ducks fed low dose of FB1 (20 
mg/kg of feed), and in young broilers fed high dose of FB1 (≥ 125 mg/kg of feed), for 
few days. By contrast, no mortality is recorded in turkeys or old broilers and laying 
hens exposed to high doses of FB1 (≥ 200 mg FB1/kg feed), for several weeks or 
months. Hence, it is suggested that ducks and younger broilers were more sensitive 
to FB1 toxicity than older broilers, and other poultry species. However, avian species 
are often taken as a homogeneous group in terms of toxicity and recommendations 
(see chapter IV) 
Liver and kidneys are target organs of fumonisins toxicity in all animal 
species. FB1 increases hepatotoxicity and biochemistry in all species. Alteration of 
sphingolipids metabolism is often observed before signs of toxicity. This observation 
and the structural analogy between fumonisins and sphingolipids make of interest 
the specific analysis of the consequences of FBs exposures on sphingolipids 
metabolism, and the relation between these alteration and organs toxicity. In 
addition, FB1 has adverse effects on the immune function system which can increase 
susceptibility to opportunistic micro-organisms invasions.  
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4. Humans  
No data was available concerning acute effects of FB1 toxicity on humans, 
although, FB1 has been reported at high concentrations (118 –155 mg/kg of food) 
from home grown maize in South Africa and China [77]. High incidence of 
esophageal cancer observed in human populations of Transkei in South Africa, and 
Henan Province in China was correlated with high intake of maize contaminated by 
FB1. By contrast, highest mortality rates for oral pharyngeal in Italy and esophageal  
cancer in Europe were not clearly correlated with consumption of contaminated 
maize with FB1[77]. IARC (International Agency for Research on Cancer) classified 
FB1 and FB2 as carcinogenic derived class 2B [267]. 
A number of estimates of human exposure to fumonisins have been made in 
different countries, such as in the USA: 0.08 μg/kg b.w. per day; in Canada: 0.017–
0.089 μg/kg b.w. per day; in Switzerland: 0.03 μg/kg b.w per day; and in the 
Transkei of South Africa: 1.2 to 355 μg/kg b.w, per day. Thence, exposure to FBs in 
human is generaly bellow than the recommended PMTDI of 2 μg/kg b.w./day 
estimated for fumonisins (page 34). 
 
IV. Fumonisin recommendations 
Fumonisins toxicosis are linked to certain diseases in several animal species 
and in human, such as pulmonary edema pigs [11-12], encephalomalacia in horses 
[9], hepatic and renal toxicities in equines, pigs, sheep, rodents and poultry [15-16-17] 
and esophageal  cancer in humans [4-21-77]. Furthermore, diagnosis of fumonisin 
toxicosis is difficult, which based on clinical signs, histopathology examination, and 
the presence of fumonisins at toxic levels in the feed. In addition, there is not specific 
treatment or antidote to fumonisin toxicosis. In order to solve these problems, the 
European Union and FDA have issued guidance levels for total fumonisins in human 
and animal feed to avoid fumonisin toxicosis (table 13, 14 and 15) [25-157-160-267]. 
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Table 13: European recommendation maximum levels for FBs in animals feed [157] 
Mycotoxins Products intended for animal feed mg/kg of feed 
FB1 + B2 
maize and maize products 60 
pigs, horses (Equines), rabbits and pet 
animals 
5 
Fish 10 
poultry, calves (< 4 months), lambs and kids 20 
adult ruminants (> 4 months) and mink 50 
Table 14: FDA-recommended maximum levels for FBs in human foods [160] 
PRODUCT 
TOTAL FUMONISINS 
(FB1 + FB2 + FB3 ng / g) 
Dry milled corn products (e.g., flaking grits, corn grits, corn meal, 
corn flour with fat content of < 2.25%, dry weight basis) 
2000 
Whole or partially dry milled corn products (e.g. flaking grits, corn 
grits, corn meal, corn flour with fat content of ≥ 2.25 %, dry weight 
basis) 
4000 
Dry milled corn bran 4000 
Cleaned corn intended for mass production 4000 
Cleaned corn intended for popcorn 3000 
Table 15: FDAa guidance levels for total FBs in animal feed [25-267]  
Animals or class 
Recommended maximum level of 
total fumonisins in corn and corn 
by-products (ppm; mg/kg) 
Recommended maximum 
level of total fumonisins in 
total ration (ppm; mg/kg) 
Horse b 5 1 
Rabbit 5 1 
Catfish 20 10 
Swine 20 10 
Ruminants c  60 30 
Poultry d    100 50 
Ruminant, poultry and 
mink breeding stock e  
30 15 
All others f  10 5 
(a) From Food and Drug Administration (2001). (b) Includes asses, zebras, and onagers. (c) Cattle, sheep, 
goats, and other ruminants that are ≥ 3 months old and fed for slaughter. (d) Turkeys, chickens, ducks, 
and other poultry fed for slaughter. (e) Includes laying hens, roosters, lactating dairy cows and bulls. (f) 
Including dogs and cats.  
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V. Fumonisin mechanism of actions 
1. Sphingolipids metabolism 
Fumonisin is structurally similar to sphinganine (Sa) and sphingosine (So) 
(figure 2). Thence, fumonisin interferes with sphingolipids biosynthesis by blocking 
the ceramide synthase enzyme [25]. The primary biological consequences to ceramide 
synthase enzyme blockage are inhibition of sphingolipids synthesis (sphingosine, 
ceramide and complex sphingolipids), and increase concentration of free 
sphingolipids and Sa:So ratio in the tissue and serum of exposed animals, or in cell 
cultures [175].  
The concentration of free sphingolipids (sphingosine, sphinganine and 
ceramide) and sphingolipids phosphorylated forms (So-1P, Sa-1P and C1P) play an 
important role in determining cell fate. Given that, they have negative effects on 
body cells [183-187]. Any disturbance in the sphingolipids metabolism balance or 
rheostat balance can lead to serious disorders, such as neurodegenerative diseases 
(Alzheimer or Parkinson), cardiovascular diseases, chronic inflammation (asthma), or 
cancer [179-197]. In addition, disturbance of the sphingolipids metabolism is 
combined with fumonisin toxicity in different animal species, such as ELEM in 
horses, PPE in pigs, as well as hepatic and renal toxicity in all animal species [9-10-11-
12-15-16-17-205]. 
 
Figure 2: Structural analogy of FB1 and sphinganine and sphingosine [25] 
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1.1. Historical background of sphingolipids 
In 1884, Johann L. W. Thudichum discovered some unknown molecules from 
brain tissue extracts. These molecules were named after the Sphinx. Few years later, 
it was considered that sphingolipids play primarily structural roles in the cell 
membrane formation. The main lipids of the cell membrane are glycerolipids, 
phospholipids and cholesterols [173-174-175]. Sphingolipids are principally found in 
all mammalian cell membranes, particularly nerve cells and brain tissue. At the end 
of the twentieth century, it was reported that sphingolipids molecules, in particular 
ceramide, play important roles in signal transmission and cell recognition that 
control cell growth, differentiation, and apoptosis. Cell membrane sphingolipids are 
amphipathic molecules that have both hydrophobic and hydrophilic properties. The 
hydrophobic molecules include sphingosine and sphinganine. In contrast, 
hydrophilic molecules include phosphate groups [sphingosine-1-phosphate (So-1P) 
and ceramide-1-phosphate (C1P)], sugar residues groups in glycosphingolipids 
(GSLs), and OH groups in ceramide [176]. Sphingolipids are derivatives of lipid 
sphingosine characterized by a long chain consisting of approximately 14 to 20 
carbons in length, with an amino group at position 2 and hydroxyl- at positions 1 and 
3 [174]. Sphingolipids are classified as simple sphingolipids (sphingosine, 
sphinganine and ceramide) and complex sphingolipids [sphingomyelin and 
glycosphingolipids (glucosylceramide and galactosylceramide) [173-175-179]. 
1.2. Sphingolipids metabolism (synthesis and catabolism) 
1.2.1. Sphingolipids synthesis pathway 
Synthesis of several sphingolipids, such as sphingosine (So), sphinganine (Sa) 
and ceramide (Cer) occurs in the endoplasmic reticulum (ER). Meanwhile, synthesis 
of sphingomyelin (SM) and glycosphingolipids (GSLs) occurs in the Golgi apparatus 
after transporting ceramide from ER to the Golgi apparatus [180-181]. Biosynthesis of 
sphingolipids is initiated in the ER by condensation and transformation of serine and 
palmytiol- CoA to 3-keto-sphinganine, which catalyzed by serine palmitoyl 
transferase enzyme (SPT). 3-keto-sphinganine is subsequently reduced to 
sphinganine (dihydro-sphingosine) by 3-keto-sphinganine reductase (3KSR). 
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Sphinganine is produced through a biosynthetic pathway, whereas the main quantity 
of sphingosine is produced by sphingolipids degeneration pathway. Ceramide 
synthase (CerS) acylates sphinganine to dihydroceramide (DHCer), which is 
converted to ceramide by dihydroceramide desaturase (DHCD). Ceramide is 
transported from ER to the Golgi apparatus by a transfer protein (CERT). There 
ceramide is transformed to sphingomyelin via sphingomyelin synthase (SMS), or to 
glucosphingolipids such as galactosyl-ceramide and glucosyl-ceramide, by using 
galactosyltransferase (CGaIT) and glucosyl-ceramide synthase (GCS), respectively, 
(figure 3) [178-180-181-203]. 
1.2.2. Sphingolipids degeneration pathway 
All steps of sphingolipids degeneration take place inside the ER [203]. 
Sphingolipid ceramide might hydrolyze to sphingosine (So) in the presence of 
ceramidase enzyme. Sphingosine is recycled to ceramide by using ceramide synthase 
(CerS). In parallel, free sphingolipids, such as sphinganine, sphingosine and 
ceramide are able to phosphorylate by kinase enzymes to generate sphinganine one 
phosphate (Sa-1P), sphinganine one phosphate (So-1P) and ceramide one phosphate 
(C1P), respectively. After that, sphinganine and sphingosine phosphorylated forms 
are hydrolyzed to ethanolamine phosphate and palmitic aldehyde by the 
phosphatelyase enzyme, (figure 3) [179-181-182-203]. 
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Figure 3: Diagram of sphingolipids biosynthesis [179-180-181-182] 
1.3. Role of sphingolipids 
Sphingolipids have important roles in cell regulation such as cell structuring, 
cell arrangement, cell growth, cell differentiation and death. They regulate signal 
transduction pathways during apoptosis, adhesion, cell proliferation, differentiation 
and migration and act as pro and anti-inflammatory mediators, (figure 4) [176-188-
189-197]. Intracellular accumulation of free sphingolipids (Sa, So and ceramide) leads 
to potential inhibition of protein kinase C (PKC) [190-199-214-215-250]. This enzyme 
has stimulant effect on the kinas enzyme, which leads to reducing of free 
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sphingolipids accumulation in the cells by enhancing sphingolipids phosphorylation. 
Therefore, PKC enzyme is recognized as a promoting factor for cell proliferation and 
anti-apoptosis. Consequently, inhibition of PKC by accumulation of free 
sphingolipids induces cell cycle arrest and apoptosis. For that reason, accumulation 
of Sa, So and ceramide are deemed as cytotoxic [187-190-191-192-197-203-214-215-
216].  
Cytokine (TNF-α, IL-1β and γINF), vit-D3, endotoxin (bacterial toxin and cell 
membrane LPS), radiations (X-ray or UV), heat stress and oxidative stress activate 
sphingomyelinase, which degenerates sphingomyelin into ceramide [179-186-199-
250-322]. Accordingly, those factors are reducing activity of kinase enzyme, decrease 
phosphorylation ability of sphingosine and ceramide, and increase conversion of 
sphingosine to ceramide. As a result of the above, concentration of intracellular 
ceramide is increased, (figure 4) [183-185-197]. 
Additionally, ceramide has pro-inflammatory mediator properties and 
enhances stimulation of IL1 and production of prostaglandins, (figure 4) [187-196]. 
Therefore, ceramide is implicated in the development of allergic asthmatic responses 
and airway inflammation, [179]. On the other hand, sphingosine and ceramide cause 
destabilization of the lysosomal membrane and release of lysosomal content enzymes 
into the cytoplasm, such as lysosomal proteases, which damages mitochondria and 
induces apoptosis [183-185-197-199-250]. 
Sufficient evidence indicates that sphingolipids phosphorylated forms (So-1P, 
Sa-1P and C-1P) have helpful effects on cell growth and survival by stimulating 
mitogen-activated protein kinase (MAPK) and extracellular regulated kinases 1-2 
(ERK1-2) [193-195]. In parallel, Sa1P and So1P act as a promoting factor for cell 
proliferation, cell growth, anti-inflammatory and anti-apoptosis [178-179-201-235]. 
Therefore, the catabolism of free sphingolipids (phosphorylation) is considered a cell 
protective mechanism against accumulation of free sphingolipids. 
However, when inflammation becomes severe or out of control, the pro-
inflammatory metabolites should be blocked or at least reduced to protect the body 
organs from major inflammatory damage [179]. So-1P regulates the inflammatory 
response via its immunosuppression effect by retaining T lymphocytes in the thymus 
and lymph nodes [201]. It also regulates lymphocyte traffic from blood to tissues. For 
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example, low doses of So-1P increase lymphocyte movement from the blood into the 
lymphoid organs, while higher doses of So-1P inhibit this movement [202].  
Ceramide one phosphate (C1P) is one of the pro-inflammatory mediators, it 
enhances Archidonic acid (AA) release and prostaglandin synthesis (PG2α), (figure 5) 
[200]. The key element in the biosynthesis of eicosanoids is Archidonic acid 
(Archidonic acid is metabolized in two ways: via cycloxygenase pathway producing 
prostaglandins (PG) and thromboxanes (TX), or via lipoxygenase pathway 
generating leukotrienes (LT)) [179-187-234]. From other side, sphingomyelinase 
enhances stimulation of IL1-β and production of prostaglandins by increasing 
ceramide production. Concurrently, inflammatory mediator IL1-β increases 
intracellular generation of C1P by stimulating ceramide kinase [179]. Thus, C1P acts 
as an anti-inflammation agent via its potential inhibition effect on sphingomyelinase 
(SMase), which in turn leads to a decreased generation of ceramide and pro-
inflammatory mediators (IL1-β and prostaglandins). Thus, inflammation is 
minimized, (figure 4) [187-196].  
 
Figure 4: Role of sphingolipids in inflammatory responses [179-187-196] 
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1.4. Impacts of fumonisin on sphingolipids metabolism 
Fumonisin toxicity has been observed in different animal species [25]. This 
toxicity could be explained by the ability of fumonisin to interfere with sphingolipids 
biosynthesis by blocking ceramide synthase enzyme (figure 5). The above is a result 
of fumonisin being structurally similar to sphinganine (Sa) and sphingosine (So) 
(figure 5) [25-205]. The disturbance of sphingolipids metabolism by fumonisin leads 
to increased intracellular sphingasine and sphingosine, which are known to be 
cytotoxic, (figure 5) [187-190-191-192-197-214-215].  
 
Figure 5: Impact of fumonisin on sphingolipids metabolism [87-192] 
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However, different studies have suggested that the hypothesis of 
sphingolipids metabolism disturbance by fumonisin is unable to explain the 
hepatotoxicity induced by a mixture of myriocin or silymarin with fumonisin.  
Myriocin is potential inhibitor to serine palmitoyl transferase, which in turn 
prevents synthesis of sphinganine and sphingosine, (figure 5). Elevations of hepatic 
toxicity enzymes (ALT and AST) and sphinganine were detected in mice treated only 
with fumonisin, when compared to a control group. Whereas elevations of ALT and 
AST without elevation of sphinganine were observed in mice injected with myriocin 
plus fumonisin, when compared to the control group. Those results are an indication 
of the ability of myriocin to prevent fumonisin caused accumulation of free 
sphingolipids, while it is unable to prevent the fumonisin toxicity effect, (figure 5)     
[87]. 
Silymarin is known as a hepatic protector and antioxidant, because it has 
strong reduction effect on the production and release of cytokines (TNF-α, γINF, and 
IL-2) and ROS from kuffer cells [65-184]. Elevations of Sa and So in mice group 
treated with silymarin plus fumonisin were more pronounced than in the group 
treated with fumonisin alone. While the elevations of hepatic toxicity enzymes (ALT 
and AST) were less pronounced in the group treated with silymarin plus fumonisin 
in comparison to the group treated with fumonisin alone. The above illustrates that a 
combination of fumonisin with silymarin leads to an increase in free sphingolipids 
(Sa and So) accumulations, and a decrease in hepatotoxicity parameters [236]. 
Consequently, fumonisin hepatotoxicity does not depend on the accumulation 
of free sphingolipids inside the hepatocytes alone, as there are other fumonisin 
mechanisms of action to induce hepatic toxicity in existence. 
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2. Macrophage cells 
2.1. Historical background of macrophage 
Monocytes are a type of white blood cell which differentiates to macrophages 
when they enter damaged tissue through the endothelium of a blood vessel. 
Macrophages have different names depending on their location: in the connective 
tissue, liver, spleen, bone and neural tissue they are called Histiocytes, Kupffer cells, 
sinusoidal lining cells, Osteoclasts and microglia, respectively. Monocytes are 
attracted to a damaged site by stimulant chemical substances, including damaged 
cells, pathogens and cytokines, released by macrophages already at the site. [172]. 
Macrophages are active cells that can detect and kill extracellular micro-organisms. 
They perform an immunoregulatory function by secreting pro-inflammatory 
cytokines [IL-1β, IL-2, IL-6, IL-8, IL-12, tumour necrosis factor-α (TNFα), and 
transforming growth factor-β (TGF-β)], and anti-inflammatory cytokines (IL-4 and 
IL-10) [234-237-238-239]. Both IL-1β and TNFα attract neutrophils to an inflamed site, 
while IL-8 is a potent chemoattractant of both lymphocytes and neutrophils to the 
inflamed site [239]. In addition, TNFα and IL-12 stimulate T lymphocytes and natural 
killer cells in the liver to produce IFNγ [238]. Macrophages eliminate micro-
organisms or xenobiotic by producing low molecular weight metabolite molecules 
which cause significant local and systemic biological changes in order to increase 
foreign body recognition. Those metabolite molecules are reactive oxygen species 
(ROS), reactive nitrogen intermediates (RNI), and the eicosanoids (prostaglandins 
(PG), thromboxanes (TX), and leukotrienes (LT)) [234].  
2.2. Impact of fumonisin on Kupffer cells 
Kupffer cells are implicated in hepatic injury induced by various 
hepatotoxicants compounds, such as carbon tetrachloride, acetaminophen, ethanol 
and cadmium [238]. It is believed that the scavenger function of Kupffer cells which 
removes chemical waste products induces liver damage, by producing superoxide 
anions and cytokines [238]. Oxidative stress and TNFα destabilize lysosomal 
membrane which in turn releases lysosomal content, such as lysosomal proteases, 
into the cytoplasm thus damaging mitochondria and inducing apoptosis [199]. 
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Kupffer cells are the main source of superoxide anions, hydrogen peroxide, nitric 
oxide (NO), nitric oxide synthase (NOS) and cytokines as TNFα, IL-1β, IL-6, and IL-
12 [238]. One of the effective ways of FB1 to induce hepatic toxicity is through 
disturbance of the balanced secretion of pro-inflammatory and anti-inflammatory 
cytokines by Kupffer cells [238]. TNFα is an important mediator of FB1 
hepatotoxicity in mice [238-240-241]. FB1 treatment causes an increased expression of 
gene cytokines in mouse liver, such as tumour necrosis factor (TNFα), interleukin 
(IL-1α, IL-1β, IL-12), and interferon (IFNγ), with the most rapid and highest 
augmentations observed in TNFα and IFNγ after 4 and 8 hours of treatment, 
respectively [240-241]. Moreover, FB1 hepatotoxicity is reduced in mice lacking either 
TNFα receptor (TNFR1 or TNFR 2) [242-243]. 
The implication of Kupffer cells in fumonisin hepatotoxicity was checked by 
exposing groups of mice to fumonisin alone or fumonisin plus gadolinium.  
Gadolinium chloride is a selective Kupffer cell toxicant that completely eliminates 
Kupffer cells from the liver. Significant elevations in hepatotoxicity enzymes (ALT 
and AST) were obtained in the group treated with FB1 alone, compared to the control 
and mixed treatment groups. Meanwhile, a significant diminishing in hepatotoxicity 
enzymes (ALT and AST) was observed in the mixed treatment group in comparison 
to the group treated with FB1 alone [238]. Therefore, the implication of Kupffer cells 
in fumonisin hepatotoxicity was proven by the ability of gadolinium to reduce 
fumonisin hepatotoxicity by completely eliminating Kupffer cells in the liver. 
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3. Conclusion  
Exposure to fumonisin leads to an increase in sphinganine and sphingosine in 
the tissues and blood of all tested animal species. This accumulation of free 
sphingolipids could explain one part of fumonisin toxicity pathway. On the other 
hand, a significant decrease of free sphingolipids (Sa and So) without significant 
decrease in hepatotoxicity was observed in mice treated with fumonisin plus 
myriocin when compared to a group treated with fumonisin alone. By contrast, a 
significant increase of free sphingolipids (Sa and So) without a significant increase in 
hepatotoxicity was observed in mice treated with fumonisin plus silymarin when 
compared to the group treated with fumonisin alone. Therefore, the hypothesis that 
fumonisin causes hepatotoxicity through its sphingolipids metabolism disturbance, is  
unable to explain the hepatotoxicity induced by the mixture of myriocin or silymarin 
with fumonisin. Subsequently, fumonisin hepatotoxicity is not only dependent on the 
accumulation of free sphingolipids inside the hepatocytes, but it also appears that 
another fumonisin mechanism of inducing hepatic toxicity exists. 
Other hypotheses of the fumonisin toxicity pathway are: i) Ability of 
fumonisin to disturb the free sphingolipids phosphorylation mechanism. ii) Ability of 
fumonisin to disturb the secretion of pro-inflammatory and anti–inflammatory 
cytokines, and secretion of ROS by Kupffer cells 
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VI. Fumonisin biomarkers  
Fumonisins are distributed worldwide, and they frequently contaminate 
maize at high concentrations. Taking into account that maize is the most important 
cereal grain in animal diets, and it is the third most important cereal grain for human 
consumption.  Therefore, many efforts have been made to find biomarker(s) of FB1 
exposure in animal species, as well as in humans.  
Fumonisins have been reported to induce hepatic and kidney toxicity in all the 
animal species (chapter III). Hepatic toxicity goes with alteration of biochemistry that 
is not specific of FBs exposure. Because FB1 block ceramide synthase (chapter V), 
alteration of sphingolipids was also reported in all species. So, biochemistry and 
sphingagnine levels in tissue and serum have been proposed as biomarkers of 
fumonisins. After a general presentation of what is a biomarker, this chapter will 
present the biomarkers used during FB1 exposure. A specific focus will be done on 
the smallest FBs exposure that could be detected by using each kind of biomarker, in 
terms of dose and duration of exposure. Moreover, the consequences of these effects 
in terms of toxicity will be reported. Indeed, although alterations of sphingolipids 
metabolism occur during FBs exposure, the link between these alterations and cell 
damage is complex. 
1. General aspect of biomarkers 
1.1. Identification and classification of biomarkers parameters 
Biomarkers of xenobiotic exposure are divided in: direct biomarker 
(biomarkers of exposure) and indirect biomarker (biomarker of effect). A biomarker 
of exposure is a quantification of the original compound, or its metabolites, in a body 
compartment or fluid, which is dependent on its pharmacokinetics [263]. A 
biomarker of effect is the presence of certain biological response following exposure 
to a xenobiotic [263]. All biomarkers are evaluated by two aspects: sensitivity and 
specificity [262]. Sensitivity is related to detection of the biomarker before the toxic 
effects or a clinical sign of toxicity appear [261]. Specificity means that the biomarker 
is specific for an agent, and not to other unrelated agents [261]. 
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1.2. Biomarker of FB1 exposure (direct biomarker) 
Direct detection of FB1 in serum or urine is difficult, because it depends on 
many factors as follows:  
 Scenario of toxin exposure: humans have interval exposure to FB1, because 
their food does not mainly include corn or corn products. Whereas animals 
have regular exposure to FB1 due to their feed mainly consisting of corn or 
corn products. 
  Bioavailability:  lower bioavailability of FB1 compared to other mycotoxins 
leads to a decrease in the possibility of direct detection of FB1 in blood and 
urine. For example: The bioavailability of aflatoxin and ochratoxin are: 50%, 
and less than 40% of administered dose, respectively. Whereas, the 
bioavailability of FB1 is less than 5% of administered dose in different animal 
species [25-265-288]. 
 Elimination half-life:  sampling time after exposure to FB1 is one of the points 
that play an important role in direct detection of FB1 in serum or urine. For 
example, elimination half-life of aflatoxin and ochratoxin are approximately 92 
hr, and 320 hr, respectively. Whereas elimination half-life of FB1 is 
approximately 3 hr, depending on animal species [25-265-266-288]. 
 Sensitivity of the measuring apparatus: TLC (thin layer chromatography) is 
low sensitive apparatus to FB1 detection, and it is unable to detect FB1 at low 
concentrations as expected in blood or urine. Because it has high limit of 
detection (1000 ng FB1/g) [18]. By contrast, HPLC or HPLC–MS are high 
sensitive apparatus to FB1 detection, because they have low limit of detection 
(13 and 5 ng FB1/g or ml [23-24-284]. 
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1.3. Biomarker of FB1 effects (indirect biomarker) 
It is divided into specific biomarker (sphingolipids parameters) and non 
specific biomarker (hepatotoxicity parameters). 
1.3.1. Specific biomarker (Sa, So and Sa:So ratio) 
Specificity of free sphingolipids as a biomarker to exposure of FB1 was 
concluded from the following several points:   
 Disturbance of sphingolipids metabolism by fumonisin was recorded in all 
observed animal species [25-81-150]. Free sphingolipids are widely distributed 
in the body, which is present in all tissue cells, and disturbance of 
sphingolipids metabolism by FB1 leads to leakage of intercellular free 
sphingolipids to extracellular, then to blood and urine [25-81-150-173-174-175]. 
 Elevation of Sa and Sa:So ratios in different body compartments (tissue, blood, 
and urine) are observed within few hours post-exposure to a low dose of FB1, 
and remain elevated for several days or weeks, depending on animal species 
[63-171-274-285].   
 Very few types of molecules (such as myriocin and silymarin) can interfere 
with FB1 effects on the sphingolipids metabolism. Myriocin, having an 
antagonistic effect on FB1, leads to a decreased production of free 
sphingolipids (Sa and So). Whereas, silymarin, having a synergic effect on 
FB1, leads to an increased production of sphingolipids [87-236].  
1.3.2. Non specific biomarker (hepatotoxicity parameters) 
There are some parameters which are used to find out the extent of FB1 effects 
on the body organs, such as total protein (TP), total cholesterol (CHOL), alanine 
transaminase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase 
(LDH), gammaglutamyl tranferase (GGT), creatinine kinase (CK), and alkaline 
phosphatase (ALP). However, these parameters are considered as non specific and 
non sensitive biomarkers to FB1 exposure due to the following reasons:  
 Several agents can increase those parameters, such as infectious agents (viral 
and parasitic), drugs (amoxicillin/clavulanic acid, aspirin, paracetamol, etc), 
or mycotoxins (aflatoxin B1, deoxynivalenol and zearalenone) [245-300-301]. 
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Moreover, those parameters are present in several tissues, and any 
disturbance of those tissues leads to secreting them in the body fluid [245-246-
251]. 
 Those parameters are elevated in the serum after several days post-exposure 
to a high dose of FB1, depending on sex and species [63-146-149-150-155-171-
264-275]. 
1.3.2.1. Total Protein (TP) 
Serum protein includes albumin, globulins, fibrinogen and lipoproteins [219-
249]. All the serum proteins are synthesized in the liver except gamma globulins, 
which are synthesized in the lymph nodes [220]. The main functions of a serum 
protein are: control of extracellular fluid distribution, control of infections by 
producing immunoglobulin (antibodies), transport function (albumin and specific 
binding proteins), control of clotting process (fibrinogen) and essential source of 
tissues nutrition [219]. Thus, the total protein assay is used to assess hydration status, 
nutritional status, liver function (capacity of liver biosynthesis), and kidney function 
[221].  
Hypoproteinemia comes from exogenous causes (lack of protein in diet, 
intestinal parasites or malabsorption syndrome) and endogenous causes, such as 
liver disease that lead to decreased serum protein synthesis (albumin), and kidney 
disease which leads to escape of proteins in the urine (albuminuria) [219]. Whereas, 
hyperproteinemia is caused by dehydration (lack of water intake or sever diarrhea), 
chronic liver disease and chronic infection [177-219]. 
In avian, the causes of hypoproteinemia and hyperproteinemia are similar to 
those in mammals. Hyperproteinemia is commonly observed in acute inflammatory 
processes, and late stages of chronic liver disease [164-246-294-295].  
1.3.2.2. Total Cholesterol (TC) 
Cholesterol is an essential molecule for cell membranes, and it is the originator 
of corticosteroid hormones, sex hormones, bile acids, and vitamin D. All tissues 
containing nucleated cells are capable of cholesterol synthesis, which occurs in the 
endoplasmic reticulum and the cytosol. The liver and intestines produce about 20-
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25% of total daily cholesterol [223]. Cholesterol is present in tissues and in serum 
either as a free cholesterol form or combined with a long-chain fatty acid as a 
cholesteryl ester. [222-223]. There are four major lipoproteins responsible for 
cholesterol and fatty acid transportation inside the body (Chylomicrons, LDL, VLDL 
and HDL). Chylomicrons are vehicles transporting dietary absorbed fats (fatty acids, 
cholesterol and cholesteryl ester) from the intestine into the lymph vessels, then 
directly to the blood circulatory system, without passing through the liver (liver 
bypass) [223-303]. Low-density lipoprotein (LDL) and very low density lipoproteins 
(VLDL) are the vehicles of uptake of fatty acids and cholesterols form the blood into 
many tissues. Cholesterol is removed from the tissues by high-density lipoprotein 
(HDL) and transported to the liver, where it is eliminated from the body either 
unchanged or after conversion to bile acids. Cholesterol is a major constituent of 
gallstones, and is an essential factor of atherosclerosis genesis [223]. 
Avian cholesterol consists of free cholesterol and cholesterol esters which are 
measured together as total cholesterol in mammals. It is an important compound 
forming hormones, bile acid and salts, as well as the plasma membrane of cells. 
Avian cholesterol is produced by all nucleated cells, mainly in the liver and intestine 
as with mammals [85-246-294-295]. Avian cholesterol is transported inside the body 
by lipoproteins (VLDL, LDL, and HDL) as in mammals [305-307]. However, the 
absorption pathway of dietary fats (fatty acids and cholesterols) is totally different 
from mammals. The absorbed fats are transported by lipoprotein called portomicrons 
from the intestinal tract into the portal vein. Then they go directly to the liver, where 
they are metabolized and transported to the blood circulatory system and bile duct 
[302]. The accumulation of fats in liver (hepatic steatosis ) is a normal physiological 
condition in migrating birds and ducks [158-302-311], while it is a pathological 
condition (steatohepatitis) in non-migrating birds and mammals [223-302-306]. 
Hypercholesterolemia was reported during acute hepatic steatosis, bile duct 
obstruction, liver disease, starvation, high fat diets and obese birds. Whereas, 
decrease of serum cholesterol level is associated with aflatoxicosis, reduction fat in 
diet and E Coli endotoxemia [85-246-294-295]. 
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1.3.2.3. Aminotransferases 
Aminotransferases include alanine transaminase (ALT) and aspartate 
transaminase (AST). These enzymes are utilized frequently as specific indicators for 
liver necrosis [245]. 
Alanine transaminase (ALT) is found predominantly in the liver, and is 
located only in the cytoplasm of hepatocytes. Elevation of ALT in the serum is 
specific and sensitive indicator for hepatitis, which leads to increased hepatocellular 
membrane permeability [245-308]. AST is present in both the cytoplasm (20%) and 
mitochondria (80%) of hepatocytes and many other cells (heart, skeletal 
muscles, kidneys, brain, pancreas and red blood cells) [245-308]. Any alteration of cell 
membrane permeability leads to slight elevation of AST in the serum as in the case of 
hepatitis. Whereas, sever cell damage leads to high elevation of AST in the serum, 
due to release of the enzyme from cytoplasm and mitochondria as hepatic necrosis 
[308]. AST is also an indicator of myocardial infarction, acute pancreatitis, 
acute hemolytic anemia, acute renal disease, musculoskeletal diseases, and trauma 
[245].  Therefore, ALT is a more specific and sensitive indicator to hepatocyte injury 
than AST [245]. Elevation of serum ALT and AST levels are indicated to viral, drug, 
toxin induced hepatitis or necrosis, and acute biliary tract obstructions. On the other 
hand, normal elevation of serum ALT is observed with physical exercise or in dietary 
choline deficiency. Moreover, ALT normally fluctuates over the course of time [251]. 
Declining of ALT and AST are indication of either hepatocyte recovery, or hepatocyte 
being unable to further release these enzymes as in the case of hepatic failure [245]. 
In avian, Alanine transaminase (ALT) and Aspartate transaminase (AST) are 
not specific indicators of hepatic injury, in contrast to mammals, because they are 
produced by muscle atrophy. Therefore, more specific tests of muscle atrophy, such 
as creatinine kinase (CK) are needed to confirm the elevation cause of those enzymes 
(ALT and AST) in avian [246-247-294-295].  
1.3.2.4. Lactate dehydrogenase (LDH or LD) 
LDH is an enzyme located in the cell mitochondria of most body tissues. 
Therefore, complete cell disruption is necessary before it is released in large 
quantities. There are five sub-classes of LDH, which are distributed in specific tissues 
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as follows: LDH-1 and LDH-2 are found predominantly in heart, kidneys and 
erythrocytes. LDH-3 is most found in the lungs, whereas LDH-4 is present in 
kidneys, placenta and pancreas. LDH-5 is found in the liver and striated muscles. The 
elevation one of LDH sub-classes in serum is indicator to disturbance in specific 
tissues [244-251]. Elevation of LHD in the serum occurs during cell necrosis or 
hemolysis conditions, such as anemia or incorrect handling of blood samples in vitro 
[173-251-308].  
In avian, LDH is distributed in a wide variety of tissues as it is in mammals. 
However, there is no information about sub-classes of LDH, in contrast to mammals. 
Therefore, LDH elevation in avian serum is not specific to any organs. In addition, 
LDH is an unstable enzyme that rises and falls more quickly in serum than AST. 
Therefore, LDH is considered a poor indicator for liver damage in avian. Regardless 
of that, the common cases which lead to increased LDH in serum of avian are liver 
necrosis, muscular damage, and blood hemolytic conditions. In the case of body 
weight decrease, differentiated test of muscle atrophy, such as creatine kinase (CK) is 
necessary [246-247-294-295-308].   
1.3.2.5. Gamma-Glutamyl Transferase (GGT)  
GGT is present in cell cytoplasm and also bound to cell membranes of many 
tissues such as, kidneys and pancreas, with more pronunciation in the liver. 
Therefore, it is considered specific biomarker for liver health status. GGT plays an 
important role in the transfer of amino acids across the cellular membrane, 
leukotrienes metabolism and intracellular regulation of reactive oxygen species by 
synthesis and degradation of glutathione (potential antioxidant) [248-251-308]. 
Elevation of serum GGT activity is a biomarker for acute viral hepatitis, bile duct 
obstruction (cholestasis), pancreatitis or drug administration (paracetamol and 
phenobarbitone) [245-251-308]. Slight elevation of GGT is observed in cardiovascular 
and circulatory diseases, such as atherosclerotic plaques [308].  
In avian, GGT enzyme is more present in the biliary and renal tubular 
epithelium. In addition, elevation of this enzyme in the serum is commonly due to a 
biliary origin. Therefore, it is the most specific indicator of cholestatic liver disease. 
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However, it is a lower sensitivity indicator of liver disease when compared to AST 
[246-295]. 
1.3.2.6. Alkaline phosphatase (ALP) 
ALP is present in the plasma membrane of cells in all body tissues, with high 
quantities in intestines, kidney, bone, bile, liver, placenta and the lactating breast 
[245-251-309]. ALP is normally elevated in the serum of growing children and 
women in the third trimester of pregnancy.  ALP is used as a biomarker for some 
liver diseases, such as hepatitis and biliary obstruction. ALP is less specific biomarker 
than GGT for hepatic and biliary injury, because ALP is released in some cases, such 
as bone tumor disease (Paget’s disease), osteomalacia, rickets and 
hyperparathyroidism [245-251].  
In avian, ALP is mainly activated in the duodenum and kidneys, with low 
activity in the liver. Concurrently, other avian organs show no ALP activity in its 
tissues, in contrast to mammals. High elevation of ALP in serum is an indicator to 
enteritis. While, slight elevation of ALP is most common in hepatocellular irritation, 
not damage. Therefore, ALP is not specific or sensitive to hepatic damage in contrast 
to mammals [246-295].  
2. Uses of biomarkers in FB1 exposure   
This part will present the biomarkers of FB1 exposure in laboratory animals 
and farm animals (high and low sensitivity animals).  
2.1. Biomarker of FB1 exposure in rodents 
In male Sprague-Dawley rats, the dose required to increase Sa:So ratio in 
kidney and  urine after 4 weeks was lower (15 mg FB1/kg of feed) than the dose 
required to increase Sa:So ratio in liver and serum and hepatotoxicity enzymes (150 
mg FB1/kg of feed) [264]. In male-F344 rats, 5 mg FB1/kg of diet was able to elevate 
Sa:So ratio in kidneys and urine after 6 and 10 weeks post-feeding, respectively . 
Whereas, 150 mg FB1/kg of diet for 2 years was unable to elevate Sa:So ratio in liver 
or hepatotoxicity enzymes, such as TP, ALT, GGT, and ALP [264]. In female-F344 
rats, Sa:So ratio in kidney was increased by half a dose ( 50 mg FB1/kg of feed) 
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necessary to increase Sa:So in liver (100 mg FB1/kg of feed) after 6 weeks of 
exposure. Moreover, hepatotoxicity enzymes were not elevated in female-F344 rats 
fed 150 mg FB1/kg of diet for 2 years,  (table 16)[264].  
Table 16: Effects of FB1 exposure on biomarkers (Sa:So and hepatic enzymes) in 
rodents 
Species 
Sa:So 
Kidney/Urine 
Sa:So  
Liver/Serum 
Biochemistry* Effect  Ref 
Rat 
SD 
Male  
15 mg/kg/4 wks 150 mg/kg/4 wks 150 mg/kg/4 wks LOEL 
[264] 
 50 mg/kg/4 wks 50 mg/kg/4 wks NOEL 
Rat 
F344 
Male 
5 mg/kg/10 wks   
LOEL 
[264] 
99 mg/kg/1 wks  484 mg/kg/1 wks 
  234 mg/kg/4 wks 
NOEL 
 150 mg/kg/2 years 150 mg/kg/2 years 
Rat 
F344 
Female 
50 mg/kg/6 wks 100 mg/kg/6 wks  
LOEL 
[264] 
99 mg/kg/1 wks  484 mg/kg/1 wks 
  234 mg/kg/4 wks 
NOEL 
15 mg/kg/2 years 50 mg/kg/2 years 150 mg/kg/2 years 
Mice 
B6C3F1 
Male 
female 
234 mg/kg/1 wks  484 mg/kg/1 wks LOEL 
[264] 
163 mg/kg/4 wks  234 mg/kg/4 wks  NOEL 
Mice 
B6C3F1 
Female 
 10 mg/kg/4 wks 50 mg/kg/4 wks LOEL 
[275] 
  10 mg/kg/4 wks NOEL 
Dose: mg FB1/kg of feed; Sa :So : sphinganine/sphingosine ratio 
*LOEL (lowest-observed-effect-level) or NOEL (No -observed-effect-level) observed on alanine 
aminotransferase, aspartate transaminase, alkaline phosphatase and  cholesterol 
 
In female and male F344 rats, the dose required to elevate Sa:So ratio in urine 
(99 mg FB1/kg of diet) was lower than the dose required to elevate Sa:So ratio in the 
urine of male and female B6C3F1mice (234 mg FB1/kg of diet), after one week of 
feeding [264]. Surprisingly, urinary Sa:So ratio in rats and mice fed a diet at 
concentration 99 and 234 mg FB1/kg, respectively, were significantly elevated 
between the 7th and 14th days in rats and only at the 7th day in mice, after that they 
declined to no significant levels at the 28th day, (table 16) [264]. 
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In female B6C3F1 mice, the dose required to elevate serum Sa:So ratio was 
lower (10 mg FB1/kg of diet) than the dose required to increase hepatotoxicity 
parameters , such as cholesterol and ALP (50 mg FB1/kg of diet), for 28 days, (table 
16) [275]. 
In male F344 rats, serum and urinary Sa:So ratio were quickly elevated after 12 
hours, and remained so far 8 days before returning to control level at day 10 post-
dosing with a single oral dose of 10 mg FB1/kg b.w. (table 16) [285].  
It is apparent from those studies that sensitivity of rodents to FB1 exposure 
was different according to exposure dose, animal strains, animal sex, and animal 
organs. On the other side, the required dose of FB1 to elevate hepatotoxicity 
parameters was higher than the required dose to elevate Sa and Sa:So in fluid and 
tissues. Also, the required dose of FB1 to increase Sa and Sa:So in the serum was 
higher than the one for tissues. Moreover, FB1 effects on sphingolipids metabolism 
and hepatotoxicity enzymes were more pronounced with short term exposure than 
with long term exposure and higher than NOAEL based on kidney toxicity during 
chronic exposure in rat used for the determination of the PMTDI (page 34). 
2.2. Biomarker of FB1 exposure in farm animals 
2.2.1. Horses and swine 
Sphinganine and sphinganine to sphingosine ratio in serum rapidly elevated 
two days post-feeding ponies with contaminated diets at level 44 mg/kg of feed. 
Hepatotoxicity parameters (ALT and AST) and ELEM signs appeared later ten days 
post-feeding [252]. In another study, sphinganine and Sa:So ratio of serum increased 
at equivalent oral doses of 0.2 mg/kg b.w./day for 28 days. Hepatotoxicity and 
ELEM were observed at equivalent oral doses ≥ 1 mg/kg b.w. /day for 28 days [150-
191-193].  
Elevation of Sa:So and  hepatotoxicity parameters in serum and ELEM signs 
did not appear in horses fed 15 mg FB1/kg of diets during 150 days [290]. A similar 
result was found with a pony fed on a diet containing maize with 15 mg FB1/kg 
during 130 days [252].   
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In piglets, Sa:So ratio in serum and urine were rapidly elevated after a single 
oral dose of 5 mg FB1/kg b.w. (6 and 12 hr post-dosing, respectively), whereas, 
toxicity signs and hepatotoxicity parameters was detected later (24 and 96 hr post-
dosing, respectively) [63]. 
Obviously, that disturbance of sphingolipids occurred rapidly before the 
appearance toxicity signs and elevations of hepatotoxicity enzymes. Besides that, the 
required dose to increase Sa and Sa:So ratio was lower than the required toxicity 
dose.  
2.2.2. Ruminants 
The information concerning biomarkers to FB1 exposure in ruminants is 
poorly documented. 
In calves, hepatotoxicity parameters, such as AST, GGT, LDH, and cholesterol 
increased 10 days after consumption of 148 mg FBs/kg of feed [133]. 
In Holstein steers, AST and GGT were elevated after 253 days of feeding on 94 
mg FB1/kg diet, other hepatotoxicity parameters, such as total protein, cholesterol 
and LDH were not affected [138].  
Meanwhile, in angora goats, cholesterol, AST, GGT, and LDH were elevated 
after 112 days of feeding on 94 mg FB1/kg diet [142]. 
Unfortunately, the effect of FB1 on sphingolipids metabolism was not studied 
in those experiments. 
2.2.3. Poultry 
The fixed standards of specific and non specific biomarker of fumonisin 
exposure were not available in poultry, because they were dependent on many 
factors such as species, sex, age, body temperature, feed quality, and hydration states 
[219-248-249].  
2.2.3.1. Layer hens and broiler 
In laying hens, decrease in serum total protein and increase in AST activity 
were observed in groups fed 200 mg FB1/kg, for 112 days. Concurrently, GGT, ALP, 
or LDH were not affected in groups fed 200 mg FB1/kg of feed for 420 days [155]. In 
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one-day-broilers which consumed contaminated diet for 21 days, AST and 
cholesterol increased at 300 mg FB1/kg of feed. But ALP, LDH and total protein were 
not affected at 400 mg FB1/kg of feed, (table 17) [148]. 
Table 17: Effects of FB1 exposure on biomarkers (Sa:So and hepatic enzymes) in 
chickens 
Species Effet Sa :So ratio Biochemistry Ref 
Laying 
hens  
White 
Leghorn 
LOEL  200 mg/kg/112d: TP, AST 
[155] 
NOEL 
 
100 mg/kg/420d: TP, AST 
200 mg/kg/420d: CHOL, ALT, GGT, 
LDH, ALP 
Broiler 
LOEL 
 
100 mg/kg/21d: AST 
200 mg/kg/21d: CHOL [148] 
NOEL  400 mg/kg/21d: TP, LDH, ALP 
Broiler 
Arbor 
Acres 
LOEL 20 mg/kg/21d liver 
80 mg/kg/day serum 
80 mg/kg/21d: AST 
[146] 
NOEL  80 mg/kg/21d: CHOL, LDH, ALP 
Broiler 
Cornish 
cross 
LOEL 25 mg/kg/42d liver  
[153] NOEL 
 
50 mg/kg/42d: TP, CHOL, AST, GGT, 
LDH, ALP 
Dose: mg FB1/kg of feed; LOEL: lowest-observed-effect-level; NOEL: No -observed-effect-
level; NC: not conducted; Sa :So : sphinganine/sphingosine ratio; TP: total protein ; ALT: 
alanine aminotransferase; AST : aspartate transaminase ; GGT : Gamma-glutamyltransferase ; 
LDH : Lactate dehydrogenase ; ALP : Alkaline phosphatase; CHOL, cholesterol 
Unfortunately, Sphinganine and sphinganine to sphingosine ratio were not 
tested in both experiments.  
In one-day-broiler chickens fed a contaminated feed for 21 day, Sa:So ratio  in 
liver increased at the group fed with 20 mg FB1/kg feed,  and  Sa:So ratio of serum 
and AST increased at the group fed with 80 mg FB1/kg feed. Other hepatic 
parameters, such as cholesterol, ALP and LDH were not affected by the 80 mg 
FB1/kg feed (table 17) [146]. 
In one-week old broilers, 25 mg FB1/kg of diet for 42 days was sufficient to 
induce a significant elevation of Sa and Sa:So ratio in the liver. By contrast, 50 mg 
FB1/kg of feed for 42 days was unable to elevate serum hepatotoxicity parameters, 
(table 17) [153]. 
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2.2.3.2. Turkeys 
In one-day old turkeys, Serum Sa:So ratio was increased by feeding them with 
75 mg FB1/kg of feed for 21 days. Unfortunately, hepatotoxicity parameters were not 
measured in this study (table 18) [154].  
Table 18: Effects of FB1 exposure on biomarkers (Sa:So and hepatic enzymes) in 
turkeys 
Species Effet Sa :So ratio Biochemistry Ref 
 
LOEL 75 mg/kg/21d serum  
[154] 
NOEL   
 
LOEL 
 
100 mg/kg/21d: CHOL, AST, 
ALP [310] 
NOEL  200 mg/kg/21d: TP, GGT 
 
LOEL 25 mg/kg/21d-liver 325 mg/kg/21d: ALT, GGT 
[149] 
NOEL  250 mg/kg/21d: ALT, GGT 
BUT 9 
LOEL 5 mg/kg/49d liver, kidneys 
20 mg/kg/7d liver, kidneys 
 
[156] 
NOEL 
20 mg/kg/63d serum 
20 mg/kg/63d: TP, CHOL, AST, 
LDH, ALP 
Nicholas 
LOEL 25 mg/kg/84d - liver  
[153] NOEL 
50 mg/kg/84d-  serum 
50 mg/kg/84d: TP, CHOL, AST, 
GGT, ALP 
Dose: mg FB1/kg of feed; LOEL: lowest-observed-effect-level; NOEL: No -observed-effect-
level; NC: not conducted; Sa :So : sphinganine/sphingosine ratio; TP: total protein ; ALT: 
alanine aminotransferase; AST : aspartate transaminase ; GGT : Gamma-glutamyltransferase ; 
LDH : Lactate dehydrogenase ; ALP : Alkaline phosphatase; CHOL, cholesterol 
In one-day turkeys fed a contaminated diet for 21 days, liver Sa:So ratio 
increased with a dose of 25 mg FB1/kg of feed. Serum GGT and AST were elevated 
at a dose of 325 mg FB1/kg of feed,(table 18) [149].  
In one-day old turkeys, elevation of Sa:So ratio in liver and kidneys was 
observed quickly at 7 days after feeding with 20 mg FB1+ FB2/kg of feed. Whereas, 
Sa:So in serum and hepatotoxicity parameters remained nearly constant over a 
period of 9 weeks. Moreover, elevation of Sa:So ratio in tissues was dose-dependent. 
It increased at 49, 35, and 7 days post-feeding turkeys with 5, 10 and 20 mg FB1+ 
FB2/kgof feed, respectively. Also, the liver and the kidneys seem to have the same 
sensitivity to fumonisin exposures, (table 18) [156].  
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In one-day old turkeys, cholesterol decreased, and AST and ALP increased 
after 21 days of receiving 100 mg FB1/kg of feed, whereas, protein and GGT was not 
affected by feeding 200 mg FB1/kg of feed during the same period, (table 18)  [310]. 
In one-week old turkeys, Sa and Sa:So ratio in liver significantly increased at a 
dose of 25 mg FB1/kg of feed for 3 months. Meanwhile, hepatotoxicity parameters 
were not affected by a dose of 50 mg FB1/kg of feed for the same period, (table 18) 
[153]. 
2.2.3.3. Ducks 
In one-day old ducks, sphinganine and Sa:So ratio in serum, liver and kidney 
were increased at a very low dose of 2 mg FB1/kg feed, for 7 days. Concurrently, 
hepatotoxicity parameters, such as cholesterol, ALT, LDH and ALP were increased at 
a dose of 32 mg FB1 /kg, for 7 days, and total protein was increased at a dose of 128 
mg FB1/kg, for 7 days, while, AST and GGT were not affected at 128 mg /kg, during 
the experimental period of 77 days. The highest increase values of Sa and Sa:So were 
recorded in the kidneys and not  in  the liver. Thus, it was suggested that the kidney 
is the most sensitive organ to FB1 exposure.  Interestingly, in this study, Sa:So ratio in 
serum and tissues, and hepatotoxicity enzymes declined after 7 to 21 days post-
intoxication. The effects of FB1 on Sa:So ratio in serum and tissues, and 
hepatotoxicity parameters from 49th to 77th days were nearly constant. Thus, it 
appears that cumulative dose of FB1 in the tissues and the serum has a more 
extensive effect on the Sa:So ratio at a short period (7–21 days) compared to a longer 
period (42–77 days). For example, the mean Sa:So ratio increased from 0.2 to 6.7 in 
ducks receiving a cumulative dose of 55 mg FB1 over 7 days, although it only 
increased from 0.2 to 0.5 when ducks received a cumulative dose of 365 mg over 49 
days, (table 19) [165-170-171]. 
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Table 19: Effects of FB1 exposure on biomarkers (Sa:So and hepatic enzymes) in 
ducks 
Species Effet Sa :So ratio Biochemistry Ref 
Mule 
Male 
LOEL 2 mg/kg/7d serum, 
liver, kidneys 
128 mg/kg/7d: TP 
32 mg/kg/7d: CHOL, ALT, LDH, ALP [165-
170-
171] 
NOEL 
 
128 mg/kg/77d: AST, GGT 
32 mg/kg/77d: TP 
8 mg/kg/77d: CHOL, ALT, LDH, ALP 
Mule 
Male 
LOEL 
60 mg/kg/6d serum* 
60 mg/kg/8d*: TP, CHOL, ALT, GGT, 
LDH [163-
164] NOEL 
60 mg/kg/5d serum* 
60 mg/kg/7d*: TP, CHOL, ALT, GGT, 
LDH 
Mule 
Male** 
LOEL 10 mg/kg/12d - liver 10 mg/kg/12d: TP, CHOL, ALT, LDH 
[158] 
NOEL  20 mg/kg/12d: GGT, ALP 
Pekin 
Male 
LOEL 100 mg/kg/21d serum 100 mg/kg/21d:  GGT 
[162] 
NOEL  400 mg/kg/12d: TP, CHOL, AST 
Dose: mg FB1/kg of feed; * Obtained by calculation from the dose administered by gavage 
** Study conducted during force feeding; LOEL: lowest-observed-effect-level; NOEL: No -
observed-effect-level; NC: not conducted; Sa :So : sphinganine/sphingosine ratio; TP: total 
protein ; ALT: alanine aminotransferase; AST : aspartate transaminase ; GGT : Gamma-
glutamyltransferase ; LDH : Lactate dehydrogenase ; ALP : Alkaline phosphatase; CHOL, 
cholesterol 
In 6-week old mallard ducks, Sa and Sa:So ratio in the serum were increased 
rapidly after daily received of 5 mg FB1/kg b.w. by oral route, for 2 and 6 days, 
respectively. Whereas, hepatotoxicity parameters were elevated later after 8 days 
post-dosing, (table 19) [163-164].   
In 12-week old mallard ducks, Sa:So ratio in the liver and serum, and 
hepatotoxicity enzymes such as protein, cholesterol, ALT, and LDH were elevated 
after force-feeding 10 mg FB1/kg of feed, for 12 days. In contrast, GGT and ALP were 
constant after force-feeding 20 mg FB1/kg of feed, for 12 days. Interestingly, in this 
study force-feeding does not create any alteration in sphingolipids metabolism of the 
control group. By contrast, hepatotoxicity parameters were increased, (table 19) [158].  
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From those studies it became clear that: ducks were more sensitive to FB1 
exposure compared to laying hens, broilers and turkeys. The required dose to elevate 
Sa and Sa:So ratio in serum and tissues was lower than the required dose to elevate 
hepatotoxicity enzymes. Sa and Sa:So ratio were more sensitive in the liver than in 
the serum. Except in ducks, 2 mg FB1/kg of feed for one week was able to increase 
Sa and Sa:So in the serum and tissues. In ducks, a disturbance of sphingolipids 
metabolism by FB1 was more pronounced in kidneys than in liver, whereas in 
turkeys it was quite similar in both tissues. Aspartate transaminase (AST) was more 
sensitive to FB1 exposure compared to other hepatotoxicity enzymes in laying hens, 
broilers and turkeys. By contrast, AST was not affected at a high dose (128 mg 
FB1/kg of feed) for a long period (77 days) compared to other hepatotoxicity 
enzymes in ducks. FB1 had clearly adverse effects on sphingolipids metabolism and 
hepatotoxicity enzymes at short exposure periods rather than long exposure periods.  
2.3. Biomarkers of FB1 exposure in human 
2.3.1. Biomarker of FB1 exposure (Urinary FB1) 
In Mexico, significant correlation between urinary FB1 (UFB1) and maize 
tortilla intake was recorded during a comparative study of three different 
consumption regions (high, medium or low). The average of urinary FB1 levels was 
threefold higher in women from a high consumption region than women from a low 
consumption region [272].   
In China, a significant correlation between urinary FB1 and dietary FB1 intake 
was obtained in Huaian and Fusui regions.  The estimated daily FB1 exposures in 
those areas were greater than the Provisional Maximum Tolerable Daily Intake 
(PMTDI) of 2 μg/kg b.w. [273].  Also, significantly correlation between urinary FB1 
and dietary FB1 intake was obtained in people from South Africa, who prepared and 
consumed maize porridge meals from home-grown maize. The mean probable daily 
intake (PDI) of FB1 was 4.84 mg/kg b.w. /day. The urinary samples were collected 
two times per day (12 hr post meal) [271]. 
Therefore, the authors suggested that urinary FB1 could be a potential 
biomarker for FB1 exposure. This explication was not precise because direct detection 
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of FB1 in urine was dependent on many factors, such as scenario of toxin exposure, 
bioavailability of FB1, sampling time, and sensitivity of apparatus used to detect FB1 
in serum or urine (LOD), as previously explained in this chapter. 
2.3.2. Biomarker of FB1 effects (sphingoid bases and their ratio) 
In recent years a lot of studies have been conducted to link dietary FB1 to 
sphingolipids disturbances in human serum and urine. 
In China, a significant correlation between urinary Sa:So ratio and dietary FB1 
intake was recorded in the regions of Huaian and Fusui, where the volunteers 
consumed contaminated diet at a high dose of FB1 (110 μg/kg b.w. per day) for one 
month. Men urinary Sa:So ratio increased three times higher compared to the control 
group of men. While, women urinary Sa:So ratio was unchanged, (table 20)  [267]. 
Adverse results were reported at the same regions (Huaian and Fusui) in China, 
which demonstrated no correlation between dietary FB1 intake and Sa:So ratio in 
serum and urine in both areas [273]. 
Table 20: Biomarkers of FB1 in human 
Regions Intake of maize Sa:So in urine 
Sa:So in 
serum 
Ref 
China (Huaian and 
Fusui) 
110 μg FB1/kg b.w. 
/day,  one month 
Men: increased 
threefold  
Women: not 
affected 
 [273] 
Southern Brazil high 1.57  
[268] 
Northern Argentina high 0.69  
Central Argentina low 0.36  
Southern Italy low 0.36  
South Africa Bizana  
6.7 to 5.8 µg FB1/ kg 
b.w./ day 
Low  
(woman > men ) 
High 
[269-
270] South Africa Centane High  
(woman > men ) 
Low 
 
Significant different elevations of urinary Sa:So ratio were recorded between 
two populations with high maize consumption in northern Argentina (0.69) and 
southern Brazil (1.57) [268]. Concurrently, similar urinary Sa:So ratio was obtained 
between two populations with low or no maize consumption in central Argentina 
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and southern Italy (0.36). The probable daily intake of FB1 (PDI) in high maize 
consumption areas was similar. The two populations of high maize consumption 
were considered treated groups, and the two populations with low or no maize 
consumption were assumed to be the control groups, (table 20) [268].   
 In South Africa, serum Sa:So ratio in men and women were significantly 
lower in Bizana (low esophageal  cancer incidence area) compared to Centane (high 
esophageal  cancer incidence area). By contrast, urinary Sa:So ratio in men and 
women were significantly higher in Bizana than Centane. The estimated mean 
probable daily intake (PDI) in both areas (Bizana and Centane) was quite similar 6.7 
to 5.8 µg FB1/ kg b.w. / day. Interestingly in both areas, urinary Sa:So ratio were 
significantly lower in men than in women, (table 20) [269-270]. 
Therefore, the authors concluded that these results negated the sphingoids 
bases (Sa and So) and their ratio as potential biomarker of fumonisin exposure in 
humans, and further studies were needed to provide a disturbance of sphingolipids 
metabolism in serum and urine as a biomarker of human fumonisin exposure. That 
conclusion was not accurate, because, strong correlation between FB1 exposure and 
disturbance of sphingolipids metabolism was recorded in all tested animals. Also, the 
disturbance of sphingolipids metabolism was more pronounced when animals were 
exposed to FB1 for a short period rather than a long period in the case of rats, ducks 
and turkeys. Furthermore, absent correlation between FB1 intake and Sa:So in serum 
and urine in south Africa did not reveal to an absence of FB1 exposure, because the 
carcinogenic effect of FB1 was recorded in its regions. 
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3. Conclusion  
Assessment of Sa and Sa:So ratio alterations in tissues, serum and urine were 
the best specific and sensitive indirect biomarkers for exposure to fumonisins in all 
tested animal species for the following reasons: 
 The lowest-observed-effect level (LOEL) required to increase Sa and Sa:So 
ratio was usually lower than LOEL of hepatotoxicity in all animal species. 
 Sphinganine and Sa:So ratio was elevated rapidly and remained elevated in 
different body compartments for several days (8 days) post-intoxication. 
From other side, biomarker of FB1 effects (indirect biomarkers) was dependent on 
many factors, such as:  
 Dose dependency: the required dose of FB1 to increase Sa and Sa:So in serum 
were higher than in the tissues (liver and kidneys) 
 Organs: Sa:So ratio in kidneys of rat and ducks were more sensitive than that 
in their liver. Concurrently, it was quite similar in turkeys.  
 Species:  mice were more resistant than rats, broilers and turkeys were more 
resistant than ducks to FB1 exposure.  
 Strains: Sa:So ratio in liver and hepatotoxicity parameters were more sensitive 
in  male Sprague-Dawley rats than male F344 rats and in male Mule ducks 
than in male Pekin ducks.  
 Sex: Sa:So ratio in kidneys and urine was more sensitive in male F344 rats than 
in female F344 rats. By contrast, Sa:So ratio in liver was more sensitive in 
female F344 rats than in male F344 rats.  
 Duration of exposure: fumonisins had a strong effect on sphingolipids 
metabolism and hepatotoxicity when animals were exposed over a short 
period rather than a longer period. That reveals to adaptation of animal cells 
to FB1 toxicity after a long exposure period. 
In conclusion, sphingolipids parameters are the best specific and sensitive 
biomarker to FB1 exposure in animals. By contrast, in the case of humans, the authors 
suggested that direct detection of urinary FB1 is better biomarkers to fumonisin 
exposure than sphingolipids parameters.   
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CHAPTER 2: MATERIALS AND METHODS 
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This part will present the material and methods which used in FB2- 
toxicokinetic, and then the FBS -toxicity studies. 
I. Safety handling procedures 
To control hazard effects of FBs, several of safety procedures have been taken 
as following to: wearing protective clothing (rubber gloves and laboratory coats) was 
during animals and laboratory manipulations. Decontamination of laboratory tools 
by soaked in sodium hypochlorite (5% w/v) for at least 30min, followed by addition 
of acetone (5% v/v) for 30 min, and then rinsed with distilled water. Laboratory 
biological wastes were collected in hygienic garbage.  
II. FB2-Toxicokinetic Experimental 
The pharmacokinetic of FB2 in rat was already described by Shephard [28]. 
The objectives of our study were to describe a validation method for extraction of FB2 
in plasma, and to evaluate the toxicokinetic parameters of the toxin in duck and 
turkey.  
1. Chemicals and apparatus 
1.1. Chemicals   
Standard of FB2 that used for analytical purpose was purchased from Biopure 
(Tullin, Austria), while standard of FB2 used in animal experimentation was 
purchased from Sigma (St. Louis, MO, USA). 
OPA (ortho-phthaladehyde) and other chemicals of the highest quality were 
purchased from Sigma (St. Louis, MO, USA). HPLC grade solvents were supplied by 
Scharlau (Barcelone, Spain).  
1.2. Apparatus 
The HPLC system used for FB2 determinations was composed as follows: an 
AL 728 auto-sampler (Alcott micrometrics, Norcross, USA), a M 2200 pump (Bischoff, 
Leonberg, Germany) and a RF 10A XL programmable fluorescence detector 
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(Shimadzu, Japan). The chromatograms obtained were exploited using PIC 3 
software from ICS (Toulouse, France).  
1.3. Materials 
Table 21: Material used in FB2-Toxicokinetic experimental 
Name Model Manufacturer Origin 
Balances 
AJ 100 classe 1 
BP2100 
Mettler 
Sartorius 
Viroflay, France 
Toledo, Espagne 
pH-meter 522 Technalab Toulouse, France 
Centrifuge GP 200 SX Jouan France 
Magnetic agitator Rotamag 10 Prolabo France 
Stir table  HS 501 Ika Labortechnik Allemagne 
Extraction vacuum Visiprep 12 ports Supelco USA 
Vacuum air pump  DAA-124-ED MFG.Corp. USA 
Teflon Potter  OT13 Braun Germany 
Ultraturrax  TP18 Ika Germany 
2. Animals and sampling protocols 
All experimental procedures using birds were in accordance with the French 
National Guidelines for the care and use of animals for research purposes. Five male 
mule ducks and five male turkeys (body weight around 2 kg) were experimented.  
Each bird received a single IV dose of 1 mg FB2 (in NaCl 0.9%)/kg b.w. under 
a volume of injection of 1 ml/kg body weight in Jugular vein. Blood samples (2 ml) 
were taken at different times after injection of the toxin:  0, 3, 10, 20, 30, 45, 60, 90, 120, 
240 min.  
Concerning oral route, eight birds from each species received a single oral 
dose of 10 mg FB2 (in NaCl 0.9%)/kg b.w. under a volume of injection of 10 ml/kg 
b.w. Jugular vein blood samples (2 ml) were collected in EDTA tubes at different 
times after injection of the toxin:  0, 30, 60, 120, 180, and 300, 420 and 600 minutes.  
All blood samples were centrifuged (15 min-3000g) and plasmas were stored 
at -20°C until use. 
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3. Extraction of FB2 
Protein was precipitated by mixing 250 μl of plasma with 500 μl of borate 
buffer (0.1M, pH 5.8) and 750μl of acetonitrile.  Samples were placed on a stir table 
for 30 min at 300 rpm and then centrifuged for 15 min at 3000 x g at room 
temperature. The supernatant fraction was then defatted by solid phase extraction on 
LC18 columns (Supelclean, Supelco, USA). Before that, LC18 columns were 
preconditioned with 3 ml of: H2O, acetonitrile, acetonitrile/borate buffer 0.1 M, pH 
5.8 (V/V), respectively. The deproteinized supernatants of the samples were passed 
through the LC18 columns. 4 ml of borate buffer (ph 5.8), and 3 ml of acetonitrile 
were used to washed the columns.  
All the eluates samples were collected (around 8 ml), vortexes, and then 
purified by strong anion exchange (SAX) solid phase extraction (Bond Elut, Varian, 
Harbor City, USA). Before that, SAX columns were preconditioned with 5ml of 
methanol and 5 ml of methanol/H2O (V/V). The SAX columns were then washed by 
8 ml of methanol/H2O (V/V) and 3 ml of methanol respectively. Finally, the samples 
were eluated by 1.5 ml of methanol/acetic acid (100/1 v/v), and evaporated at 40 °C 
in the dark under a gentle stream of Nitrogen. The dry residues were re-suspended 
with 250 μl of acetonitrile/water (1:1) before HPLC analysis. 
4. OPA derivatization and HPLC analysis 
OPA (Ortho-Phtalaldehyde) reagent was prepared by mixing of 25mg OPA, 
500μL ethanol, 25 µl β mercaptoethanol and Borate buffer QSP 50ml, and stored at 
4°C. 20μl of β mercaptoethanol was added into OPA reagent every 2 days in order to 
maintain its reaction ability, according to Rice et al [277]. Borate buffer was prepared 
by mixing of 3g Boric acid, 30ml distilled water, 30ml KOH1M+KOH1M QSP (pH-
10.5), and distilled water QSP 100 ml.   
50µl of OPA, 50µl of 0.1M borate buffer (pH 8.3), and 50µl of H2O were added 
to 50µl of re-suspended sample (or standard) and finally mixed by the auto-sampler. 
After one minute, 20 µl of the derivatized sample were injected in the HPLC system. 
The HPLC conditions were: 
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Column: prontosil C18 column, 5μm, 250mm×4.6mm, 120 ˚A (Bischoff, Leonberg, 
Germany).  
Mobile phase: CH3OH/NaH2PO4-0.1M pH 3.35 (75/25 v/v)  
Flow rate: 1.00 ml/min 
Fluorescence detection: excitation and emission wavelength of 335 and 440 nm 
respectively.  
5. Calibration curve of FB2   
The calibration curve was performed to calibrate the equipments used in the 
experimental. FB2 standard [50.5µg/ml] was diluted in acetonitrile/water (1:1) to 
prepare ten standard solutions (0, 0.001, 0.006, 0.013, 0.025, 0.063, 0.125, 0.250, 0.650, 
1.250 µg/ml). These standards were injected in triplicate, and the average values 
were taken to check the relationship between the injected concentration and the 
observed response of the detector. The observed relation was linear between 0.0125 
and 1.250 µg/ml of FB2. The observed relation was y = 2E-07x - 0.0033, and the 
determination coefficient (R2) was 0.9995, (figure 6). 
 
Figure 6: Calibration curve of FB2. Standards were injected in triplicate, and 
values were expressed as mean ± SD 
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6.   Validation of HPLC method of FB2 
Repeatability and reproducibility conducted with standard solution [0.625 
µg/ml] injected several times (n = 6) over a day, or over the week. The coefficient of 
variation (CV%) of repeatability and reproducibility were 3.79 and 5.46 % 
respectively. These results were satisfactory because the CV% were lower than 5%.  
7. Validation of the whole method of FB2 
Typical chromatogram obtained from blank plasma of duck fortified to a final 
concentration of 0.250 µg FB2/ml of plasma is shown in figure 7. Although some 
peaks were observed in the first part of the chromatogram, they did not interfere 
with the FB2 retention time (around 15 min). These peaks may correspond to 
substances with primary amine groups that are more polar than FB2 [277]. 
 
 Figure 7: Typical chromatogram of FB2 was extracted from blank plasma of duck 
fortified to a final concentration of 0.250 µg FB2/ml of plasma 
The linearity of the whole method was obtained from fortified plasmas with 
FB2 in a range of 0.025 to 0.250 µgFB2/ml (with R² = 0.994). All samples with higher 
FB2 concentrations must be diluted and re-analyzed to be within the range of 
linearity of the method. The limit of detection (LOD) was defined as the smallest FB1 
amount that yielded a signal three times higher than the noise ratio obtained with 
blank tissues. The limit of quantification (LOQ) was then defined as the smallest 
amount of compound for which the methodwas validated with sufficient accuracy 
(<25% in both intra- and inter-day assay). The limit of detection (LOD) and 
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quantification (LOQ) were estimated at around 0.01, and 0.025 µg FB2/ml of plasma, 
respectively. The chromatograms of the plasma supplemented with 0.0125µg/ml 
were not different from blank plasma. These results agree with the results of 
Shephard, in which the LOD obtained by using SAX extraction for plasma was 0.020 
µg/ml [28]. The mean recovery rate of FB2 from plasma for each level of 
contamination was 63% +/- 5. This recovery rate obtained was lower than the only 
one already described for plasma (80.4%) [58].   
8. Data analysis  
The concentrations of FB2 in plasma after IV dosing were plotted against time. 
The curves were fitted by non-linear least-squares analysis with the SigmaPlot 
Software (Systat software Inc., http://www.systat.com/products/sigmaplot/). The 
plasma curve of FB2 obtained for each animal after a single IV dose was fitted using 
the two-compartment models.  
Toxicokinetic parameters after IV dosing were determined for each animal 
according to the equations described in Table 22, and expressed as mean +/- SE.  
Table 22: Toxicokinetic parameters and formula of determination after IV dosing 
Parameter Abreviation Formula* 
Area under the curve AUC (A/α) + (B/β) 
Total plasma clearance Cl dose/AUC 
Mean residence time MRT (A/α²+B/β²)*(1/AUC) 
Apparent volume of distribution Vdarea Cl/β 
Volume of the central 
compartment 
Vc dose/ (A+B) 
Volume of distribution at the 
steady state 
Vdss MRT*Cl 
* The plasma curve was fitted using the two-compartment models according to the following 
exponential equations: f=A*exp (-α*x) +B*exp (-β*x).  
f is the function that describes the change in plasma concentration over time (x). A, B are 
mathematical coefficients; α is the rate constant for the distribution phase; β is the rate 
constant for the terminal elimination phase. 
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III. FBs-Toxicity Experimental 
For memory, the objectives of this study were to compare the effects of FBs on 
sphingolipids metabolism in two avian species (ducks and turkeys), and to evaluate 
the toxicity of FBs on in each one. 
1.  Chemicals and apparatus 
1.1. Chemicals   
The standard of FB1 was purchased from Sigma (St. Louis, USA), while 
sphingolipids standards, such as C18 sphinganine (D-erythro dihydrosphingosine), 
C18 sphingosine (D-erythro sphingosine), and C20 sphinganine were provided by 
Matreya (Pleasant Gap, U.S.A). 
The OPA (ortho-phthaldiadehyde) and other chemicals were of the highest 
quality and purchased from Sigma (St. Louis, USA). HPLC grade solvents were 
supplied by Scharlau (Barcelone, Spain). In all studies, distilled and deionized water 
was used. 
1.2. Apparatus 
The HPLC system used for FB1 and sphingolipids determinations was 
composed as follows: an AL 728 auto-sampler (Alcott micrometrics, Norcross, USA), 
a M 2200 pump (Bischoff, Leonberg, Germany) and a RF 10A XL programmable 
fluorescence detector (Shimadzu, Japan). The chromatograms obtained were 
exploited using PIC 3 software from ICS (Toulouse, France) 
Materials used were already described in table 21. 
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2. Fumonisins production 
To conduct this experiment, it was necessary to have a great quantity of toxins, 
due to duration of study, the weight and the number of the animals experimented. 
Concurrently, the price of FBs standards was higher. So we decided to produce the 
toxins 
2.1. Fungal culture 
The strain of Fusarium verticillioides (NRRL-3428) used for the production of 
FB1 was isolated in the laboratory from horses corn feed infected with ELEM in 
Toulouse area. The NRRL-3428 strain was stored on malt agar and re-cultured 
regularly. The culture medium used for the isolation and identification of Fusarium 
was PDA (Potato Dextrose Agar). Culture was carried out by plating in Petri-dishes 
(9 cm in diameter), and containing 17 ml of malt agar [105].   
2.2. Toxins production  
Maize was used as culture medium for toxins production. First, maize was 
manually sorted (to remove visibly moldy grain). Afterward, maize was sterilized by 
placed 50 g of crushed maize with 50 ml of distilled in Petri-dishes of 15 cm diameter, 
and then they were sterilized by using autoclave (121 ° C for 30 minutes). Sterilized 
maize was inoculation with Fusarium verticillioides (0.5 cm x 0.5 cm; cultivated age of 
5-7 days in PDA). The boxes were incubated at 20 -23 ° C, for 4-5 weeks. The all boxes 
are dried by oven at 80 ° C for 3 hr. Then all cultures grind by mixer, and filtered by 
sieve. Then quantities of FBs are measured in the collected powder.     
2.3. FBs extraction and dosing  
According to the required quantity, culture material was dried in an oven at 
80-90 ° C (90 min), and milled into fine flour. 25 g of powder were placed in glass 
bottle 250 ml, and extracted with 100 ml of acetonitrile-water (50/50 v/v) by using 
mechanical agitation on a stir table (300 rpm) overnight. The extract was filtered and 
concentrated by evaporation of the solvent. The FBs were diluted and justified by 
deionised water before quantification. Finally, FB1 was quantified by HPLC, 
according to Rice et al [277]. 
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Purity of the crude extract was of 54% FB1, 8% FB2, and 9% FB3. Twenty-nine 
percent of the extracts were maize pigments.  
The extract was diluted in deionized water before administration to birds to 
reach a final concentration of 2 mg FB1 + FB2/ml (the respective concentrations of 
FB1, FB2, and FB3 of dosing solution were of 1.742, 0.258, and 0.290 mg/ml).  
3. Animals and sampling - experimental protocol 
All experimental procedures using birds were in accordance with the French 
National Guidelines for the care and use of animals for research purposes. 50 male 
turkey poults of  B.U.T. 9 strain (GFA Pierpont, Castelnau Montmirail, France), and 
50 male mule ducks (Pygavi, Muret, France) at 15 days of age were adapted for 1 
week at the experimental station ENSAT (Ecole Nationale Superieure Agronomique 
de Toulouse - France) with free access to feed and water. Mycotoxins concentrations 
in feed, such as fumonisins B1 + B2, aflatoxin B1, ochratoxin A, zearalenone, 
deoxynivalenol, and T2 toxin were below the detection limits (50, 1, 2, 25, 50, and 50 
µg/kg, respectively), by using ELISA kits.  
At the end of adaptation phase, birds were divided into four groups of 25 
birds (two control groups and two treated groups with FBs). The four groups were 
reared separately to avoid cross-contamination by FBs and a suitable light and feed 
program was used. For example, birds have a free feed access between 06:30 and 
08:00 AM and between 03:00 and 05:00 PM.  
Each day, all animals received per oral route a dose of 5 ml/kg b.w. of dilute 
culture extract :  FBs free for the controls, and with a concentration of 2 mg FB1 + 
FB2/ml for the treated groups (1 hr after the beginning of the light program), for 21 
days. That equal to a daily dose of 10 mg FB1 + FB2/kg b.w. 
Weight and the feed consumption of birds were measured on days 0, 3, 7, 11, 
14, 18, and 21.  
Blood samples were collected from five random birds of each groups 8 hours 
after the administration of the dose, at day 0 (8hr), 3, 7, 14 and 21. The serum was 
collected from centrifuged dry blood tubes during 15 min at 3000 g and stored at -
20°C until use. All the analysis concerning biochemical parameters in serum 
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(Proteins, cholesterol, AST, ALT, LDH) were provided by Vitros laboratory (Issy-Les-
Moulineaux, France). 
The euthanasia was conducted immediately following blood sample collection 
by bleeding after electric narcosis to permit post-mortem investigations and tissues 
samples collection (liver and kidney). Tissues samples were stored at -20°C until use. 
4. Fumonisin determination   
4.1. Extraction of FB1  
Extraction procedure and determination of FB1 in tissues was described by 
Tardieu (2008) [280]. 
4.1.1. Preparation of tissue homogenates 
One gram of liver or kidney samples were first homogenised in 2 ml of 
distilled water with 25mg of NaCl by teflon Potter (500 rpm) and (or) an Ultra turrax 
TP18. Then, 2ml of acetonitrile/methanol (1:1) was added. Samples were placed on a 
stir table for 120 min at 300rpm, and then centrifuged for 15min at 3000×g at room 
temperature. The supernatant fraction was collected and stored at -20°C until use. 
4.1.2. Extraction protocol 
Three ml of the supernatant fraction was defatted twice with 4ml of hexane 
and centrifuged for 15min at 3000×g at room temperature. 2 ml of the aqueous phase 
were diluted with 8ml of Phosphate Buffer Saline (PBS, pH 7.4). All of The solution 
was passed through immunoaffinity columns as recommended by the manufacturer 
(FUMONIPREP, R. Biopharm, Glasgow, Scotland). The column was then washed 
with 10 ml of PBS. Finally, FB1 was eluted with 1.5 ml of methanol, and with 1.5ml of 
water, respectively. The eluate was evaporated at 40°C in the dark under a gentle 
stream of Nitrogen. The dry residue was re-suspended with 200µl of 
acetonitrile/water (1:1). 
4.2. OPA derivatization and HPLC analysis of FB1 
The preparation of OPA (Ortho-Phtalaldehyde) was described previously in FB2-
toxicokinetic experimental. 
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The dried sample was re-suspended with 200µl of acetonitrile/water (1:1), and 
placed in an ultrasonicated bath for 10min.   
Then 50 µl of samples (or standard) were placed on the autosampler plate of 
the HPLC system. Before injection, the autosampler added 50µl of OPA reagent, 50µl 
of 0.1M borate buffer at pH 8.3, and 50µl of H2O. All the mixture was then mixed; 
and 20 µl of the derivatized mixture were injected in the HPLC system. 
The HPLC conditions were: 
Column: Prontosil C18 column, 5μm, 250mm×4.6mm, 120 ˚A (Bischoff, Leonberg, 
Germany).  
Mobile phase: CH3OH/NaH2PO4-0.1M pH 3.35 (75/25 v/v)  
Flow rate: 1.00 ml/min 
Fluorescence detection: excitation and emission wavelength of 335 and 440 nm 
respectively.  
4.3. Calibration curve of FB1  
Purified FB1 standard [51.1µg/ml] was diluted in acetonitrile/water (1:1) to 
prepare ten standard solutions (0, 0.001, 0.006, 0.013, 0.025, 0.063, 0.125, 0.250, 0.650, 
1.250 and 2.50 µg/ml). These standards were injected in triplicate, and the average 
values were taken to check the relationship between the injected concentration and 
the observed response of the detector. The observed relation was linear between 
0.001 and 2.50 µg/ml of FB1. The observed relation was y = 1E-07x - 0.0019, (figure 8). 
The determination coefficient (R2) was 0.999.  
 
Figure 8: Calibration curve of FB. Standards were injected in triplicate, and 
values were expressed as mean ± SD 
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4.4. Validation of HPLC method of FB1 
Validation of the analytical methods permits assessing analytical parameters 
such as repeatability and reproducibility which are important to control the 
dispersion during repetition of measurements. 
Repeatability was conducted with two standard solutions (0.625 and 2.50 
µg/ml) injected several times (n = 6) over a day. The variation coefficients (CV %) of 
theses standard solutions were 4.09 and 4.15 % respectively. These results were 
satisfactory, because all of the CV% were lower than 5%. Reproducibility was 
suitable, because the variation coefficients of standard solutions (0.625 and 1.250 
µg/ml) obtained over the course of one week (n = 6) were below 5 % (4.70 and 4.79 % 
respectively). 
4.5. Validation of the whole method of FB1 
The whole method validation was conducted with fortified blank samples. 1 g 
of blank tissues (liver, kidney and muscle samples) was fortified with 100µl of FB1 
standard solutions (0.063, 0.125, 0.250, 0.625, 1.250 and 2.5µg/ml), to produce final 
samples concentration [0.0063, 0.0125, 0.025, 0.0625, 0.125 and 0.250 µg FB1/g of 
tissue]. No interfere peak was seen on chromatograms of fortified samples, (figure 9). 
The variation coefficients of repeatability and reproducibility in tissues were at range 
from 3.2 to 16.5 % and 2.2 to 12.5 % respectively. The limit of detection (LOD) defined 
as the smallest FB1 amount that yielded a signal 3 times higher than the noise ratio 
(obtained with blank serum or tissues) was estimated at around 0.010 µg of FB1/g for 
tissue. The limit of quantification (LOQ), defined as the smallest amount of the 
compound for which the method could quantified, was determined of 0.013 µg 
FB1/g of tissues.  The extraction rate of FB1 was 75% for the liver and the kidney. 
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Figure 9: Typical chromatograms of FB1 was extracted from blank plasma of duck 
fortified to a final concentration of 0.250 µg FB1/ml of plasma 
5. Sphingolipids determination   
5.1. Extraction of free and phosphorylated sphingolipids   
The extraction and determination procedure of sphingoid bases was described 
by Merrill et al. [278], and Riley et al. [279]. While, the extraction and determination 
procedure of sphingoid bases 1-phosphates was described by Jung-Kee Min and 
Hwan-Soo Yoo [281]. 
5.1.1. Preparation of tissue homogenates 
One gram of tissue samples was first homogenised with 1ml of K buffer [200 
ml of KH2PO4 -0,1M + 800 ml of K2HPO4 0,1M] by using a teflon Potter (500 rpm). 
The Potter rinsed twice with 1ml of K buffer. The samples were then centrifuged for 
15min at 3000×g at room temperature. The upper phase was kept and stored at -20°C 
until use.   
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5.1.2. Extraction protocol of free sphingoid bases 
An internal standard (SaC20) was used to determine the percentage of 
extraction of sphingoid base for each sample [279].  
100μL of SaC20 [10 µM] were evaporated in a glass tube. 100μL of serum or 
homogenate tissue, 1500μL methanol/ chloroform (4v/1v), and 100µl KOH 1M 
solution were added in the glass tubes containing evaporated SaC20. Adding of KOH 
permits basic hydrolysis to release free Sa and So from samples [283].  Samples were 
vortexed, and incubated at 37°C for 1hr. After cooling the samples at room 
temperature, 1000µl of chloroform and 2000 µl of alkaline water [100µl of NH4OH 2N 
+ 250 ml distilled water] were added to the samples. Tubes were gently shacked (20 
times), and centrifuged for 20 min at 3000×g at room temperature. The upper alkaline 
aqueous phase contained sphingoid base 1- phosphates, and the lower chloroform 
organic phase contained free sphingoid bases. The lower chloroform phase was 
transferred to a new tube, and was washed with 3000µl alkaline water. This 
composition was centrifuged again. The new chloroform phase was dried under 
nitrogen at a temperature of 45-50 °C.   
5.1.3. Extraction protocol of sphingoid bases 1- phosphates  
In our work, according to Jung-Kee Min and Hwan-Soo Yoo [281] we have 
measured the amount of sphingoid bases 1 phosphate in the form of free sphingoid 
bases after dephosphorylation of sphingoid bases 1 phosphate by phosphatase 
enzyme. 100μL of SaC20 at concentration [10 µM] was evaporated in a glass tube. 
100μL of serum or homogenate tissue, 250μL methanol and 0.6µl of concentrated HCl 
were added. The sample was placed in an ultrasonic bath for 5min in ice-cold water. 
The lipids were extracted by adding 500μL chloroform/NaCl 1M (1v/1v), and 25µl of 
NaOH-3M. The sample was vortexed for 30 s, and centrifuged for 3 min at 7500×g at 
room temperature. Upper alkaline aqueous phase, which contained sphingoid base 1- 
phosphates was kept in new glass tube. The residual sphingoid bases 1 phosphate in 
the lower chloroform phase were further extracted with 250µl methanol/ NaCl-1M 
(1v/1v) and 13µl NaOH-3M, and centrifuged again for 3 min at 7500×g at room 
temperature. All the upper alkaline aqueous phase fractions were collected in the 
same tube for each sample. Then, 130µl of reaction buffer pH 9.0 [200 mM Tris-HCl 
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(PH 7.4) with 75mM MgCl2 in 2M glycine buffer] and 50 units of Alkaline 
Phosphatase were added to alkaline aqueous phase fractions. This mixture was 
mixed by vortex. 200μL of chloroform was carefully placed at the bottom of the 
mixture to enhance the extraction and released of free sphingoid bases after 
dephosphorylation of sphingoid base 1- phosphates. The tubes were sealed with 
parafilm and incubated at 37°C for 1hr. The dephosphorylated sphingoid bases (on 
free sphingoid base forms) were extracted with 300µl chloroform and 500µl 
methanol, and a second time with 300µl of chloroform. The lower chloroform organic 
phases which contained free sphingoid bases were transferred to a new tube, and 
washed with 3000µl of alkaline water. This composition was centrifuged again. The 
chloroform phase was dried under nitrogen at a temperature of 45-50 °C.  
5.2.  OPA derivatization and HPLC analysis of free sphingoid bases 
The preparation of OPA (Ortho-Phtalaldehyde) was described previously in FB1 and 
FB2 determination. 
The dried sample was dissolved with 20µl ethanol (or 20µl of standard), 40µl 
of OPA and 140µl of methanol/ water (90v/10v). All the mixture was placed in an 
ultrasonic bath for 10 min, centrifuged for 10 min at 3000×g at room temperature, 
and 20 µl was injected with the auto-sampler of HPLC. 
The HPLC conditions were: 
Column: Prontosil C18 column, 5μm, 250mm×4.6mm, 120 ˚A (Bischoff, Leonberg, 
Germany).  
Mobile phase: CH3OH/H2O (90v/10v)  
Flow rate: 1.20 ml/min 
Fluorescence detection: excitation and emission wavelength of 335 and 440 nm 
respectively.  
5.3. Calibration curves of free sphingoid bases 
Purified Sa and So standards were diluted in ethanol to prepared a range of 
standard at concentrations (0.005, 0.01, 0.05, 0.125, 0.25, 0.5μM). These standards were 
injected in triplicate, and the average values were taken to check the relationship 
between the injected concentration and the observed response of the detector. The 
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observed relation was linear between 0.005 and 0.5 μM. The observed relationships 
were [Sa] y = 2E-07x - 0.002, and [So] y = 2E-07x - 0.0036. The determination 
coefficients (R2) for Sa and So were 0.997 and 0.996 respectively, (figure 10).  
 
Figure 10: Calibration curve of free sphingoid bases. Standards were injected in 
triplicate, and values were expressed as mean ± SD 
 
5.4. Validation of HPLC method of free sphingoid bases 
Repeatability was achieved with a mixture of two standard solutions Sa and 
So at concentrations (0.01 and 0.125 µM) injected several times (n = 6) the same day. 
The variation coefficient (CV %) of Sa were 2.44% and 3.47%, CV% of So were 3.75% 
and 3.32% respectively. The results were satisfactory because all of the CV% were 
lower than 5%. The reproducibility was also correct, because the variation coefficient 
(CV %) of mixture standard solutions Sa and So at concentrations (0.125µM) obtained 
over the course of 1 week (n=5) was also below 5%. 
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5.5. Validation of the whole method of free sphingoid bases 
The validation of the whole method was conducted by mixing 100 µl of 
evaporated SaC20, 100 µl of blank serum or homogenates liver obtained from ducks 
fed mycotoxin-free feed, with 100µl of mixed standards Sa and So at concentration 
[0.005, 0.01, 0.05, 0.125, 0.25, 0.5μM]. In serum, the extraction repeatability was 
achieved with standard solution [0.5μM], (figure 11). The variation coefficients (CV 
%) of Sa, So, SaC20 were of 8.48%, 8.01% and 4.14%, respectively. All of the CV% 
values are lower than 10. Moreover, reproducibility was obtained with the same 
standard Sa + So solution [0.5μM] during 1 weak (n=5). The variation coefficient 
(CV%) of Sa, So, SaC20 were 8.25%, 7.10% and 5.53%, respectively. The average of 
recovery rate in serum of Sa and So was 75% ± 8% in respect of the internal standard. 
In liver, the results were quite similar to those obtained in serum. The recovery rates 
obtained were in agreement with those obtained by M. Castegnaro, L. Garren et al for 
blood sample of male BDIV rats by using HPLC liquid chromatographic system to 
determine sphinganine and sphingosine after FB1 exposure [282]. The limit of 
detection (LOD) and the limit of quantification (LOQ) were estimated around 0.025 
and 0.05 µM, respectively.   
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Figure 11: Typical chromatograms of mixed standards Sa and So were extracted 
from blank plasma of duck fortified to a final concentration of 0.25 µM 
6. Determination of oxidative stress 
6.1. Preparation of homogenates tissue 
Liver was rinsed with Phosphate-Buffered Saline (PBS) pH-7.4 to remove red blood 
cells and clots. One gram of liver was homogenised with 5 ml of K-buffer pH-7.4 [794 
ml of K2HPO4-0.1 M + 206 ml of KH2PO4-0.1 M + 1 mM EDTA] by using a teflon 
Potter (500 rpm). Samples were centrifuged for 15min at 10000×g at - 4C. Then, the 
supernatant fraction without fatty layer was collected and stored at -80°C until use. 
6.2. Protein assay 
The protein assay was conducted with Bio-Rad Protein Macro-assay, which 
was able to measure protein at range of 0.2-1.4 mg/ml of tissue homogenates as 
described by Bradford [296]. Bovine serum albumin (BSA) was diluted with distilled 
water to prepared standard solutions ranging from 0.2 to 1.4 mg/ml. 100µl of 
standard solutions or diluted samples were mixed with 5ml of diluted dye reagent 
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(Bio-Rad) by Vortex tubes. The mixture was incubated at room temperature for 5 
min. Spectrophotometer at 595 nm was used to measure standards or samples 
absorbance. The protein assay was conducted three times for each sample, and the 
average value was considered as the final result.  
6.3. Determination of catalase activity 
The concentration of catalase activity was measured according to a method of L.Goth 
[297].  
All the chemicals were purchased from Sigma (St. Louis, USA).  
Na-K buffer-0.06M (pH 7.4) was prepared by mixing mono-potassium phosphate 
(KH2PO4-0.06M) and di-sodium hydrogen phosphate (Na2HPO4-0.06M), to reach pH-
7.4 (1:1.5 V: V).  
 H2O2 substrate (65 µmole/ml) in Na-K buffer was prepared by mixing 0.737 ml of 
mother solution (H2O2-30%) with 100ml of Na-K buffer. This diluted solution has to 
be prepared in amber flasks and is stable for to two days. Ammonium molybdate 
32.4 mM was prepared in H2O. 
With L.Goth’s [297] method a control was prepared by mixing 1ml of substrate 
H2O2, 1ml of molybdate, and 0.2 ml of homogenates tissue, respectively. Two kinds 
of blank were realized: Blank 2 and Blank 3. For Blank 2: 1ml of substrate H2O2, 1ml 
of molybdate, and 0.2ml of Na-K buffer were mixed respectively. For Blank 3: 1ml of 
Na-K buffer, 1ml of molybdate, and 0.2ml of Na-K buffer were mixed respectively. 
The sample tissue was treated as follows: 0.2ml of tissue homogenates sample was 
incubated with 1ml of substrate H2O2 at 37°C for 60 sec. then, the enzymatic reaction 
was stopped by addition of 1.0 ml molybdate. The yellow complex of molybdate and 
hydrogen peroxide was measured by spectrophotometer at 405 nm, against blank 3.  
The results were calculated according to the formula: 
CAT activity (kU/l) = (ABS sample - ABS control/ ABS blank 2 - ABS blank 3) x 271. 
Samples which exceeded 100kU/L must be diluted by Na-K buffer. The final results 
were expressed in U/mg of protein. 
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6.4. Determination of GSH activity 
The concentration of GSH activity was performed by using the Ellman method 
(1958) [298]. All the chemicals were purchased from Sigma (St. Louis, USA).  
Phosphate buffer (K buffer -0.3M, pH 7.4) was prepared by mixing mono-
potassium phosphate (KH2PO4-0.3M) with di-potassium phosphate (K2HPO4-0.3M). 
The volume was justified to reach pH-7.4. 
DTNB or 5, 5-dithiobis-(2-nitrobenzoic acid) (0.1M) was prepared by mixed 3.96g 
of DTNB with 1000ml H2O  
0.1ml of tissue homogenates sample was mixed with 0.85 ml of phosphate buffer 
(0.3M, pH-7.4) and 0.05 ml of (DTNB-0.01M). The GSH absorbance was read by 
spectrophotometer at 412 nm, against blank (0.95ml of K buffer + 0.05ml of DTNB). 
The GSH content in sample was calculated by using the formula:  
Concentration (mole/L) = ABS/∑ x L. Epsilon (∑) = 14150 M −1 cm−1 according to 
(Eyer et al., 2003) [299]. Length of Cuve = 1cm.  The final data were expressed as 
nmole GSH/mg of protein. 
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7. Serum Protein Electrophoresis (SPEP)  
Serum Protein Electrophoresis (SPEP) was analysed by Saint-Gilles laboratory 
(la Salvetat Saint Gilles, France). Serum Protein Electrophoresis was conducted by 
using agarose gel electrophoresis, which purchased from Sebia. 
Albumin, the largest peak, located closest to the positive electrode. The next 
five components (globulins) were labeled alpha1, alpha2, beta1, beta2, and gamma. 
The peaks for these components located toward the negative electrode, with the 
gamma peak being closest to that electrode (figure 12 ).  
 
Figure 12: Typical serum protein electrophoresis for ducks by using Agarose gel 
electrophoresis. Samples were stained by Coomassie Blue staining. Result were obtained 
calculated against total amount of proteins.   
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8. Statistical analysis 
Statistical analysis of all data was done by GraphPad Prism-5 programme. 
Data for all response variables were reported as means ± SD. Two-way ANOVA was 
done to compare two variations in treated and control groups by species after 
determination of the homogeneity of variance (Hartley test). A t-test was done to 
compare one variation. The correlation between variables was checked by 
D'Agostino-Pearson test. Significant differences between controls and treated (P 
value < 0.05) were noted by an asterisk.   
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CHAPTER 3: RESULTS 
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I. FB2-Toxicokinetic Experimental 
In the bibliography part, it was demonstrated that FBs had more toxic effect on 
ducks than turkeys. At the same time, FB1 was more abundant than other types of 
fumonisins in poultry feed. For that reason, the toxicokinetics of FB1 was studied in 
ducks, turkeys and laying hens, whereas toxicokinetics of other types of FBs, such as 
FB2 and FB3 were still unknown in these species. Therefore, it was important to 
study the toxicokinetics parameters of FB2 in ducks and turkeys in order to 
understand their different toxicity to FBs exposure. 
 The aim of this study was: i) to validate a method for the quantification of FB2 in 
plasma, ii) to reveal that toxicokinetic parameters of FB2 were different from those of 
FB1 in ducks and turkeys. 
In all tested birds, neither mortality nor signs of pathology were observed 
during the toxicokinetic study. The plasma concentrations of FB2 after intravenous 
(IV) dosing were decreased gradually over time in both species, more rapidly in 
turkeys than in ducks. They were below the limit of quantification (LOQ) in turkeys 
and ducks after one hour and two hours post-dosing, respectively, (figure 13). 
 
Figure 13: Plot of plasma concentration of FB2 (1 mg/kg of BW), after IV injection. Mean 
values ± SE (n = 4). 
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The semi-logarithmic curve obtained suggests that elimination of FB2 from the 
plasma was biphasic in both species [an initial very rapid distribution phase (α), 
followed by a slower elimination phase (β)], (figure 14). Therefore, the elimination of 
FB2 from plasma was fitted according to a bi-exponential equation:  f(x) = A*exp (-
α*x) + B*exp (-β*x). 
 
Figure 14: Semi-logarithmic plot of plasma concentration of FB2 (1 mg/kg of BW), after IV 
injection, showing both distributional and elimination phases. Mean values ± SE (n = 4). 
 
(f) is the function that describes the change in plasma concentration over time 
(x). A and B are mathematical coefficients; α is the rate constant for the distribution 
phase; β is the rate constant for the terminal elimination phase. The very high 
coefficient of determination (R2) obtained from bi-exponential equation (high than 
0.9995 and 0.9991 in ducks and turkeys, respectively), revealed that this model was 
representative of FB2 elimination from plasma in those species.  
The initial half-life of distribution (T1/2α) was rapid in both species, with a 
faster rate in turkeys than in ducks (1 and 3.8 min, respectively). It was followed by a 
slower terminal phase of elimination, which was longer in ducks than in turkeys 
(T1/2 β = 32 and 12.4 min, respectively). The area under the curve (AUC) was quite 
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similar in ducks and turkeys (107.3 ± 4.5 and 115.47± 0.48 µg/ml/ min, respectively). 
The serum clearance (Cl) of FB2 was near value in ducks and turkeys (9.3 ± 1.2 and 
8.7± 0.7 ml/ min/kg, respectively). The mean residence time (MRT) was higher in 
ducks than in turkeys (12.9 ± 5.1 and 5.0 ± 3.2 min). The volume of distribution 
(Vdarea), volume of the central compartment (Vc), and volume of distribution at the 
steady stage (Vdss) were higher in ducks than in turkeys. In ducks, they were 442 ± 
73, 61 ± 12 and 120 ± 32 ml /kg, respectively, whereas in turkeys, they were 154 ± 88, 
16 ± 10 and 43 ± 9 ml /kg, respectively, (table 23). 
Table 23: Toxicokinetic parameters of FB2 after IV injection (1mg/kg) in ducks and 
turkeys 
Parameter 
                             Value (mean ± SE) 
Duck Turkey 
A (ng/ml) 15952 ± 198 62906 ± 3314 
α (min-1) 0.18 ± 0.08 0.69 ± 0.11 
B (ng/ml) 400 ± 187 1401 ± 159 
β (min-1) 0.02 ± 0.01 0.056 ± 0.03 
t1/2α (min) 3.8 ± 1.6 1 ± 0.2 
t1/2β (min) 32 ± 11 12.4 ± 6 
AUC (ng/ml/min) 107303 ± 4439 115470 ± 477 
MRT (min) 12.9 ± 5.1 5.0 ± 3.2 
Cl (ml/min/kg) 9.3 ± 1.2 8.7 ± 0.7 
Vdarea(ml/kg) 442 ± 73 154 ± 88 
Vc (ml/kg) 61 ± 12 16 ± 10 
Vdss (ml/kg) 120 ± 32 43 ± 9 
A, B: mathematical coefficients; Α: rate constant for the distribution phase; B: rate 
constant for the elimination phase; T 1/2 α: distribution half-life;  T 1/2 β: terminal 
elimination half-life; AUC: area under plasma concentration-time curve from t = 0 to 
infinity; MRT: mean residence time; Cl: total plasma clearance; Vdarea: volume of 
distribution; Vc: volume of the central compartment; Vdss: volume of distribution at the 
steady state.  
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After the oral administration of 10 mg/kg b.w., traces amount of FB2 was 
below the LOQ (25 ng FB2/ml of plasma), which were detected in plasma of ducks. 
Only two turkeys showed plasmatic levels of FB2 higher than the LOQ, but they 
were below 50 ng/ml (figure 15). The values were below 50 ng/ml cannot be fitted 
by exponential equation. The curves presented in figure 15 were not precise, because 
most of values was below the LOQ and higher then LOD (25 and 10 ng FB2/ml of 
plasma, respectively).  
 
Figure 15: Plasma concentration of FB2 (1 mg/kg of BW) after oral dose. Mean values ± SE 
(n = 4). 
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II. FBs-Toxicity Experimental  
From the previous data it became clear that ducks were more sensitive to FBs 
toxicity than turkeys. Unfortunately, those researches were not conducted at the 
same time and under same conditions (age of birds, source of toxin, dose of 
treatment, and duration of exposure). Hence, the judgment that ducks were more 
sensitive to FBs toxicity than turkeys was not rigorous. In order to avoid the 
experimental variation and to confirm the different sensitivity between ducks and 
turkeys to FBs toxicity, the present study was conducted on both species at the same 
time and under the same conditions. Two week old birds (ducks and turkeys) 
received per oral route a dose of 10 mg FB1 + FB2/kg b.w. /day, for 21 days.  
1. General toxicity and serum biochemistry 
In treated ducks, one case of death was recorded after two weeks of exposure, 
and postmortem examination failed to identify cause of death. Body weight gain was 
significantly decreased, with high standard deviation (SD) at the end of the study by 
up to 0.6 kg (17% of body weight) in treated compared to control groups (Figure 16). 
This high standard deviation (SD) was a result of different sensitivity of ducks to FBs 
toxicity. That means some ducks were more affected than others to fumonisin 
exposure. The average of feed consumption during 21-day period was decreased in 
treated groups compared to control groups. In control ducks, it was 3424 g/bird 
during the experiment. While in treated ducks, it was 2909 g/bird. By contrast, in 
treated turkeys, neither mortality nor signs of illness were observed during the 21 
days of exposure (Figure 16). Body weight gain did not decrease compared to the 
control groups. The average of feed consumption was also not affected in control and 
treated groups during the experiment. It was 3181 and 3056 g/bird, respectively. In 
both species, feed conversion ratio (FCR) was constant during the study. 
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Figure 16: Effects of FBs on body weight gain in ducks and turkeys treated with                   
10 mg FB1 + FB2/kg b.w/day, during 21 days. Values were expressed as mean ± SD 
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No macroscopic lesions were discovered by postmortem examination of 
tissues in all treated birds. In ducks, FB1 had increased liver weight after 7 days of 
exposure, while heart and gizzard weights were not affected. By contrast, in turkeys, 
FB1 had increased gizzard weight after 14 and 21 days of exposure, while liver and 
heart weights were not affected, (table 24).    
Table 24: Effects of FBs on the relative organ weights  
FB1 + FB2 (mg/kg 
b.w.) 
Duck Turkey 
0 10 0 10 
Liver (%)     
day 0 3.58 ± 0.32 3.64 ± 0.38 2.35 ± 0.30 2.26 ± 0.09 
day 3 3.54 ± 0.53 3.28 ± 0.42 2.43± 0.30 2.26 ± 0.11 
day 7 2.70 ± 0.18 3.05 ± 0.16* 2.47 ±0.19 2.45 ± 0.37 
day 14 2.49 ± 0.21 2.75 ± 0.33 2.43 ± 0.09 2.29 ± 0.13 
day 21 2.27 ± 0.19 2.30 ± 0.15 2.01 ± 0.21 1.91 ± 0.12 
Heart (%)     
day 0 0.77 ± 0.03 0.75 ± 0.08 0.55 ± 0.05 0.52 ± 0.06 
day 3 0.70 ± 0.04 0.74 ±0.08 0.50 ± 0.09 0.50 ±0.07 
day 7 0.69 ± 0.04 0.69 ± 0.08 0.49 ± 0.08 0.49 ± 0.03 
day 14 0.64 ± 0.06 0.66 ± 0.04 0.46 ± 0.04 0.48 ± 0.05 
day 21 0.66 ± 0.07 0.67 ± 0.05 0.46 ± 0.03 0.43 ± 0.02 
Gizzard (%)     
day 0 3.44 ± 0.42 3.43 ± 0.38 2.17 ± 0.33 2.28 ± 0.22 
day 3 3.48 ± 0.57 3.54 ± 0.32 1.92 ± 0.27 1.96 ± 0.49 
day 7 3.03 ± 0.39 2.74 ± 0.27 1.95 ± 0.38 1.94 ± 0.25 
day 14 2.83 ± 0.25 2.32 ± 0.29 1.63 ± 0.29 2.20 ± 0.15* 
day 21 2.41 ± 0.38 2.83 ± 0.19 1.50 ± 0.27 2.05 ± 0.27* 
Values were obtained from five birds per group (four birds on day 21 for ducks that received 
FBs) 8 hr after the first administration of FBs (day 0) and at days 3, 7, 14, and 21 and expressed 
as mean ± SD. *Two-way ANOVA was done to compare treated and control groups by species 
(significantly different, P < 0.05). 
In treated ducks, FBs increase hepatotoxicity parameters such as protein, 
cholesterol, and LDH after three days of exposure until the end of the study, (table 
25). Except AST which was increased only after 21 days of exposure. ALT was nearly 
constant during the study. By contrast, hepatotoxicity parameters in treated turkeys 
were not affected during the study, except an increase of AST and LDH, which 
significant elevated on days 14 and 7, respectively, (table 25).  
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Table 25: Effects of FBs on serum biochemistry  
FB1 + FB2 (mg/kg b.w.) 
                   Duck              Turkey 
0 10 0 10 
Proteins (mg/L)     
day 0 35 ± 2 37 ± 2 37 ± 2 39 ± 2 
day 3 34 ±2 40 ± 2* 36±3 40 ± 2 
day 7 37 ±4 39 ±3 38 ±3 39 ± 5 
day 14 36 ±2 46 ± 5* 36 ±5 36 ± 1 
day 21 34 ±2 45 ± 2* 36 ±3 36 ± 3 
Cholesterol(mmol/L)     
day 0 1.81 ± 0.20 2.01 ± 0.19 1.20 ± 0.03 1.32 ± 0.10 
day 3 1.90 ± 0.12 2.31 ± 0.16* 1.09 ± 0.18 1.31 ± 0.10 
day 7 2.12 ± 0.24 2.96 ± 0.45* 1.39 ± 0.16 1.27 ± 0.12 
day 14 2.11 ± 0.16 4.46 ± 3.42* 1.40 ± 0.27 1.64 ± 0.15 
day 21 1.72 ± 0.14 3.75 ± 1.06* 1.59 ± 0.13 1.75 ± 0.19 
AST (U/L)     
day 0 46 ± 25 30 ± 9 263 ± 18 289 ± 42 
day 3 24 ± 15 44 ± 20 278 ± 25 348 ± 62 
day 7 23 ± 5 23 ± 16 327 ± 46 399 ± 69 
day 14 37 ± 20 43 ± 16 291 ± 32 354 ±15* 
day 21 13 ± 5 56 ± 18* 289 ± 20 307 ± 37 
ALT (U/L)     
day 0 18 ± 6 28 ± 3 3± 1 3± 2 
day 3 21 ± 5 35 ± 13* 3± 1 4±  1 
day 7 14 ± 6 27 ± 3* 4 ± 1 5±  2 
day 14 13 ± 6 27 ±  4* 3 ± 1 3 ± 1 
day 21 14 ± 5 29 ±  11* 3 ± 1 2±  1 
LDH (U/L)     
day 0 895 ± 353 736 ± 240 1403 ± 151 1633 ± 395 
day 3 524 ± 153 1639±  866* 1406 ± 245 2328 ± 748 
day 7 448 ± 71 1058 ± 455* 1385 ± 284 3385 ± 1029* 
day 14 816 ± 262 1913 ± 1069* 2231 ±1084 3398 ± 1237 
day 21 399 ± 30 3122 ± 1725* 1287 ± 306 2592 ± 595 
Values were obtained from five birds per group (four birds on day 21 for ducks that 
received FBs) 8 hr after the first administration of FBs (day 0) and at days 3, 7, 14, and 21 
and expressed as mean ± SD. *Two-way ANOVA was done to compare treated and 
control groups by species (significantly different, P < 0.05). 
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2. Sphingolipids alterations 
Because FBs toxicity varies between ducks and turkeys, and because this 
toxicity could be related to disruption of the sphingolipids metabolism, we 
investigated the effects of FBs on the free and the phosphorylated forms of 
sphingolipids in tissue and serum and tried to correlate them with serum 
biochemistry. Results were presented, as follow: 
1. Effects of FBs on amount of free sphingolipids in tissue and serum. 
2. Correlation between accumulation of free sphingolipids in liver and 
hepatotoxicity. 
3. Effects of FBs on amount of sphingolipid phosphorylated forms in liver 
and serum. 
4. Correlation between accumulations of sphingolipid phosphorylated forms 
in liver and hepatotoxicity. 
5. Correlation between accumulations of free sphingolipids and sphingolipid 
phosphorylated forms in liver 
2.1. Free sphingolipids 
2.1.1. Free sphingolipids in tissues 
In both species, liver was less sensitive to FBs exposure than kidneys. Also, the 
accumulation of sphinganine in tissues was more pronounced in treated turkeys than 
ducks during the experiment. In livers and kidneys of treated ducks, the mean 
accumulation value of Sa was 14 and 42 fold higher than the control, respectively. 
Whereas in treated turkeys, it was 32 and 105 fold higher than the control, 
respectively. The concentration of sphinganine in liver increased over time during 
the experiment in treated groups of both species. By contrast, the  concentration of 
sphinganine in kidneys increased from the first day (8 hr) until day 7, and then it 
decreased in treated groups of both species, (figure 17).  
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Figure 17: Effects of FBs on sphinganine in tissues in ducks and turkeys treated 
with 10 mg FB1 + FB2/kg b.w/day, during 21 days. Values were expressed as mean ± SD, 
[Sp: slope of accumulation curve]   
Interestingly in treated groups of both species, a significant increase in Sa was 
detected rapidly in livers and kidneys 8 hr (day 0) after first dosing. In ducks, the 
accumulation of sphinganine in liver and kidneys reached the maximum after 14 and 
7 days, respectively. In turkeys, it reached the maximum 3 days post exposure in 
liver and kidneys, (figure 17 and table 26).   
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Table 26: Effects of FBs on sphinganine, sphingonine and Sa:So ratio in tissues  
FB1 + FB2 (mg/kg BW) 
                            Duck                        Turkey 
0 10 0 10 
Sa in liver  (nmol/g)     
day 0 1.10 ± 0.31 4.69 ± 1.08* 1.37 ± 0.14 18.92 ± 7.52* 
day 3 1.59 ± 0.80 11.48 ± 1.59* 1.80 ± 0.74  62.23 ± 9.96* 
day 7 1.78 ± 0.45 22.61 ± 5.27* 1.75 ± 0.36 55.03 ± 12.65* 
day 14 1.90 ± 0.47 39.53 ± 33.04* 2.31 ± 0.49 76.42 ± 11.05* 
day 21 2.32 ± 0.79 41.9 ± 11.39* 1.77 ± 0.36 78.62 ± 16.78* 
So in liver  (nmol/g)     
day 0 7.38 ± 3.83 7.22 ± 4.69 7.49 ± 1.37 9.03 ± 2.97 
day 3 7.08 ± 1.41 7.06 ± 1.63 9.01 ± 2.49 13.19 ± 2.59 
day 7 9.18 ± 3.02 9.57 ± 1.76 13.8 ± 1.75 18 ± 4.08 
day 14 8.41 ± 0.91 11.6 ± 8.35 13.5 ± 2.89 17.7 ± 2.06 
day 21 9.96 ± 3.13 14.2 ± 3.83 8.56 ± 4.67 17.4 ± 3.08* 
Sa:So in liver     
day 0 0.16 ± 0.04 0.65 ± 0.13* 0.19 ± 0.03 2.07 ± 0.25* 
day 3 0.22 ± 0.09 1.67 ± 0.3* 0.22 ± 0.04 4.78 ± 0.69* 
day 7 0.2 ± 0.03 2.36 ± 0.3* 0.13 ± 0.02 3.08 ± 0.67* 
day 14 0.23 ± 0.05 3.27 ± 1.28* 0.19 ± 0.07 4.31 ± 0.26* 
day 21 0.23 ± 0.06 3.01 ± 0.78* 0.15 ± 0.05 4.61 ± 1.26* 
Sa in kidneys (nmol/g)     
day 0 0.33 ± 0.24 2.32 ± 0.56* 0.13 ± 0.03 0.39  ± 10.08* 
day 3 0.34 ± 0.07 8.35 ± 2.21* 0.22  ± 0.08 42.60  ± 13.2* 
day 7 0.24 ± 0.03 12.90 ± 8.2* 0.27  ± 0.07 43.30  ± 13.3* 
day 14 0.10 ± 0.02 11.50 ± 3.45* 0.09  ± 0.02 31.90  ± 11.3* 
day 21 0.11 ± 0.12 12.40 ± 1.7* 0.59  ± 0.53 18.60  ± 6.5* 
So in kidneys (nmol/g)     
day 0 1.71 ± 0.82 3.09 ± 1 1.36 ± 0.19 3.13 ± 0.9* 
day 3 1.67 ± 0.49 3.59 ± 0.78* 1.55 ± 0.83 14.2 ± 4.1* 
day 7 1.83 ± 0.38 4.59 ± 1.28* 3.1 ± 1.63 14.4 ± 1.2* 
day 14 1 ± 0.19 3.39 ± 1.25* 1.16 ± 0.31 12.4 ± 3.5* 
day 21 0.42 ± 0.4 3.28 ± 0.78* 1.62 ± 0.28 7.14 ± 1.6* 
Sa:So in kidneys     
day 0 0.18 ± 0.03 0.77 ± 0.07* 0.09 ± 0.02 0.13 ± 0.03* 
day 3 0.22 ± 0.09 2.31 ± 0.33* 0.29 ± 0.4 3.09 ± 0.85* 
day 7 0.14 ± 0.05 3.33 ± 0.75* 0.22 ± 0.33 3.04 ± 1.09* 
day 14 0.1 ± 0.01 3.4 ± 0.61* 0.08 ± 0.02 2.53 ± 0.96* 
day 21 0.26 ± 0.07 3.89 ± 0.7* 0.37 ± 0.34 2.5 ± 0.45* 
Values were obtained from five birds per group (four birds on day 21 for ducks that received FBs) 8 hr 
after the first administration of FBs (day 0) and at days 3, 7, 14, and 21 and expressed as mean ± SD. *Two-
way ANOVA was done to compare treated and control groups by species (significantly different, P < 
0.05). 
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More interestingly, the slope of sphinganine accumulation curve in liver was 
quite similar to the slope of sphinganine accumulation curve in kidneys in treated 
groups of both species. But unexpectedly, the slope of sphinganine accumulation 
curve in liver and kidneys were stronger in turkeys than in ducks. In treated ducks, 
they were 2.6 and 2.3 in liver and kidneys, respectively, while in treated turkeys, they 
were 16.2 and 15.8 in liver and kidneys, respectively, (figure 17).  Those results 
revealed that the accumulation of Sa in treated ducks and treated turkeys was not 
tissue-dependence (liver and kidney). However, it was dependent on the different 
species (ducks and turkeys). Furthermore, the slope of sphinganine accumulation 
curve was in accordance with a more rapid accumulation of Sa in turkeys than in 
ducks. 
In treated groups of both species, sphingosine in liver was not affected during 
the study, except in turkeys, where a significant increase was observed on day 21. By 
contrast, sphingosine in kidneys increased from day 3 until day 7 in ducks, whereas 
it rapidly increased from the 8th hour on day 1 until day 7 in turkeys. Afterward, 
their levels decreased during the study, (table 26). Sa:So ratio in tissues was rapidly 
elevated 8 hours post-exposure in both species, (table 26). The elevation of Sa:So ratio 
in liver and kidneys were dependent on the increase of Sa in those tissues, because 
sphingosine in liver was not affected during the study in both species, and elevation 
of sphingosine in duck kidneys was recorded 3 days post-dosing.  
2.1.2. Free sphingolipids in serum 
In treated groups, sphinganine was elevated faster in ducks than in turkeys, (8 
hr and 3 days post-dosing, respectively). In control groups, the average amount of Sa 
in serum was quite similar in ducks and turkeys (0.144 and 0.112 µM, respectively). 
Whereas in treated groups, the average amount of Sa in serum was 2 times higher in 
ducks than turkeys (0.760 and 0.362 µM, respectively). The liberation ability of Sa was 
slightly similar in treated ducks and turkeys (5 and 3 folds than control, respectively), 
(table 27).  
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Table 27: Effects of FBs on free sphingolipid forms in serum  
FB1 + FB2 (mg/kg b.w.) 
                   Duck                   Turkey 
0 10 0 10 
Sa in serum  (µM)     
day 0 0.15 ± 0.1 0.24 ± 0.04 0.14 ± 0.06 0.13 ± 0.08 
day 3 0.11 ± 0.06 0.55 ± 0.24* 0.11 ± 0.04 0.35 ± 0.12* 
day 7 0.12 ± 0.08 0.38 ± 0.15* 0.13 ± 0.05 0.44 ± 0.11* 
day 14 0.21 ± 0.11 1.48 ± 0.84* 0.07 ± 0.03 0.49 ± 0.11* 
day 21 0.13 ± 0.06 1.15 ± 0.21* 0.11 ± 0.08 0.40 ± 0.06* 
So in serum  (µM)     
day 0 0.45 ± 0.32 0.33 ± 0.04 0.37 ± 0.14 0.24 ± 0.22 
day 3 0.26 ± 0.12 0.39 ± 0.19 0.3 ± 0.15 0.32 ± 0.12 
day 7 0.3 ± 0.16 0.22 ± 0.09 0.43 ± 0.23 0.38 ± 0.06 
day 14 0.55 ± 0.26 0.73 ± 0.34 0.19 ± 0.07 0.39 ± 0.08 
day 21 0.33 ± 0.11 0.59 ± 0.12* 0.34 ± 0.19 0.35 ± 0.05 
Sa:Soin serum     
day 0 0.3 ± 0.06 0.73 ± 0.14* 0.36 ± 0.04 0.62 ± 0.26* 
day 3 0.11 ± 0.06 0.55 ± 0.24* 0.11 ± 0.04 0.35 ± 0.12* 
day 7 0.4 ± 0.07 1.72 ± 0.05* 0.31 ± 0.04 1.18 ± 0.24* 
day 14 0.38 ± 0.05 1.97 ± 0.2* 0.35 ± 0.02 1.26 ± 0.11* 
day 21 0.38 ± 0.05 1.95 ± 0.16* 0.3 ± 0.07 1.15 ± 0.08* 
Values were obtained from five birds per group (four birds on day 21 for ducks that received 
FBs) 8 hr after the first administration of FBs (day 0) and at days 3, 7, 14, and 21 and 
expressed as mean ± SD.*Two-way ANOVA was done to compare treated and control 
groups by species (significantly different, P < 0.05). 
As for the liver, the amount of Sa in serum was increased with the duration of 
the exposure in treated groups of both species. On day 3, the amounts of Sa in treated 
ducks and turkeys were significantly increased: 5 and 3 times higher than control 
groups, respectively. On day 21, the amount of Sa in treated ducks and turkeys was 
significantly increased: 9 and 4 times higher than control groups, respectively, (table 
27). 
In treated groups of both species, no significant elevation of sphingosine was 
recorded in the serum of treated groups as compared with control groups. Except for 
day 21 when an elevation of So two times higher in treated ducks than control ones, 
was recorded, (table 27). 
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Significant elevation of Sa:So ratio was recorded from the 8th hr post-dosing 
until the end of the study in treated groups of both species. Concurrently, the 
increase of Sa and decrease of So were not significant at the 8th hr of exposure in 
treated groups. This phenomenon proven that: Sa:So ratio was highly sensitive to FBs 
exposure, (table 27). 
The accumulation of Sa in treated ducks livers showed a significant correlation 
(P < 0.05) with hepatotoxicity parameters, such as protein (R² = 0.4699), cholesterol 
(R² = 0.7535) and LDH (R² = 0.5206). By contrast, no correlation was observed 
between accumulation of Sa in liver of turkeys and hepatotoxicity. Only cholesterol 
was slightly correlated with Sa accumulation in liver (R² = 0.4086), (figure 18 and 
table 28). 
 
           Figure 18: Correlation between Sa in liver and cholesterol in treated groups. 
[(R²) was linear regression. D'Agostino-Pearson test was done to check the correlation 
between variables (significantly correlation, P < 0.05)]. 
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Table 28: Correlation between Sa in liver and hepatotoxicity parameters  
Objects Treated ducks (R²) Treated turkeys (R²) 
Sa in liver/proteins 0.4699* 0.0215 
Sa in liver /cholesterol 0.7535* 0.4086* 
Sa in liver /AST 0.1570 0.1033 
Sa in liver /ALT 0.0936 0.0025 
Sa in liver /LDH 0.5206* 0.1802 
(R²) linear regression.* D'Agostino-Pearson test was done to check the 
correlation between variables (significantly correlation, P < 0.05). 
Interestingly, the quantity of Sa in serum was dependent on the quantity of Sa 
in liver, (figure 19). This result was concluded from the significant correlation 
obtained between the amount of Sa in liver and serum in both treated groups (in 
ducks R² = 0.6370, and in turkeys R² = 0.7201). However, the equation of the 
correlation was different between the species, (figure 19). Also Sa:So ratio in serum 
showed strong significant correlation with Sa:So ratio in liver of ducks and turkeys 
(R² = 0.8849 and 0.8316, respectively) (P < 0.001).  
 
Figure 19: Correlation between Sa in liver and Sa in serum of treated groups.  
[(R²) was linear regression. D'Agostino-Pearson test was done to check the correlation 
between variables (significantly correlation, P < 0.05)]. 
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2.2. Sphingolipid phosphorylated forms 
Because, the amount of Sa was higher in turkey livers than duck livers, the 
amount of Sa in serum was higher in ducks than turkeys, the accumulation of Sa in 
duck livers was correlated with hepatotoxicity, while the accumulation of Sa in 
turkey livers was not correlated with hepatotoxicity. The investigations done on free 
sphingolipids could not explain the different toxicity between ducks and turkeys to 
FBs exposure. Therefore, the effects of FBs on sphingolipid phosphorylated forms in 
liver and serum, and the effects of sphingolipid phosphorylated forms on 
hepatotoxcity were studied in both species to answer their different toxicity to FBs 
exposure.   
2.2.1. Sphingolipid phosphorylated forms in liver 
The phosphorylation ability of free sphingoid bases in the presence of FBs was 
tested in ducks and turkeys to answer their different toxicity to FBs exposure.  
The phosphorylation ability was quite similar in ducks and turkeys (8 and 6 
times higher than control groups, respectively). However, the average amount of 
Sa1P was 3 times higher in turkeys than in ducks in both groups (control and 
treated). Interestingly, in treated groups, significant elevation of Sa1P rapidly 
appeared 8 hr post-dosing, but Sa1P reached the maximum level faster in turkeys 
than in ducks (3 and 7 days post-dosing). Those results were in accordance with 
slope of Sa1P accumulation curve in liver, which was stronger in treated turkeys than 
in treated ducks (177 and 36, respectively), (figure 20, and table 29) 
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Figure 20: Effects of FBs on Sa1P in liver of ducks and turkeys treated with 10 mg 
FB1 + FB2/kg b.w/day, during 21 days. Values were expressed as mean ± SD, [Sp: slope of 
accumulation curve]   
Table 29: Effects of FBs on sphingolipid phosphorylated forms in liver  
FB1 + FB2 (mg/kg b.w.) 
                        Duck                     Turkey 
0 10 0 10 
Sa1P in liver  (nmol/kg)     
day 0 18.96 ± 6.5 37.52 ± 15.99* 37.45 ± 26.72 274.85 ± 60.61* 
day 3 28.02 ± 15.23 142.48 ± 45.58* 94.29 ± 51 749.27 ± 67.62* 
day 7 23.64 ± 17.17 280.62 ± 159.73* 113.51 ± 78.71 764.03 ± 144.58* 
day 14 28.05 ± 9.48 242.89 ± 79.94* 194.62 ± 40.67 895.22 ± 110.06* 
day 21 29.09 ± 17.30 318 ± 63.73* 109.97 ± 66.94 753.27 ± 84.05* 
So1P in liver  (nmol/kg)     
day 0 99.66 ± 55.15 156.67 ± 141.7 149 ± 93.3 253.75 ± 57.86 
day 3 96.16 ± 46.21 98.97 ± 47.78 195.45 ± 127.84 298.78 ± 144.79 
day 7 94.54 ± 88.56 197.89 ± 124.02 313.09 ± 259.07 533.62 ± 300.14 
day 14 45.47 ± 13.57 185.59 ± 54.28* 306.68 ± 133.55 345.51 ± 83.3 
day 21 87.72 ± 58.51 209.52 ± 62.26* 180.16 ± 89.14 284.77 ± 19.36* 
Sa1P/So1P in liver     
day 0 0.25 ±  0.12 0.38 ± 0.25 0.25 ± 0.11 1.13 ± 0.31* 
day 3 0.36 ± 0.22 1.74 ± 0.93* 0.53 ± 0.18 2.78 ± 0.68* 
day 7 0.39 ± 0.4 1.34 ± 0.33* 0.39 ± 0.08 1.84 ± 0.89* 
day 14 0.63 ± 0.13 1.33 ± 0.33* 0.69 ± 0.18 2.64 ± 0.26* 
day 21 0.35 ± 0.12 1.39 ± 0.36* 0.76 ± 0.20 2.65 ± 0.34* 
Values were obtained from five birds per group (four birds on day 21 for ducks that received FBs) 8 
hr after the first administration of FBs (day 0) and at days 3, 7, 14, and 21 and expressed as mean ± 
SD.*Two-way ANOVA was done to compare treated and control groups by species (significantly 
different, P < 0.05). 
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Concerning So1P a significant elevation was recorded 14 and 21 days after 
exposure in ducks and turkeys respectively. The average amount of So1P was 2 times 
higher in turkeys than in ducks, but the phosphorylation ability was similar in both 
species (2 times higher than control groups), (table 29).   
Sa1P:So1P ratio was significantly increased 8 hours and 3 days post-dosing in 
turkeys and ducks, respectively, (table 29). This result revealed that elevation of 
Sa1P:So1P ratio in liver was dependent on elevation of Sa1P, which increased rapidly 
before the increase of So1P in both species 
2.2.2. Sphingolipid phosphorylated forms in serum 
The Sa1P increased after 3 days post-dosing in both species. In control groups, 
the average amount of Sa1P was similar in ducks and turkeys (0.233 and 0.277 µM, 
respectively), whereas in treated groups, it was 1.5 times higher in ducks than in 
turkeys (1.033 and 0.803 µM, respectively), (table 30). 
Table 30: Effects of FBs on sphingolipid phosphorylated forms in serum  
FB1 + FB2 (mg/kg b.w.) 
Duck Turkey 
0 10 0 10 
Sa1P in serum  (µM)     
day 0 0.25 ± 0.16 0.32 ± 0.13 0.49 ± 0.19 0.25 ± 0.19 
day 3 0.23 ± 0.06 1.34 ± 1.14* 0.29 ± 0.09 0.84 ± 0.50* 
day 7 0.27 ± 0.18 0.99 ± 0.19* 0.21 ± 0.03 0.98 ± 0.40* 
day 14 0.20 ± 0.06 1.73 ± 0.82* 0.18 ± 0.02 1.13 ± 0.21* 
day 21 0.23 ± 0.13 0.79 ± 0.43* 0.21 ± 0.14 0.82 ± 0.07* 
So1P in serum  (µM)     
day 0 0.53 ± 0.37 0.47 ± 0.43 1.91 ± 0.76 0.48 ± 0.35* 
day 3 0.49 ± 0.15 0.48 ± 0.13 0.40 ± 0.09 0.61 ± 0.38 
day 7 0.65 ± 0.43 0.56 ± 0.10 0.68 ± 0.15 0.88 ± 0.32 
day 14 0.45 ± 0.18 0.37 ± 0.20 0.37 ± 0.12 0.56 ± 0.25 
day 21 0.78 ± 0.58 0.40 ± 0.14 0.82 ± 0.74 0.65 ± 0.41 
Sa1P/So1P in serum     
day 0 0.48 ± 0.04 0.90 ± 0.41* 0.25 ± 0.01 0.50 ± 0.09* 
day 3 0.50 ± 0.19 2.53 ± 1.67* 0.73 ± 0.11 1.49 ± 0.76* 
day 7 0.44 ± 0.14 1.81 ± 0.53* 0.32 ± 0.06 1.10 ± 0.09* 
day 14 0.44 ± 0.07 6.98 ± 6.88* 0.51 ± 0.10 2.78 ± 2.43 
day 21 0.36 ± 0.13 1.89 ± 0.39* 0.31 ± 0.07 2.22 ± 2.33 
Values were obtained from five birds per group (four birds on day 21 for ducks that received FBs) 8 hr 
after the first administration of FBs (day 0) and at days 3, 7, 14, and 21 and expressed as mean ± 
SD.*Two-way ANOVA was done to compare treated and control groups by species (significantly 
different, P < 0.05). 
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The liberation ability of Sa1P was quite similar in ducks and turkeys (4 and 3 
times higher than control, respectively), (table 30). 
The amount of So1P in the serum of control groups was not different to the 
treated groups in both species, (table 30). Sa1P:So1P ratio was highly sensitive to FBs 
exposure, which was elevated 8 hr post-exposure in both species, (table 30). 
The amount of Sa1P in liver was strongly significantly correlated with the 
amount of Sa in liver in treated groups of both species (in ducks R² = 0.8813, and in 
turkeys R² = 0.8856) (P value < 0.001), (figure 21).  
 
Figure 21: Correlation between Sa1P and Sa in liver of treated groups.  
[(R²) was linear regression. D'Agostino-Pearson test was done to check the correlation 
between variables (significantly correlation, P < 0.05)]. 
Interestingly, the equation of correlation was very close in ducks and turkeys. 
This result demonstrated that the amount of Sa1P in liver was very dependent on the 
amount of Sa in liver. Moreover, the accumulation of Sa1P in liver was not correlated 
with hepatic toxicity parameters in both species, nor with Sa1P in serum (in ducks R² 
= 0.368, and in turkeys R² = 0.5501), (table 31).   
Table 31: Correlation between Sa1P in liver and hepatotoxicity parameters  
Objects Treated ducks (R²) Treated turkeys (R²) 
Sa1P/proteins 0.2543 0.0056 
Sa1P/cholesterol 0.3985 0.065 
Sa1P/SAT 0.0181 0.2763 
Sa1P/ALT 0.0493 0.078 
Sa1P/LDH 0.1378 0.5271 
 (R²) linear regression. D'Agostino-Pearson test was done to check the correlation between 
variables (No significantly correlation was obtained, P > 0.05). 
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No correlation was obtained between So1P and So in liver of ducks and 
turkeys (R² = 0.0663 and 0.2113, respectively). This result was expected, because So in 
liver was not affected by FBs exposure in both species. 
From the previous results it became clear that sphinganine was highly 
sensitive to FBs exposure in both species. In addition, the accumulation of 
sphinganine was implicated in hepatotoxicity in ducks, but that was not the case in 
turkeys. Therefore, the correlation between accumulation of FBs and free 
sphingolipids in liver was interesting to be investigated in both species.  
The average amount of FB1 in liver was higher in treated turkeys than in 
treated ducks (table 32). The amount of FB1 in controls was always below the limit of 
quantification (13 ng/g). The level of FB2 was below the LOQ in all samples. 
Table 32: Amount of FB1 in liver (ng/g) of ducks and turkeys fed 10 mg FB1+FB2/kg 
 Ducks Turkeys 
day 0 35.7 ± 4.2 44.0 ± 2.3 
day 3 52.9 ± 3.1 91.5 ± 3.5 
day 7 43.2 ± 1.2 128.9 ± 7.4 
day 14 78.1 ± 8.3 97.3 ± 6.8 
day 21 113.2 ± 8.4 130.0 ± 7.6 
 
Values were obtained from five birds per group (four birds on day 21 for ducks 
that received FBs) 8 hr after the first administration of FBs (day 0) and at days 
3, 7, 14, and 21 and expressed as mean ± SE. 
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Interestingly, significant correlation was recorded between accumulation of Sa 
and FBs in the liver of ducks and turkeys (R² = 0.7801 and 0.7128, respectively), but 
the equation of correlation was different between two species, (figure 22).   
 
Figure 22: Correlation between Sa and FBs in liver.  
[(R²) was linear regression. D'Agostino-Pearson test was done to check the correlation 
between variables (significantly correlation, P < 0.05)]. 
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3. Oxidative damages  
The effects of FBs on free sphingolipids and sphingolipid phosphorylated 
forms failed to explain the different toxicity between ducks and turkeys to FBs 
exposure. On the other hand, oxidative damage effects of FBs have been reported in 
rodents [314-315-316].     
Catalase (CAT) and glutathione (GSH) concentrations have been also 
investigated to reveal whether FBs produces oxidative damages in the liver (figure 
23). Statistical analysis (t-test) of these parameters did not reveal significant 
difference between control and treated groups in both species. 
 
Figure 23: Effects of FBs on oxidative damage parameters in ducks and turkeys 
treated with 10 mg FB1 + FB2/kg b.w/day, during 21 days. Values were expressed as mean 
± SD 
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4. Inflammatory response 
The elevation of serum total protein was recorded only in treated ducks from 
day 3 post-dosing until the end of the study, but not in turkeys. For that reason, it 
was important to induce further investigation on inflammatory proteins in ducks and 
turkeys as way to explain their different toxicity to FBs exposure.   
Interestingly, serum protein electrophoresis analysis appeared a significant 
augmentation in inflammatory proteins only in treated ducks, which refer to hepatic 
inflammation. 
In control ducks, the inflammatory proteins parameters were stabilized. By 
contrast, in treated ducks, all the inflammatory proteins levels, such as: alpha 1 
globulins, alpha 2 globulins, beta globulins and A/G ratio were increased over time 
during the study, except serum albumin, which was nearly constant. Moreover, 
significant elevation was observed in those parameters when compared treated 
ducks at the 8th hr with the 21st day post-dosing. Also significant elevation was 
recorded in alpha 1 globulins at days 3 and 7, alpha 2 globulins at days 14 and 21, 
beta globulins and A/G ratio from day 7 until the end of the experiment. By contrast 
in turkeys, serum protein electrophoresis analysis was nearly constant during the 
experiment in both groups (control and treated), except  for a slightly significant  
increase which was recorded in alpha 2 globulins at day 3, and in A/G ratio at 8th hr 
post-dosing, (table 33). 
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Table 33: Effects of FBs on serum protein electrophoresis  
FB1+FB2  mg/kg.BW 
 
                         Duck                        Turkey 
0 10 0 10 
 Albumine (g/l)     
0 17.76 ± 0.5 17.78 ± 1.1 17.42 ± 0.6 18.08 ± 0.9 
3 16.66 ± 2.5 18.5 ± 2.2 14.06 ±1.3 16.44 ± 1.3 
7 16.52 ± 1.6 16.66 ± 0.8 14.76 ± 0.4 14.44 ± 1.3 
14 15.9 ± 1.6 18.4 ± 2.2 15.72 ± 1.4 14.42 ± 1.1 
21 15.46 ± 1.3 14.77 ± 3.2 15.86 ± 1.2 15.38 ± 0.9 
Alpha-1 globulin    (g/l)     
0 1.74 ± 0.4 1.5 ± 0.3 2.84 ± 0.3 2.65 ± 0.3 
3 1.82 ± 0.4 2.66 ± 0.6 * 2.36 ± 0.4 2.34 ± 0.2 
7 1.28 ± 0.3 2.26 ± 0.5 * 2.16 ± 0.5 3.02 ± 0.8 
14 1.72 ± 0.5 2.78 ± 2.5 2.32 ± 0.6 2.42 ± 0.3 
21 1.96 ± 0.4 3.37 ± 1.9 2.82 ± 0.1 2.88 ± 0.4 
Alpha-2 globulin (g/l)     
0 6.84 ± 0.6 6.9 ± 0.9 5.72 ± 0.3 5.7± 0.5 
3 7.46 ± 1.8 8.14 ± 1.2 4.82± 0.4 5.54 ± 0.3 * 
7 8.66 ± 0.8 9.38 ± 0.7 6.2 ± 0.8 7.44 ± 4.8 
14 7.9 ± 0.9 9.66 ± 1.3 * 6.06 ± 0.9 5.96 ± 0.3 
21 6.96 ± 0.6 9.41 ± 2 * 6.28 ± 0.5 6 ± 0.2 
Beta globulin (g/l)     
0 8.64 ± 0.5 9.08 ± 0.5 10.18 ± 0.9 9.83 ± 0.3 
3 8.86 ± 2 10.38 ± 1.2 9.02 ± 2.3 9.86 ± 0.7 
7 8.3 ± 1.4 11.96 ± 2 * 9.78 ± 2.4 10.12 ± 2.6 
14 8.32 ± 0.9 12.24 ± 0.8 * 9 ± 1 8.32 ± 0.4 
21 8.32 ± 0.9 11.72 ± 3.4 * 8.74 ± 0.4 9.24 ± 0.8 
Gamma globulin (g/l)     
0 1.28 ± 0.4 1.28 ± 0.2 4.24 ± 0.9 3.78 ± 0.4 
3 1.82 ± 0.5 2.36 ± 0.7 3.78 ± 1.1 4.22 ± 1 
7 1.8 ± 0.3 2.6 ± 0.3 6.06 ± 1.8 5.8 ± 1.5 
14 1.94 ± 0.4 1.92 ± 0.2 4.48 ± 0.9 4.48 ± 1.2 
21 1.74 ± 0.3 2.21 ± 0.6 3.46 ± 0.2 3.5 ± 0.7 
Albumin to globulins A/G     
0 0.96 ± 0.1 0.95 ± 0.1 0.76 ± 0.04 0.82 ± 0.04 * 
3 0.84 ± 0.1 0.79 ± 0.04 0.71 ± 0.1 0.75 ± 0.1 
7 0.83 ± 0.04 0.64 ± 0.04 * 0.68 ± 0.1 0.56 ± 0.1 
14 0.8 ± 0.1 0.69 ± 0.1 * 0.73 ± 0.1 0.68 ± 0.1 
21 0.81 ± 0.04 0.58 ± 0.2 * 0.74 ± 0.1 0.71 ±  0.1 
Values were obtained from five birds per group (four birds on day 21 for ducks that received FBs) 8 hr after 
the first administration of FBs (day 0) and at days 3, 7, 14, and 21 and expressed as mean ± SD.*Two-way 
ANOVA was done to compare treated and control groups by species (significantly different, P < 0.05) 
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In the literature review part it has been demonstrated that, ducks are more 
sensitive to FBs toxicity than turkeys, whereas, the accumulation of FB1 and Sa in 
tissues are higher in turkeys than in ducks. The objective of the PHD was to 
investigate the causes which lead to different toxicity between ducks and turkeys to 
FBs exposure. Two experiments were conducted on ducks and turkeys under the 
same conditions in order to explain their different toxicity to FBs exposure. i) 
Toxicokinetics of fumonisin B2 experiment was conducted to investigate if the 
absorption and/or eliminations of FB2 are different between the two species. ii) FBs-
toxicity experiment was investigated, if  the FBs have different toxicity effects 
between ducks and turkeys in several aspects: general toxicity (mortality, body and 
organs weight, and hepatotoxicity parameters), amount of free sphingolipids in 
tissue and serum, correlation between accumulation of free sphingolipids in liver and 
hepatotoxicity, amount of sphingolipid phosphorylated forms in liver and serum, 
correlation between amount of sphingolipid phosphorylated form in liver and 
hepatotoxicity, correlation between accumulation of free sphingolipids and 
sphingolipid phosphorylated forms in liver, correlation between amount of FBs and 
free sphingolipids, oxidative damages, and serum inflammatory proteins.   
I. FB2-Toxicokinetic Experimental 
Toxicokinetics of FBs, such as FB2 and FB3 are poorly documented when 
compared to FB1. The toxicokinetics of FB2 had only been studied in rat and non-
human primates [28-51], whereas toxicokinetics of FB1 had been investigated in 
several animal species, including avian species [23-24-30-31-32-34-35-55]. In parallel, 
FB2 has similar structure to FB1 [18-21], and it has similar toxic and carcinogenic 
effects to FB1 in rodents [48]. Hence, the results obtained here in this study were 
compared with available data derived from FB2 and FB1 by using different doses, in 
different animal species.  
The method of analysis used for the quantification of FB2 in plasma is similar 
to the described method for FB1 analysis in serum and tissues of ducks and turkeys 
[23-24-280]. The results obtained by this method were within the same ranges of 
those obtained by using SAX column for the extraction of FBs from plasma of rat, 
ducks and turkeys [23-24-28-58-280]. 
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Strong linearity of the whole method validation (with R² = 0.994) was obtained 
from fortified plasma with standards 0.025 to 0.250 µgFB2/ml. The limit of detection 
(LOD) and quantification (LOQ) were estimated at around 0.01 and 0.025 µg FB2/ml 
of plasma, respectively. These results agreed with the results obtained from rat 
plasma fortified with FB2, in which the LOD obtained by using SAX extraction was 
0.02 µg FB2/ml [28]. Also, they agreed with data obtained from ducks and turkeys, in 
which the LOQ obtained by using SAX extraction for serum fortified with FB1 was 
0.025 µg FB1/ml [23-24]. The mean recovery rate of FB2 from fortified plasma for 
each level of contamination was 63% +/- 5. This recovery rate obtained was lower 
than the only one already described by Shephard for FB2 in rat plasma (80.4% +/- 
4.5) [58]. By contrast, it was close to the recovery rate of FB1 in the plasma of ducks 
and turkeys (60%) [23-24].   
The elimination of FB2 from plasma after intravenous dosing in ducks and 
turkeys was fitted according to a bi-exponential equation, as reported in monkeys 
injected with FB2 [51], and rats, monkeys, layer hens, and ducks injected with FB1 
[23-30-32-55]. 
Distribution phase (T1/2 α) of FB2 in ducks and turkeys (3.8 and 1 min, 
respectively) was rapid as the T1/2 α obtained for FB1 in ducks, turkeys, layer hens 
and pigs (2.6, 1.7, 2.5 and 2.2 min, respectively) [23-24-30-31].   
The elimination half life (T1/2 β) was slower in ducks than in turkeys (32 and 
12.4 min, respectively). However, the elimination half life of FB2 in both species was 
at the same range with data only available on monkeys (18 min) by using quite 
similar dose to our study (2 mg FB2/kg b.w.) [51]. These results support and explain 
the prolonged quantification of FB2 in duck serum when compared to turkey serum, 
after IV injection (two and one hours after dosing, respectively). Also, these results 
reveal the most important persistence of FB2 in duck tissues than in turkey ones. On 
the other hand, in ducks, the elimination half life of FB2 (32 min) was quite similar to 
the one obtained for FB1 (26.2 min), whereas, the MRT of FB2 (12.9 min) was 2 times 
lower than FB1 (24.2 min), (table 34) [23]. In turkeys, the elimination half life (T1/2 β) 
and the MRT of FB2 (12.4 and 5 min, respectively) were 5 times lower than the one 
obtained for FB1 (85.5 and 25 min, respectively), (table 34) [24]. These results suggest 
that FB2 persistence in tissues is less pronounced than FB1.  
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The clearance of FB2 was similar in ducks and turkeys (9.3 and 8.7 
ml/min/kg, respectively). By contrast, the clearance of FB1 was higher in ducks than 
in turkeys (19.3 and 8.7 ml/min/kg, respectively), (table 34) [23-24]. Interestingly, in 
turkeys the same value of clearance was recorded with FB2 and FB1 (8.7 
ml/min/kg). By contrast, the clearance of FB2 in ducks was lower than FB1 (9.3 and 
19.3 ml/min/kg, respectively). The differences between clearances of FB2 and FB1 in 
ducks are probably due to incorrect estimation of clearance of FB2, because, FB2 and 
FB1 have similar chemical structure [18-21], and the experimental dose of FB2 was 
small (1 mg/kg b.w.).  
Table 34: Toxicokinetic parameters of FBs after IV dosing in ducks and turkeys 
Parameters 
         FB2 (1 mg/kg .b.w.)       FB1 (10 mg/kg .b.w.) [23-24] 
Duck Turkey Duck Turkey 
T1/2α (min) 3.8 1 2.6 1.7 
T1/2β (min) 32 12.4 26.2 21.3 
MRT (min) 12.9 5 24 25 
Cl (ml/min/kg) 9.3 8.7 19.3 8.7 
T 1/2 α: distribution half-life; T 1/2 β: elimination half-life; MRT: mean residence 
time; Cl: total plasma clearance  
The bioavailability of FB2 was very low in ducks and turkeys. This result was 
estimated by lack of detection of FB2 in plasma after oral dosing in both species, 
except two cases of turkeys when toxin level was higher than LOQ, and lower than 
50 ng/ml.  These results agreed with previous data obtained in rats and monkeys by 
using the same method and near dose of our experimental (7.5 mg FB2/kg b.w.) [28-
51]. No detection of FB2 in plasma was reported in rats (as in ducks) [28], whereas, 
trace amount of FB2 (20-40 ng/ml) was recorded in the plasma of monkeys (as in 
turkeys) [51]. On the other hand, the bioavailability of FB2 is less pronounced than 
that of FB1 in all tested animal species. Bioavailability of FB1 in ducks, turkeys, rat 
and monkeys were 2.3, 3.2, 3.5 and 2 %, respectively [23-24-32-35]. Interestingly, the 
bioavailability of FB1 and FB2 are more pronounced in turkeys than in ducks. 
Apparently, the toxicokinetic parameters of FB2 do not differentiate greatly 
between ducks and turkeys. In addition, the absorption of FB2 is lower than FB1 in 
those species. Thence, the toxicokinetics of FB2 could not explain the different 
 135 
toxicity between those species to FBs exposure. Furthermore, the risk of toxicity by 
FB2 is less pronounced than FB1 in those species.  
II. FBs-Toxicity Experimental 
All previous researches which studied the FBs toxicity in ducks and turkeys 
were conducted by different protocols (bird age, tested dose, duration of experiment, 
and route of administration), which made it very difficult to get precise comparative 
details between those works. Therefore, the present study investigated the causes of 
different toxicity between ducks and turkeys to FBs exposure by using the same time 
and conditions. 
The results obtained in this study were discussed with previous data reported 
in avian and /or other animal species. Also, the results were discussed with 
fumonisin mechanism of action, and new hypotheses of different toxicity between 
ducks and turkeys to FBs exposure were proposed.  
1. General toxicity and serum biochemistry 
The mortal effect of FBs was observed in ducks, but not in turkeys. These 
results were in agreement with previous data. The FBs was able to induce mortality 
at low dose in ducks fed 20 mg FB1/kg of feed per day, by force feeding over 12 days 
[158], and at high dose in young broiler fed 125 mg FB1/kg of diet for 3 days [147]. 
By contrast, mortal effect of FBs was not reported in turkeys exposed to low dose of 
20 mg FB1/kg of feed, for long period 63 days [156], or high dose of 475 mg FB1 /kg 
of diet for short period of 21 days [154], and in laying hens fed high dose of 200 mg 
FB1/kg of diet for long period 14 months [155]. Those results demonstrated that 
turkeys were more resistant to FBs exposure than ducks, and that ducks showed the 
highest sensitivity to FBs exposure among avian species.  
Decrease of feed intake and body weight gain were only observed in ducks, 
and not in turkeys. Decrease of feed intake and body weight were commonly 
observed in poultry after exposure to FBs, but they were dose-dependent. For 
example, they were reported in ducks and broilers which had consumed 
contaminated diet at a level higher than 30 mg FB1/kg for few weeks and in turkeys 
fed high dose of 75 mg FB1/kg for 3 weeks [150-154-165]. In our study, the decrease 
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of body weight gain in ducks was not linked to malabsorption of feed, because feed 
conversion ratio was constant during the experimental. However, it was linked to the 
decrease of feed intake. In parallel, the decrease of feed intake in ducks was not 
linked to the bad flavor of feed, because exposition of the toxin was conducted by 
force feeding. It was a consequence of FBs toxicity. Therefore, those results showed 
better tolerance to FBs exposure in turkeys than in ducks.  
FBs increased liver weight in ducks, whereas FBs increased gizzard weight in 
turkeys. These results agree with previous studies. Heavy liver was recorded in 
ducks fed low dose of 32 mg FB1/kg for 77 days [165], in turkeys fed mild dose of 75 
mg FB1/kg for 21 days [149-154], and broiler which consumed high dose of 450 mg 
FB1/kg for 21 days [151]. Also, increased gizzard weight was noticed in ducks fed 
high dose of 128 mg FB1/kg for 77 days [165], and in turkeys fed high dose of 100 mg 
FB1/kg for 21 days [310]. The main causes of heavy liver are: i) hepatic steatosis 
which is considered a normal physiological condition in migrating birds, geese and 
ducks [158-302-311], and pathological condition in non-migrating birds including 
geese, ducks and turkeys [223-302-306]. ii) Cell proliferation, strong hepatocellular 
hyperplasia was observed in ducks receiving 5 mg FB1/kg .b.w. by daily oral 
administration over 12 days [163], and in turkeys which consumed contaminated diet 
at a level of 75 mg FB1/kg for 21 days [149-154]. iii) Inflammatory cases, which led to 
escape of intravascular fluid and blood cells from blood vessels to interstitial tissue. 
Inflammatory infiltrations was reported in ducks receiving 5 mg FB1/kg .b.w., by 
daily oral administration over 12 days [163], and in ducks consuming contaminated 
diets higher than 30 mg FB1/kg of feed, for one week [170-171]. Unfortunately, 
histological examination was not conducted in our study. However, heavy duck 
livers in the present study could be attributed to liver inflammation.  
The serum biochemistry analyses were investigated to confirm the different 
toxicity between ducks and turkeys to FBs exposure. 
Hyperproteinemia was only observed in ducks, but not turkeys. These results 
were in agreement with previous data. Hyperproteinemia was obtained in ducks 
receiving 5 mg FB1/kg .b.w., by daily oral administration over 12 days [163], and in 
ducks fed 128 mg FB1/kg of diet for 7 days [165-170-171]. While, concentration of 
total serum proteins was constant in turkeys fed low dose of FBs 20 mg FB1+FB2/kg 
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of feed, over long a period of 9 weeks [156], in turkeys which consumed mild dose of 
50 mg FB1/kg of diet for long period 3 months [153], in turkeys which consumed 
high dose of 200 mg FB1/kg of diet for short time 21 days [310], and broiler fed high 
dose 400 mg FB1/kg of diet for 21 days [148]. The hyperproteinemia is commonly 
observed in dehydration cases [219], but in our experiment, ducks were not 
dehydrated. On the other hand, hyperproteinemia was also combined to 
inflammatory processes, as it will be discussed later in section- 4 (inflammatory 
response). 
Hypercholesterolemia was only observed in ducks, while cholesterol remained 
constant during the study in turkeys according with previous data.  
Hypercholesterolemia was recorded in ducks fed more than 30 mg FB1/kg of diet for 
7 days [165-170-171], and in broilers which consumed high contaminated diets at 
level 400 mg FB1/kg of feed for 21 days [148]. Whereas, serum cholesterol was not 
affected in turkeys fed mild dose of 50 mg/kg of diet for a long period (more than 9 
weeks) [153-156], laying hens consumed high contaminated diet of 200 mg FB1/kg of 
feed for a long period of 420 days [155], broilers were fed mild dose of 80 mg FB1/kg 
feed for 21 days [146]. Hypercholesterolemia has been reported during acute hepatic 
steatosis in ducks [158-302-311]. However, post-mortem examination of ducks did 
not show any signs of hepatic steatosis such as, an increase in liver size and a change 
of liver color. Additionally, it has been demonstrated that disturbance in 
sphingolipids metabolism leads to disturbance in lipids metabolism pathways 
including cholesterol, and inducing hypercholesterolemia [190-214-250-312]. This 
hypothesis showed that ducks are more sensitive to disturbance of sphingolipids 
metabolism than turkeys, as discussed later in section- 2 (Sphingolipids alterations). 
ALT remained nearly constant during the study in both species. This result 
agreed with data obtained in ducks fed dose 8 mg FB1/kg of diet for a long period of 
77 days [165], turkeys fed low dose of 20 mg of FB1+FB2/kg of feed over a long 
period of 9 weeks [156], turkeys which consumed high dose 250 mg FB1/kg of diet 
for a short period of 21 days [149], and laying hens fed 200 mgFB1/kg of diet for a 
long period of 420 days [155]. By contrast elevation of ALT was detected in other 
animal species, such as pigs exposed to single oral dose of 5 mg FB1/kg b.w. [63], 
ponies fed contaminated diets at level 44 mg FB1/kg of feed, for 10 days [252], calves 
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which consumed 148 mg FBs/kg of feed, for 10 days [133]. The insensitivity of ALT 
to FBs exposure in avian species is maybe linked to the lower concentration of ALT in 
their cytoplasm [246-247-294-295], when compared to mammals. 
In both species, AST was less sensitive to FBs exposure, which increased latter 
after several days post-dosing. However, AST was more sensitive to FBs exposure in 
turkeys (appeared at day 14 of treatment) than ducks (appeared at day 21 of 
treatment). The lower sensitivity of AST to FBs exposure in ducks and turkeys agreed 
with previous data obtained in avian species, in which AST was only elevated at high 
doses of FBs exposure. The elevation of AST was reported in broilers fed 
contaminated diets with 80 mg FB1/kg of feed for 21 days [146],  turkeys fed high 
dose of  100 mg FB1/kg of diet for 21 days [310], laying hens supplied with high dose 
of  200 mg FB1/kg of diet for a long period of 112 days [155]. Whereas, insensitivity 
of AST was demonstrated in ducks which consumed high dose of 128 mg FB1/kg of 
diet for 77 days [165], turkeys fed with 20 mg of FB1+FB2/kg of feed over long a 
period of 9 weeks [156], and laying hens which consumed contaminated diet with 
100 mg FB1/kg of diet for a long period of 420 days [155]. The lower sensitivity of 
AST to FBs exposure in avian species is maybe related to AST position inside the cell 
(20% in cytoplasm and 80% in mitochondria) [245-308]. On the other hand, the 
different sensitivity of AST between ducks and turkeys to FBs exposure is probably 
correlated to higher concentration of AST in turkeys (control and treated groups) 
when compared to ducks.  
LDH increased rapidly after 3 days of treatment until the end of the study in 
ducks, While LDH was only observed after 7 days of exposure in turkeys. The faster 
raise of LDH after FBs exposure in ducks when compared to turkeys was in 
agreement with previous data. The elevation of LDH was recorded after 7 days of 
feeding ducks with 32 mg FB1/kg [165]. By contrast, LDH was not affected in turkeys 
which consumed 20 mg FB1+ FB2/kg of diet for 63 days [156], and in broilers fed 400 
mg FB1/kg of diet for 21 days [148]. The common causes which lead to an increase in 
LDH are: hepatic cells damages, muscular disorder and atrophy and hemolysis [246-
247-294-295-308]. Additionally, muscular disorder disease and muscular atrophy 
cases were combined with a decrease in body weight [246-294-295], which was not 
reported during our study in both species. Also, sample hemolysis which leads to 
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false elevation of LDH was not observed during the experimental manipulation. 
Hence, elevation of LDH in ducks was an indication of hepatic damage.  
Obviously, the serum biochemistry analysis confirms the different toxicity 
between ducks and turkeys to FBs exposure, as it shows marked elevation of 
hepatotoxicity parameters in ducks when compared to turkeys.  
2. Sphingolipids alterations 
2.1. Free sphingolipids 
2.1.1. Free sphingolipids in tissues 
In both species, Sa in liver and kidneys showed high sensitivity to FBs 
exposure, which elevated rapidly after 8 hr post-toxication. This result agreed with 
previous studies, which reported an increase of Sa and Sa:So ratio in tissues in ducks 
fed very small dose of 2 mg FB1/kg feed, for 7 days [165-170-171], in turkeys which 
consumed maximum level of fumonisins in avian feed recommended by the 
European Union (20 mg/kg of feed), for 7 days [156], and broiler  fed with 25 mg 
FB1/kg of diet, for 42 days [153]. This study confirms rapid sensitivity of 
sphingolipids metabolism to FBs exposure in both species. 
In both species, the disturbance of sphingolipids metabolism by FBs exposure 
was more pronounced in the kidneys than in the liver, in agreement with data 
obtained with ducks fed 2 mg FB1/kg of feed, for one week [165-170-171], Sprague-
Dawley rats which consumed 15 mg FB1/kg of feed, for 4 weeks [264], and F344 rats 
fed 5 mg FB1/kg of feed, for 6 weeks [264]. By contrast, the liver and kidneys had the 
same sensitivity to fumonisins exposure in turkeys fed 20 mg FB1+FB2/kg of feed, 
for one week [156]. The different sensitivity between liver and kidneys to FBs in both 
species could be attributed to different sensitivity of cell death and cell generation 
programs in those tissues [171].  
 Interestingly, the accumulation of Sa in tissues is higher in turkeys than in 
ducks, whereas, signs of FBs toxicity (mortality, decreased body weight gain and 
hepatotoxicity parameters) were more pronounced in ducks than in turkeys. This 
result agreed with previous researches which demonstrated higher sensitivity of 
ducks to FB1 toxicity than turkeys, as written above [149-154-156-158-165]. 
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Surprisingly, accumulation of Sa in tissues reached the maximum level faster in 
turkeys (3 days post-dosing) than in ducks (7 days post-dosing). This result was 
confirmed by the slope of sphinganine accumulation curve in tissues, which were 
stronger in turkeys (≈ 16) than in ducks (≈ 2.5). Indeed, the slope of sphinganine 
accumulation curve in liver was quite similar to the slope of sphinganine 
accumulation curve in kidneys in ducks and turkeys. Those results revealed that the 
accumulation capacity of Sa in both species was not tissue-dependence (liver and 
kidney). However, it was dependent on the differences between avian species. 
Furthermore, the slope of sphinganine accumulation curve was in accordance with 
rapid accumulation of Sa in turkey tissues compared to duck tissues. Unfortunately, 
those results are difficult to compare with other data, because, all previous research 
protocols measured the disturbance of sphingolipids metabolism in tissues after 
several days post FBs exposure.  
2.1.2. Free sphingolipids in serum 
The amount of Sa in serum was higher in ducks than in turkeys. In addition, 
the escape of Sa from tissues to serum was faster in ducks than in turkeys, which 
appeared after 8 hr and 3 days post dosing, respectively. These results show higher 
sensitivity of ducks to FBs exposure than turkeys, in agreement with previous data. 
The elevation of Sa in serum was observed in ducks which had consumed very low 
dose of 2 mg FB1/kg feed, for 7 days [165-170-171], and in turkeys and broilers fed 
mild contaminated diet of more than 70 mg FB1/kg of feed for 21 days [146-154]. 
Whereas, elevation of Sa and Sa:So in the serum was not detected in turkeys which 
had received mild dose of 50 mg FB1 /kg of feed, for a long period (3 months) [153], 
and broilers which had consumed 40 mg FB1 /kg of feed, for 21 days [146]. 
Interestingly, the liberation ability of Sa was quite similar in treated ducks and 
turkeys (5 and 3 times higher than control groups, respectively). Consequently, the 
liberation ability of Sa from tissue to serum is unable to explain the different toxicity 
between ducks and turkeys to FBs exposure.   
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2.1.3. Correlations between Sa in liver, Sa in serum and hepatotoxicity 
parameters  
In both species, sphinganine in tissues and serum was rapidly increased after 8 
hr post-dosing. Except in turkey serum, where it increased after 3 days post-dosing. 
By contrast, hepatotoxicity parameters were elevated later after 3 days post-dosing in 
ducks, and they were not affected in turkeys. Those results agreed with previous 
researches, which demonstrated higher sensitivity of sphingolipids metabolism to 
FBs exposure than hepatotoxicity parameters. Lowest-observed-effect-level (LOEL) 
to increase Sa and Sa:So ratio in liver was 2 and 20 mg FB1/kg feed, for 7 days in 
ducks and turkeys, respectively [156-165-170-171], and 20 mg FB1/kg feed, for 21 
days in broilers [146],whereas Lowest-observed-effect-level (LOEL) to increase 
hepatotoxicity parameters was 32 mg FB1/kg feed, for 7 days in ducks [165-170-171], 
and more than 80 mg FB1/kg feed, for 21 days in turkeys and broilers [146-148-149-
310]. Thence, the present study confirms that disturbance of sphingolipids 
metabolism is the best biomarker to FBs exposure when compared with other toxicity 
parameters in both species.  
Additionally, the accumulation of Sa in duck liver was significantly correlated 
with hepatotoxicity parameters, such as protein and LDH. By contrast, no correlation 
was obtained between accumulation of Sa in turkey liver and hepatotoxicity 
parameters. These results agreed with previous data. Strong correlation between 
accumulation of Sa in liver and hepatotoxicity parameters was reported in ducks 
which received a dose of 5 mg FB1/kg b.w via oral administration over 8 days [164], 
and in ducks fed a dose higher than 30 mg FB1/kg of feed for 7 days [170]. By 
contrast, accumulation of Sa in liver, without any increase of hepatotoxicity 
parameters were observed in turkeys fed maximum level of fumonisins in avian feed 
recommended by the European Union (20 mg FB1+FB2/kg of feed), for 63 days [156]. 
Also, strong correlation between accumulation of Sa in liver and hepatotoxicity 
parameters was observed in other species, such as rats fed contaminated diet at level 
88.6 mg FB1/kg of feed for 10 days [26]. This result demonstrates that turkeys are 
more tolerant than ducks to accumulation of Sa in liver. Subsequently, it is suggested 
that accumulations of free sphingolipids in tissues are not responsible for different 
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toxicity to FBs exposure between ducks and turkeys. This suggestion agreed with 
previous data obtained in mice, which demonstrated a significant decrease of free 
sphingolipids (Sa and So) without a significant decrease in hepatotoxicity in mice 
treated with fumonisin plus myriocin when compared to a group treated with 
fumonisin alone [87]. By contrast, a significant increase of free sphingolipids (Sa and 
So) without a significant increase in hepatotoxicity was observed in mice treated with 
FB1 plus silymarin when compared to the group treated with FB1 alone [236]. 
Concurrently, that suggestion was in opposition with the rat study, which 
demonstrated the responsibility of free sphingolipids to induce hepatotoxicity [26]. In 
fact, the rat study was not as precise as our study. That is because the rat study was 
not a comparative study between high and low sensitive rat strains to FBs exposure, 
but it was only conducted on highly sensitive rat strains to FBs exposure. By contrast, 
our study was a comparative experiment between high and low sensitive avian 
species (ducks and turkeys) to FBs exposure. 
In both species, the accumulation of Sa in liver was correlated with 
hypercholesterolemia. Similar result was demonstrated in ducks which consumed a 
contaminated diet at a dose higher than 30 mg FB1/kg of feed for 7 days [170], and in 
ducks which received 5 mg FB1/kg, b.w. orally, for 8 days [164]. Moreover, the 
correlation between accumulation of Sa in liver and hypercholesterolemia was 
reported in other species, such as rats fed 71 mg FB1/kg of feed for 4 weeks [313]. 
This phenomenon could be linked to the ability of accumulate free sphingolipids 
inside the cells to disturb lipid metabolism pathways (including cholesterol 
metabolism) by activating certain lipid metabolism enzymes, such as phospholipase 
D, and inhibiting others (monoacylglycerol acyltransferase, and protein kinase C) 
[190-214-250-312].  
For both species, the amount of Sa in serum was in a significant correlation 
with the amount of Sa in liver. This result showed that the amount of Sa in serum is 
strongly dependent on the amount of Sa in liver in ducks and turkeys. On the other 
hand, the equations of correlation coefficient of Sa were different between ducks and 
turkeys (R² = 0.6370 and 0.7201, respectively). These differences in the equations 
reveal to higher rate of Sa escape from liver to serum in ducks compared with 
turkeys, which explains the higher amount, and quickly elevation of Sa in duck 
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serum when compared with the turkeys. Therefore, those results are probably 
indicative of duck hepatocyte damage. 
Actually, all investigations on free sphingolipids failed to explain the different 
toxicity between ducks and turkeys to FBs exposure. Thence, it was interesting to 
study the impact of FBs on cell sphingolipids phosphorylation mechanism in both 
species in order to explain their different toxicity to FBs exposure. 
2.2. Sphingolipids phosphorylated forms (liver and serum) 
In the literature review part it was demonstrated that a portion of the 
accumulated free sphingolipids in the cells are metabolized into sphingolipid-1-
phosphate (Sa/So1P) and then cleaved into a fatty aldehyde and ethanolamine 
phosphate [79-180-181-188]. In parallel, Sa1P and So1P act as a promoting factor for 
cell proliferation, cell growth, anti-inflammatory and anti-apoptosis [178-179-201-
235]. Therefore, the catabolism of free sphingolipids (phosphorylation) is considered 
a cell protective mechanism against accumulation of free sphingolipids, which was 
studied in ducks and turkeys as way to answer their different toxicity to FBs 
exposure. 
In both species, elevation of Sa1P in liver was rapidly detected after 8 hr post-
dosing. This result agreed with previous data. Elevation of Sa1P in liver was 
observed in ducks after consuming a high dose of more than 30 mg FB1/kg of feed, 
for 7 days [171]. Also, implication of FBs in the increase of sphingolipid 
phosphorylated forms has been reported in different animal species such as mice 
injected via IP route with 20 mg FB1/kg.b.w/day, for 2 days [208], piglets fed 
contaminated diet with 30 mg FB1/kg of feed for 42 days [102], and in cell culture 
[312].  Unexpectedly, the phosphorylation ability of Sa in liver was quite similar in 
ducks and turkeys (8 and 6 times higher than control groups, respectively). This 
result demonstrated that cell catabolism of free sphingolipids (phosphorylation) are 
not responsible for different toxicity between ducks and turkeys to FBs exposure. 
However, the slope of Sa1P accumulation curve was stronger in treated turkeys than 
in treated ducks (177 and 36, respectively). This result is in accordance with rapid 
elevation of Sa1P in turkey liver than in duck liver, which reached maximum levels 
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after 3 and 7 days, respectively.  These results also reveal to high phosphorylation 
capacity of Sa in turkeys than in ducks.  
In both species, the elevation of Sa1P in serum appeared later after 3 days 
post-dosing. Interestingly, the liberation ability of Sa1P in ducks and turkeys was 
quite similar (4 and 3 times higher than control, respectively). But, the average 
amount of Sa1P in serum was 1.5 times higher in ducks than in turkeys. 
Unfortunately, no information about Sa1P in avian serum is available for comparison 
with our results. The higher amount of Sa1P in duck serum compared to turkey 
serum is may be due to higher rate of Sa1P escape from liver to serum in ducks, 
which reveals hepatocyte damage in ducks. This suggestion is supported by the 
results obtained in ducks during the present study, which demonstrated an elevation 
of serum protein, cholesterol, LDH, and Sa at same time with Sa1P, after 3 days post-
dosing. 
In both species, very strong significant correlation was obtained between the 
amount of Sa1P and Sa in liver, and the equations of correlation were very similar 
(ducks R² = 0.8813, and turkeys R² = 0.8856) (P value < 0.001). This result has been 
recorded in ducks fed more than 30 mg/kg of feed, for one week [171]. The result 
shows that the amount of Sa1P is strongly dependent on the amount of Sa in liver in 
both species. Furthermore, no correlations were observed between the accumulation 
of Sa1P in liver and hepatotoxicity parameters in both species.  
Therefore, those results suggest that the phosphorylated forms of 
sphingolipids are not responsible for different toxicity between ducks and turkeys to 
FBs exposure.    
2.3. Correlation between amount of FBs and Sa in liver 
In the present study, the amount of FBs in liver was higher in turkeys than in 
ducks. This result agreed with prior results obtained from toxicokinetics studies of 
FB1 in these species, in which the absorption of FB1 was higher in turkeys than in 
ducks (F (%) = 3.2 and 2.3, respectively), and the excretion of FB1 was lower in 
turkeys than in ducks (CL (ml/min/kg) = 7.5, and 19.3, respectively) [23-24]. Also, it 
supports our toxicokinetic study of FB2 in ducks and turkeys, which recorded 
slightly higher absorption of FB2 in turkeys than in ducks.   
 145 
On the other hand, significant correlation was recorded between the 
accumulation of Sa and FBs in the livers of ducks and turkeys (R² = 0.7801 and 0.7128, 
respectively). However, the equations of correlation were different between ducks 
and turkeys. This result has been reported for the first time in avian species. 
Furthermore, strong correlation between accumulation of FB1 and Sa in liver was 
observed in other animal species such as rodents (for example: rats which had 
consumed contaminated diet at level 88.6 mg FB1/kg of feed for 10 days [26]). Those 
results show that the amount of Sa in the liver is strongly dependent on the amount 
of FBs in the liver of ducks and turkeys. This correlation was linked to the ability of 
fumonisin to interfere with sphingolipids biosynthesis by blocking ceramide 
synthase enzyme [187-190-191-192-197-214-215]. 
Eventually, the accumulation of Sa in liver was more pronounced in turkeys 
than in ducks. Whereas, the amount of Sa in serum was higher in ducks than turkeys. 
In addition, signs of toxicity were clear in ducks than turkeys, and hepatotoxicity 
parameters were correlated with the amount of Sa in the liver of ducks, but not in 
turkeys. Therefore, it was suggested that accumulations of free sphingolipids in liver 
are not responsible for different toxicity between ducks and turkeys to FBs exposure. 
Furthermore, elevation of Sa in serum is a consequence of FBs exposure, which 
reveals hepatocyte damage in ducks. 
Accumulation of Sa1P in liver was more pronounced in turkeys than in ducks, 
whereas, phosphorylation ability of Sa was quite similar in both ducks and turkeys. 
In parallel, the amount of Sa1P in liver was strongly dependent on the amount of Sa 
in liver in both species. Moreover, the accumulation of Sa1P in liver was not 
correlated to hepatotoxicity parameters in both species. Thence, the phosphorylation 
mechanism of free sphingolipids and accumulation of Sa1P in liver are insufficient to 
explain the different toxicity between ducks and turkeys to FBs exposure. On the 
other hand, a higher amount of Sa1P in duck serum compared to turkey serum is 
probably an indication of hepatocyte damage in ducks.     
Interestingly, in both species, the amount of Sa in liver was dependent on the 
amount of FBs.  
Finally, it appears that disturbance sphingolipids metabolism by fumonisins 
are not responsible for different toxicity between ducks and turkeys to fumonisins 
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exposure. Also, it is probable that fumonisins have other mechanisms to induce 
hepatic toxicity, such as oxidative damage effects and/or inflammatory response. 
3. Oxidative damages 
In this study, FBs did not induce significant changes in oxidative damage 
parameters, such as CAT and GSH, which tested in both species. Unfortunately, the 
oxidative damage effects of FBs are poorly documented in poultry. However, FBs 
inducing hepatotoxicity by their oxidative damage effects have been observed in few 
studies in vitro and vivo at high doses, such as in rats fed high dose of 250 mg FB1 
/kg diet for 21 days [314], rats fed 0.08 – 0.16 mg FB1/100g b.w/day for 2 years [45], 
rats injected IP with 0.5mg FB1/kg b.w/day for 7 days [315], and also in cell culture 
[316]. Failure of FBs at low dose (as used in our study) to increase oxidative damages 
parameters was  reported in ducks which received 45 mg FB1/kg b.w. by daily oral 
administration over 12 days [163], and  other animal species, such as rats which 
consumed contaminated diet at level of 10 mg FB1/kg diet for 21 days [314].  
Additionally, the results obtained in the present study were supported by 
recent results obtained in our lab after feeding ducks, turkeys and broilers with same 
dose and period used in our experimental (10 mg FB1/kg diet for 21 days). The 
recent lab results demonstrated absent effects of FBs on several oxidative damage 
parameters, such as SOD, CAT, GSH peroxydase, GS reductase, GSH, GSSG, and 
MAD (data not shown).  
It is clearly that oxidative damage effect of FBs failed to explain the different 
toxicity between ducks and turkeys to FBs exposure.  
4. Inflammatory response 
Fumonisins increased inflammatory proteins only in ducks, but not turkeys. 
The increase of alpha-1 and 2 globulins, beta globulins, gamma globulins, and A/G 
ratio were more pronounced when comparing ducks at the first day to the last days 
of treatment, rather than when comparing treated and control groups at the day of 
exposure. The separation of alpha-1 on alpha-2 globulins was difficult. Thence, its 
values were not precise. The inflammatory response of FBs was evaluated by its 
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effect on increase of beta globulins, gamma globulins, and A/G ratio. The elevation 
of A/G ratio in ducks was a consequence of elevation of globulins, but not albumin. 
These results agreed with the results obtained in this study and with previous 
researches, which demonstrated the ability of FBs to induce hyperproteinemia in 
ducks, but not in turkeys as discussed above in section-1 (General toxicity and serum 
biochemistry). Hyperproteinemia without clear histological signs of hepatic 
inflammation was observed in ducks exposed to 5 mg FB1/kg .b.w. by daily oral 
administration over 12 days [163], and in ducks fed with contaminated feed at doses 
higher than 30 mg FB1/kg of feed, for 7 days [170-171]. For this reason, 
Serum Protein Electrophoresis was studied for the first time in both species after FBs 
exposure. 
Concurrently, elevation of alpha and gamma globulins were observed in acute 
and chronic inflammatory response cases due to infectious diseases, nephritis, and 
hepatitis [319-320-321]. Therefore, the elevations of inflammatory proteins in our 
study are probably indicator of duck hepatotoxicity, as post-mortem examination of 
ducks did not reveal infection or nephritis. Also, elevation of beta globulins was used 
as an indicator for hyper lipoproteinemia, in particular hypercholesterolemia [319-
320]. For that reason, an increase of beta globulins in ducks, but not in turkeys 
supported and confirmed our hypercholesterolemia results, which was reported only 
in ducks, but not in turkeys, as discussed above in section-1 (General toxicity and 
serum biochemistry).  
On the other hand, FBs inducing hepatotoxicity by its impact on inflammatory 
cells (Kupffer cells) has been reported in rodents [166-233-238]. For example, 
elevation of hepatotoxicity enzymes (ALT and AST) were obtained in mice treated 
with FB1 alone. Meanwhile, a significant diminishment in hepatotoxicity enzymes 
(ALT and AST) was observed in mice treated with mixture of fumonisin and 
gadolinium (complete elimination of Kupffer cells) [238]. 
Apparently, the different inflammatory response between ducks and turkeys, 
and role of Kupffer cells to induce hepatotoxicity could explain the different toxicity 
between those species to FBs exposure.  
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III. Conclusion 
The objective of this work was to investigate several hypotheses that could 
explain differences of FBs toxicity between ducks and turkeys.  
Toxicokinetic evaluation of FB2 was investigated because previous studies 
have suggested that parameters of absorption and elimination of this mycotoxin 
could be different from FB1. The results obtained here reveal only weak differences 
between these two species. Additionally, the values obtained from toxicokinetics 
studies of FB2 and FB1 were at the same range, except for the absorption of FB2 
which was found to be lower than FB1 in both species.  
The FBs-toxicity experiment confirms higher sensitivity of ducks than turkeys 
to FBs exposure and demonstrates that:   
 The increase of sphingolipids contents in tissue and serum is rapid and 
precede signs of toxicity in both species, which confirmed that sphingolipids 
parameters are the best biomarkers to FBs exposure.  
 Accumulation of Sa in liver is correlated with toxicity in ducks and not in 
turkeys whereas the amount of Sa in liver was higher in turkeys than in ducks.  
 Accumulation of Sa1P in liver is strongly correlated with the amount of Sa, the 
Sa1P to Sa ratio is the same in the two species, so, the phosphorylation rate 
fails to explain the difference of toxicity.   
 The amount of Sa in liver is correlated with the amount of FBs in ducks and 
turkeys, the amount of FB1 being more important in turkeys than in ducks.  
 FBs had no significant effect on oxidative damage parameters whereas 
preliminary investigations on inflammatory response revealed the ability of 
FBs to increase inflammatory proteins in ducks, but not in turkeys. 
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IV. Prospective studies   
Although phosphorylation of Sa into Sa1P failed to explain the differences of 
toxicity of FBs between ducks and turkeys, it cannot be excluded that differences of 
sphingolipids metabolism between the two species could be related to differences of 
toxicity. Indeed several metabolites of Sa are formed in cells, some of them being 
cytotoxics, others being protective [68-174-188-192-323]. Thence, it would be of 
interest to study the effect of FBs on ceramide metabolism in ducks and turkeys.  
The FBs-toxicity study revealed the ability of FBs to increase inflammatory 
proteins in ducks but not in turkeys. This result agrees with literature data 
demonstrating hyperproteinemia in ducks, but not in turkeys [153-156-163-165-170-
171-310]. Although the mechanism of this increase remain uncertain, it can be 
pointed out that an effect of FBs on cells involved in the immune response has been 
reported as a key mechanism of toxicity in rodents [166-233-238]. Therefore, a specific 
effect of FBs on Kupffer cells may induce hepatotoxicity in ducks but not in turkeys. 
This hypothesis is under investigation, as the effect of mycotoxins at low doses of 
exposure in the avian species.  
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